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There is no doubt a strong genetic component to psychosis, but family and twin 
studies have shown that simple genetic transmission is far from the whole story. 
Furthermore, a number of environmental factors have also been shown to increase 
risk of psychosis. Among these non-genetic causes, Obstetric Complications (OCs) 
are among the best replicated.  
In order to get a better insight into the mechanisms by which OCs impact on brain 
development to increase the risk of psychosis, I employed a Gene X Environment 
causation model.  
A total of 377 psychotic patients, 65 controls and 103 unaffected siblings were 
available for my project. I obtained data concerning clinical and socio-demographic 
status, obstetric history, together with samples of blood/cheek swabs for genetic 
analysis from these subjects. I also genotyped most of the subjects (N=399) for 
selected genetic variants that might have functional significance in relation to the 
individual’s exposure to OCs (namely AKT1 rs 2494753, rs1130233, rs3803300; 
BDNF rs2049046, rs56164415; DNMBP1 rs875462; GRM3 rs7808623; AK573765-
TWIST2 rs9751357; CACNA1C rs4765905; CEACAM21 rs4803480; CNNM2 
rs7914558; CSMD1 rs10503253; Erbb4 rs1851196; ITIH3/4 rs2239547; 
LOC645434-NMBR rs2066036; LRRFIP1 rs12052937; MIR137 rs1625579; MMP16 
rs7004633; NKAPL rs1635; NRG rs12807809; NT5C2 rs11191580; PCLO 
rs6979348; PLXNA2 rs752016; PGBD1 rs2142731; PCGEM1 rs17662626; RELN 
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rs7341475; SDCCAG8 rs6703335; STT3A rs548181; TCF4 rs17512836; UGT1A1 
HJURP rs741160; rs10489202; rs16887244).  
In a case-control design, I investigated how exposure to OCs influenced the risk of 
psychotic disorder.  
Then, I tested, under a multiplicative model, the hypothesis that a range of genetic 
variants interacted with OCs in increasing the risk of psychotic disorder. 
Lastly I examined whether rats that had experienced perinatal asphyxia during birth 
show abnormalities in gene expression and methylation status at various 
developmental periods. 
My findings didn’t show any interaction between genes and OCs in increasing the 
risk of psychosis. On the other hand, in rats following hypoxic insult many of the 
genes had heterogeneous pattern of expression, suggesting an important role for genes 
in mediating the reactions of the CNS to environmental stimuli such hypoxia. In 
general, at post neonatal day CNNM2 was down regulated, whereas CSMD1 and 
TCF4 were up regulated; at 5 weeks CNNM2, CSMD1, MMP16, STT3a were down 
regulated, whereas TRIM26 was overexpressed. Hypoxia in the prenatal and perinatal 
period could regulate the expression of specific genes contributing to the 
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ORGANIZATION OF THE THESIS 
 
 
The thesis comprises of a total of 11 Chapters. CHAPTERS 1, 2, 3 and 4 are 
introductory chapters to psychosis, obstetric complications, research on genetic 
predisposition to psychosis and epigenetics. General aims, methods and statistical 
analyses are presented in CHAPTER 5. The experimental part of the thesis is presented 
in CHAPTERS 6, 7, 8, 9 and 10. Each of these chapters has a brief introduction, 
followed by the specific methods, results, summary of results, discussions and limits. 
In CHAPTER 11 a general discussion about the findings is presented. A chart 
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1.1     Introduction 
The term psychosis - from the Greek “psyche”, for mind/soul, and “- osis” for 
abnormality- was introduced in 1845 by Von Feuchtersleben with the meaning of 
“mental illness or madness” (Feuchtersleben, 1985). It now refers to a severe 
alteration of mental balance, characterised by a set of “psychotic” symptoms in which 
thoughts, feelings, affective response, ability to recognize reality and ability to 
communicate and relate to others are sufficiently impaired to interfere grossly with 
the individual’s capacity to deal with reality (Sadock and Sadock, 2003).  
The “psychotic” symptoms are classified as positive and negative symptoms (Crow, 
1980).  
Positive symptoms include: Hallucinations are defined as sensory perceptions in the 
absence of external stimuli and may occur in any of the five senses. They have 
qualities of normal perceptions and are independent from the person’s will; they can 
be auditory, visual, olfactory, gustatory, tactile or somatic in nature.  Auditory 
hallucinations are a common and often prominent feature of psychosis. A Delusion 
“is a false, unshakeable idea or belief, which is out of keeping with the patient’s 
educational, cultural and social background; it is held with extraordinary conviction 
and subjective certainty” (Sims, 2003). Delusions can be classified according to their 
content (e.g. persecutory, grandiose, depressive, reference, religious, jealous, 
erotomanic, of misidentification, somatic, nihilistic).  Disorders of thought are 
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disturbances in the thought process characterized by disorganized speech, and 
loosening of association.  
Negative symptoms are deficits of normal emotional responses or of other thought 
processes. They commonly include flat or blunted affect and emotion, poverty of 
speech (alogia), inability to experience pleasure (anhedonia), lack of desire to form 
relationships (asociality), and lack of motivation (avolition).  
It is still controversial whether negative symptoms are primary or in part secondary to 
either severe positive symptoms or treatment side effects. Depending upon severity, 
all psychotic symptoms can lead to impaired social interaction and poor self-care, and 
result in an overall decline in level of functioning. 
 
 
1.2     Classification of Psychotic Disorders  
Psychosis is generally subdivided into organic and functional: an organic psychosis is 
a condition due to a physical illness (for instance a consequence of dementia or of a 
brain injury) while a functional psychosis is a primary disorder not related to other 
physical disease. In current diagnostic systems, Diagnostic and Statistical Manual of 
Mental Disorders (DSM IV-TR) and the International Classification of Diseases 
(ICD-10), psychotic disorders are classified following a categorical model. According 
to the DSM IV-TR there are nine types (codes in bracket) of functional psychotic 
disorders: Schizophrenia (that has five subtypes: paranoid type - 295.30; disorganized 
type - 295.10; catatonic type - 295.20; undifferentiated type - 295.90; residual type - 
295.60), schizophreniform disorder (295.40), schizoaffective disorder (295.70), 
delusional disorder (297.1), brief psychotic episode (298.8), shared psychotic disorder 
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(297.30), substance-induced psychotic disorder (291.3 and 291.5 or 292.11 and 
291.12 according to the presence of hallucinations and substance of abuse), psychotic 
disorder not otherwise specified (298.9) and psychosis due to a general medical 
condition (293.81 and 293.82 according to the presence of hallucinations).  
Psychotic symptoms can also occur in mood disorders, such as major depressive 
episodes and manic episodes (296.04, 296.24, 296.34, 296.44, 296.54, 296.64 
according to the mood disorder). In the case of mood disorders, psychotic features 
generally occur only when the mood disorder is at a severe level and psychotic 
features can be either congruent or incongruent with the mood.  
The above classification systems are currently under revision in preparation for the 
general release and implementation of the DSM-5 (http://www.dsm5.org) and ICD-
11. 
The classification depends upon type of symptoms, their duration and the presence or 
absence of prominent affective symptoms.  
 
 
1.3     Historical Views and Current Position 
Schizophrenia is the major psychotic disorder and is the eighth cause of disability 
worldwide in adolescents and adults (World Health Report, 2011). The first to 
describe it was the German psychiatrist Kraepelin (1896) with his famous concept of 
“dementia praecox” (Kraepelin, 1986); since then the description of the disease, its 
causes and treatment has undergone a very considerable evolution; in 1911 the Swiss 
psychiatrist Eugene Bleuler used the current term of “schizophrenia” (Bleuler, 1911).  
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The term schizophrenia is derived from the Greek “split mind” σχίζω (schizo, split) 
and φρενός (phrenos, brain). While Kraepelin considered as key elements of the 
syndrome, an early onset and inevitable progress towards the mental deterioration, 
Bleuler put the emphasis on mental dissociation, with the splitting of the unity of 
mind as an essential aspect of psychopathology of schizophrenia.    
A few decades later, another German psychiatrist, Kurt Schneider (1957), proposed 
the basis of the definition and symptoms of schizophrenia that we are using today 
(Schneider, 1957). Schneider’s main concern was to improve diagnosis in psychiatry. 
He was also interested in differentiating schizophrenia from other forms of psychosis 
by listing the psychotic symptoms that are particularly characteristic of schizophrenia. 
These have become known as Schneider’s First-Rank Symptoms or simply, first-rank 
symptoms.  
A further turning point came with Crow in 1980; he proposed different syndromes 
which integrated type I schizophrenia presenting clinically with positive symptoms 
such as delusions and hallucinations and type II schizophrenia, presenting with 
symptoms such as affective flattening and poverty of speech, negative symptoms 
(Crow, 1980).  
However, further investigations suggested the positive-negative dichotomy to be an 
oversimplification and provided evidence for the existence of a third core syndrome, 
called the disorganized syndrome, which is characterised by symptoms such as formal 
thought disorder and inappropriate affect (Bilder et al., 1985; Liddle, 1987; 
Andreasen et al., 1995; Mass et al., 2000). 
The prevalent view among most researchers today is that schizophrenia is a syndrome 
rather than a specific disease and it may include several conditions.   In thisI will 
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briefly review the Epidemiology (PARAGRAPH 1.4) and Aetiological Theories 
(PARAGRAPH 1.5) of the condition before going on in the next chapters to discuss 
Early Environmental Hazards (CHAPTER 2), Gene X Environment Interactions 
(CHAPTER 3) and Epigenetics (CHAPTER 4). 
 
 
1.4     Epidemiology 
Schizophrenia occurs most frequently towards the end of adolescence or at the start of 
adult life (Almeida et al., 1995) and affects approximately 0.7% of the world 
population (Mueser and McGurk, 2004). The lifetime prevalence rates for psychotic 
disorders according to DSM IV- TR are: 0.87% for schizophrenia, 0.32% for 
schizoaffective disorders, 0.24% for bipolar I disorders, 0.35% for major depressive 
disorders with psychotic features (Perälä et al., 2007) (FIGURE 1.1).  
 
 
FIGURE 1.1   Lifetime Prevalence Estimates of DSM-IV Psychotic and BPI Disorders. Taken 
from Perälä et al., 2007. 
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The risk of morbidity, that is the probability that a person born in a particular 
population/group develop the disease if he/she survives during the entire period of 
risk for this disease (ranging from 15 to 54 years in schizophrenia), is estimated to be 
in the range of 0.5/100 to 1.6/100 persons (World Health Organization (WHO), 
1992).  
Contrary to previous interpretations, the incidence of schizophrenia shows prominent 
variation between sites with rates for incidence from 7.7 to 43 per 100000 with a 
worldwide variation up to fivefold and a male to female ratio of 1.4 (McGrath et al., 
2008). In particular, it is higher among migrants (Cantor-Graae and Selten, 2005) and 
people living in urban areas (Mortensen et al., 1999). Moreover the incidence of 
schizophrenia can also vary over time (Boydell, et al., 2003).  
 
 
1.5    Aetiological Theories  
“It is easy enough to speculate about an illness which has been the subject of so much 
investigation and remains so barren in established aetiology, but the first essential for 
any directed programme of research is a hypothesis based on fact, otherwise 
observation hardly progresses beyond the stage of cataloguing” (Osmond and 
Smythies, 1952). 
The aetiology of schizophrenia has been the subject of much research, and a single 
common cause can be excluded. Rather epidemiological studies suggest that 
biological risk, such as genetic factors, early environmental hazards, substance abuse 
and social factors, such as urbanicity, migration, social adversity are important 
contributory factors (reviewed by Stilo and Murray, 2011). Thus, it results from a 
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combination of both brain vulnerabilities (either inherited or acquired) and life events 
(Murray et al., 2002). From a biological point of view, the symptoms of psychosis 
have a possible mechanistic cause in organic changes at various levels, from genetic 
predisposition to the altered functioning of neurotransmitters such as dopamine, 
serotonin, glutamate, gamma-aminobutyric acid, N-Methyl-D-Aspartate (NMDA), 
peptides, and others (Sadock and Sadock, 2003).   
1.5.1     Neurochemistry 
1.5.1a   Model Psychosis and The Serotonin Hypothesis 
In 1938 Hofmann synthesized the Lysergic Acid Diethylamide (LSD), but only 5 
years later did he discover its hallucinogenic properties when, after accidentally 
spilling some on his skin, he experienced “its unforeseeable effects in my own body – 
or rather, in my own mind,” seeing uninterrupted streams of “fantastic pictures, 
extraordinary shapes with intense kaleidoscopic play of colours” (Hofmann, 1980). In 
the 1960s, the use of LSD and other recreational drugs spread among young people 
across the Western world. Neuropharmacologists began to ask whether schizophrenia 
might be caused by chemical alterations similar to those produced by LSD. Shaw and 
Woolley (1956) hypothesized that LSD might act on 5-hydroxytryptamine (5-HT) 
receptors, and later Anden et al. (1968) suggested a direct agonist effect at 5-HT 
receptors in the Central Nervous System (CNS) (Shaw and Woolley, 1956; Anden et 
al., 1968). The idea that the psychotic state induced by LSD resulted from actions at 
serotonin receptors led to the suggestion that LSD provides a “model psychosis” and 
to the serotonin hypothesis of schizophrenia. Glennon et al. (1983) proposed the 5-
HT2 receptor subtypes as the specific target of hallucinogenic drugs such as LSD, 
later supported by studies in rodents (Nichols, 2004), and in humans (Vollenweider et 
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al., 1998; Carter et al., 2007). The serotonin hypothesis received further support from 
the finding of 5-HT2-receptor abnormalities in post-mortem schizophrenic brains, but 
in vivo studies of 5-HT2-receptor abnormalities reported conflicting results (Mita et 
al., 1986; Gurevich and Joyce, 1997). The evidence that clozapine is particularly 
efficacious in the care of treatment resistant schizophrenia provoked further interest 
because of the 5-HT2 receptor antagonism induced by this drug and other atypical 
antipsychotics (Lieberman et al., 1998; Meltzer, 1999; Tamminga and Holcomb, 
2005). 
1.5.1b   The Dopamine Hypothesis 
The “Dopamine Hypothesis” is still the best-known theory of schizophrenia (Kapur et 
al., 2003). This hypothesis was developed following the discovery, in the 1950s, of 
drugs that improved the acute psychotic phase of the disease (Carlsson, 1957). The 
first of these drugs was chlorpromazine, followed by other molecules later called 
“typical antipsychotics”, such as haloperidol. The first useful key to understand the 
mechanism of antipsychotics came from the analysis of their major side effects. In 
fact, these molecules frequently cause Parkinsonian-like syndrome. Carlsson and 
Lindqvit (1963) identified that antipsychotic drugs increased the metabolism of 
dopamine when administered to animals (Carlsson and Lindqvit, 1963). Following 
the intuition of Arvid Carlsson, several studies showed that, despite differences in 
chemical structure, all clinically effective antipsychotic drugs block dopamine 
receptors. From there the idea developed that an excess of dopaminergic transmission 
could play an important role in the pathogenesis of schizophrenia.  
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Additional support for the dopamine theory came from the evidence that certain drugs 
lead to schizophrenia-like psychosis. The similarity of amphetamine psychosis to 
schizophrenia was first clearly described in the 1950s by Tatetsu et al. (1956) and was 
substantiated by a similar report in Britain from Connell (1958) (Tatetsu et al., 1956; 
Connel, 1958). Subsequently, Angrist et al. (1974) found that amphetamine 
administered experimentally produced a picture similar to paranoid psychosis in 
healthy individuals and exacerbated psychotic symptoms in approximately one-third 
of schizophrenic patients (Lieberman et al., 1987); moreover antipsyhcotic drugs 
blocked these psychotogenic effects of amphetamines (Espelin and Done, 1968). 
Amphetamine was found to stimulate dopamine outflow, while, in contrast, 
antipsychotics were found to block dopamine receptors in the brain (Carlsson and 
Lindqvist, 1963; Van Rossum, 1967). Subsequently Single Photon Emission 
Tomography (SPET) and Positron Emission Tomography (PET) studies demonstrated 
that acute administration of amphetamine induced greater striatal dopamine release in 
first-episode schizophrenia patients compared to healthy controls (Laruelle et al., 
1996; Breier et al., 1997). Together these observations provided the basis for the 
dopamine hypothesis of schizophrenia (Snyder, 1972; Kapur, 2003). 
In 1991 Davis et al. showed a different brain distributions of D1 and D2 dopamine 
receptors (respectively predominantly cortical and subcortical), suggesting that the 
effects of abnormalities in dopamine function could vary by brain region (Davis et al., 
1991). Subsequent PET and animal studies provided the best evidence of regional 
brain dysfunction in schizophrenia showing a regionally specific prefrontal 
hypodopaminergia and a subcortical hyperdopaminergia (Pycock et al., 1980; Scatton 
et al., 1982; Howes and Kapur, 2009).   
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This provided a mechanism to propose that schizophrenia is characterized by frontal 
hypodopaminergia and striatal hyperdopaminergia (Howes and Kapur, 2009). In 
particular, negative symptoms of schizophrenia seemed to be related to frontal 
hypodopaminergia while positive symptoms were hypothesized to result from striatal 
hyperdopaminergia (Davis et al., 1991). Therefore it would be more correct to talk 
about an imbalance of dopaminergic tone (Abi-Dargham et al., 2000; Kapur et al., 
2005). 
In rodents, repeated administration of amphetamine leads to reversed tolerance and an 
increased neurochemical and behavioural reaction to each dose. Boileau et al. (2006) 
tested whether this might happen also in humans (Boileau et al., 2006). They 
administered dextroamphetamine by mouth on days 1, 3, and 5 to 10 healthy 
volunteers, and measured the effect on striatal dopamine release before exposure, 
then the day of first exposure, then 2 weeks later after the third dose, using the 
PET/[11C] raclopride technique. Each dose of amphetamine caused greater dopamine 
release in the ventral striatum together with greater behavioural responses. Indeed, 1 
year later there was a greater psychomotor response and greater increase dopamine 
release compared to the initial dose, in the ventral striatum, progressively extending 
to the dorsal caudate and putamen (Boileau et al., 2006). Such findings have led to the 
“dopamine sensitization” hypothesis of schizophrenia, which postulates that a 
sensitized dopamine system is responsible for the genesis of psychotic symptoms 
(Peleg-Raibstein et al., 2009). 
Since then many articles have been published on the dopamine hypothesis of 
schizophrenia but it was not until recent years that we were able to develop the 
“Dopamine Hypothesis -version III”, that incorporates the most comprehensive 
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understanding of the role of dopamine in schizophrenia and psychosis in particular 
taking in account the multiple environmental and genetic risk factors for the illness 
finally leading to a final common pathway of presynaptic striatal hyperdopaminergia 
(Howes and Kapur, 2009). These authors hypothesized that the interaction of multiple 
‘‘hits’’ results in dopamine dysregulation and that this dysregulation was at 
presynaptic dopaminergic control level (Di Forti et al, 2007; Howes and Kapur, 
2009).  Furthermore, the dopamine dysregulation is hypothesized to alter the 
valuation of stimuli through a process of aberrant salience (Howes and Kapur, 2009). 
Thus dopamine abnormalities may represent an end state for multiple environmental 
and genetic factors that operate together to push a vulnerable individual to 
symptomatic onset (Eyles et al., 2012). 
1.5.1c   The Glutamate Theory 
The “dopamine theory” of schizophrenia has dominated attempts to explain the 
positive symptoms seen in schizophrenic patients (Kapur and Mamo, 2003) but is less 
able to account for negative symptoms. Drugs acting on the glutamate system have 
been proposed to model these. Kotz and Merkel (1926) discovered the compound, 1-
piperidinocyclohexanecarbonitrile, and thus laid the groundwork for the preparation 
of Phencyclidine (PCP) which was developed as an intravenous general anesthetic in 
the 1940s by Parke, Davis & Co. Unfortunately, up to 50% of adult patients given 
PCP developed agitation and hallucinations (Greifenstein et al., 1958; Johnstone et 
al., 1958; Collins et al., 1960), so the focus of investigation of PCP shifted from its 
possible use as an anesthetic to its capacity to produce model psychoses (Luby et al., 
1962). Subsequently, ketamine, another glutamate antagonist was introduced as an 
anesthetic, and later reports of ketamine induced psychosis started to appear. In 1983 
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Anis et al. (1983) showed that ketamine and PCP selectively reduce responses of 
central neurons acting at the NMDA receptor (Anis et al., 1983; Seeman and 
Tallerico, 2005). The observation that PCP and ketamine are NMDA antagonists 
together with the findings of lower levels of glutamate (by about 50%) in 
cerebrospinal fluid samples from schizophrenic patients compared to controls gave 
rise to the “Glutamate Hypothesis of Schizophrenia” (Kim et al., 1980). Although, 
this latter finding was not consistently replicated, the idea of hypoglutamatergic 
transmission in schizophrenia has continued to attract great interest as has the effects 
of NMDA antagonists (Tamminga and Holcomb, 2005). A dissenting view comes 
from Pomerol- Clotet et al. (2006) who gave ketamine to 10 healthy volunteers 
(Pomerol- Clotet et al., 2006). The commonest feature was referential thinking of a 
delusional nature, together with a range of perceptual abnormalities perhaps best 
described as dissociative. However, it did not induce hallucinations, and the authors 
were doubtful about its ability to cause thought disorder; furthermore, although 
negative-like symptoms resulted they could not exclude the possibility that this was 
simply due to its anesthetic effects (Pomarol-Clotet et al., 2006). 
1.5.2      The Neurodevelopment Model of Schizophrenia 
The theory that psychosis might be, in part, a developmental disorder was first 
proposed in the late 1800s by Thomas Clouston who identified a “developmental 
insanity” (O'Connell et al., 1997). However, this was subsequently forgotten. It is 
now more than two decades since Weinberger, Murray and Lewis re- formulated the 
neurodevelopmental hypothesis of schizophrenia as opposed to the degenerative 
hypotheses (Weinberger, 1986; Murray and Lewis, 1987). They suggested that subtle 
brain lesions acquired during intrauterine life initiate a process that could cause 
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dysfunction of the mature brain, predisposing to schizophrenia later in life 
(Weinberger, 1986; Murray and Lewis, 1987).  
Major supports to the formulation of the neurodevelopmental hypothesis came from 
the evidence that pregnancy and delivery complications (collectively termed obstetric 
complications (OCs)) increase risk of schizophrenia (Murray et al., 1985) 
(PARAGRAPH 2.2). Moreover children who later develop schizophrenia tend to 
display early neurological and cognitive problems such as delayed milestones, speech 
problems, poor motor co-ordination, attention and information processing deficits 
(Jones et al., 1994; Erlenmeyer-Kimling et al., 2000; Cannon et al., 2002).  
Since then it has been the dominant paradigm for schizophrenia research and received 
support from epidemiological, developmental and neuroimaging studies (Marenco 
and Weinberger, 2000; McDonald and Murray, 2000).  
Schizophrenic subjects present morphological abnormalities in the brain such as 
enlargement of the lateral and third ventricles and a specific volume reduction in the 
medial temporal lobe, superior temporal gyrus, prefrontal cortex, cingulate gyrus, 
thalamus and insula (Wright et al., 2000). Many of these abnormalities are detectable 
in patients at the onset of psychosis suggesting pathophysiologic processes affecting 
the early developing brain (De Lisi et al., 1991; Hyrayasu et al., 1998; Fannon et al., 
2000). In adult schizophrenic patients some of the brain abnormalities identified such 
as aqueduct stenosis, arachnoid and septal cysts, and agenesis of the corpus callosum 
cannot be wholly secondary to disease progression or due to treatment, they are likely 
to result from impairment of normal neurodevelopment (Lewis, 1990; Murray et al., 
2002). 
! 45 
Some of the brain abnormalities identified in adult schizophrenic patients are also 
found in the unaffected relatives of patients suggesting that such abnormalities are a 
manifestation of familial risk factors, the most likely candidates being genes 
influencing neurodevelopment. (Murray et al., 2003).  
It has been suggested schizophrenia may result from an interplay between genes 
involved in the development of the CNS and exposure to environmental factors 
capable of alternating gene expression (Basset et al., 2001). A series of correlations 
have been reported between early environmental risk factors for schizophrenia and 
structural deviations in the adult brain (reviewed by McGrath and Murray, 1995). 
Some evidence points to an interaction between genetic risk for schizophrenia and 
hypoxic birth events upon structural abnormalities (Staal et al., 2000; Stefanis et al., 
1999; McNeil et al., 2000).  
Recent advances in molecular technologies have made mouse genetic models the first 
choice for most human genetic diseases; so it is with schizophrenia (reviewed by 
Chen et al., 2006). These models suggest that animals with mutations in the genes 
involved in brain development show abnormalities of cortical development that 
remain silent mostly until early adulthood, providing evidence in support of the 
abnormal neurodevelopment hypothesis (Chen et al., 2006).   
 “Static” neurodevelopmental models implicate events occurring around the time of 
birth, while “progressive” or “cumulative” neurodevelopmental models include 
insults that may occur until the final stages of brain development such as childhood 
maltreatment, head trauma, or adolescent cannabis use (King et al., 2010). Genetic 
and environmental risk factors may combine in additive or multiplicative ways to 
increase an individual’s risk (Malaspina et al., 1999). The neurodevelopmental model 
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suggests that different varieties of environmental insults can act early, during the 
most critical phase of the formation of the CNS, but also later in childhood or 
adolescence, in an individual genetically vulnerable (Murray et al., 2002) (FIGURE 
1.2). The neurodevelopmental impairment resulting would determine the onset of 
schizophrenia later in life (Murray, 1994).   
 
 
FIGURE 1.2   Developmental Cascade Towards Schizophrenia. Taken from Stilo and Murray, 
2010. 
 
1.5.3   Childhood Adversity and Social Disadvantage 
Compatible with the Neurodevelopmental Theory of Schizophrenia, childhood 
represents a critical period of exposure to adversities that might increase the risk of 
developing psychosis later in life. Why and how childhood trauma leads to psychosis 
is still debated. One suggestion is that exposure to traumatic experiences early in life 
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might alter the function of the hypothalamus-pituitary-adrenal axis, impairing its 
healthy response to stress across the life span (Read et al., 2005). 
A recent meta-analysis including 41 studies examined the association between 
childhood adversity and trauma (sexual abuse, physical abuse, emotional/ 
psychological abuse, neglect, parental death, and bullying) and psychotic outcome 
(Varese et al., 2012). They found evidence for an interaction between childhood 
adversity and psychosis with an overall effect of OR 2.78 (95% CI = 2.34–3.31) 
(Varese et al., 2012) (FIGURE 1.3).  
 
FIGURE 1.3   Studies Suggesting an Association Between Childhood Adversity and Psychosis. 
Taken from Varese et al., 2012. 
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These findings combined with the literature on the impact of childhood adversity in 
the general population and other mental illnesses (Kessler et al., 2010) point out the 
importance of these disruptive experiences early in development on subsequent 
abnormal functioning in adult (Varese et al., 2012). Moreover, they also suggest that 
future studies should focus on differentiating adversity type, as well as consider the 
possible interaction between trauma and other risk factors (eg, cannabis, genetic risk), 
the developmental stage of exposure to trauma, and mechanisms linking adversity to 
specific positive and negative symptoms (Varese et al., 2012). 
It has been consistently reported that an association between loss of a parent in 
childhood either by death or separation increases risk of psychosis in adulthood of 
about 3 fold (Agid et al., 1999; Morgan et al., 2007).  Parental separation is often 
associated with a range of adverse early experiences, including family conflict, 
socioeconomic disadvantage, neglect and abuse (Rutter, 2006). Therefore, it is 
difficult to separate the impact of each of these social factors from their cumulative 
effect on the risk of psychosis (Rutter, 2006). Moreover individuals with established 
psychotic disorders often experience marked social disadvantage in adult life such as 
being unemployed, living alone, lack of a long-term relationships, with consequent 
social isolation and exclusion (Stilo and Murray, 2010).  It is uncertain whether the 
association between social disadvantage and psychosis is a consequence of the 
developing disorder itself, or a contributory cause of the illness.  
In this regards Stilo et al. (2012), using as a marker of social disadvantage in 
childhood long-term separation from, or death of, one or both parents, explored, in a 
sample of 278 first episode psychotic patients and 226 healthy controls, social 
disadvantage (1) in childhood, (2) at 5 years and 1 year prior to first presentation to 
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psychiatric services, (3) at first presentation with psychosis and (4) their association 
with psychosis while controlling for a wider range of potential confounders (Stilo et 
al. , 2012).  
They found that exposure to social disadvantage prior to onset increases the risk of 
psychosis, both during childhood and adulthood. Consistent with published studies 
long-term, separation from and death of a parent before the age of 17 were both 
strongly associated with approximately 2- to 3-fold-increased odds of psychosis 
independent of a number of potential confounders. Secondly, social disadvantage in 
adult life (living alone, being single, and unemployment) was also strongly associated 
with psychosis. Third, their results show an association between early disadvantage 
and adult social disadvantage (OR 1.73, 95% CI 1.00–2.99, P = .04) explaining in 
part how adulthood social disadvantage in first-episode psychosis patients could be a 
possible a consequence of childhood disadvantage. Finally when they looked at the 
cumulative impact of social disadvantage, they found that the odds of being a case 
increased in line with increasing number of indicators of disadvantage present.  
Furthermore, social disadvantage was not simply a consequence of the patients 
having a long history of untreated psychosis, suggesting that disadvantage is already 
well established before onset of first symptoms (Stilo et al., 2012). 
1.5.4     Drug Use  
Certain drugs can contribute to the onset of schizophrenia-like psychosis.  As shown 
previously, the major pharmacological theories of schizophrenia have their origins in 
the effects of drugs of abuse; in chronological order, the effects of LSD initiated the 
serotonergic model; amphetamines the dopamine hypothesis, PCP, and ketamine the 
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glutamatergic model (PARAGRAPH 1.5.1). Most recently, the effects of cannabis have 
provoked interest in the role of endocannabinoids (Paparelli et al., 2011).  
1.5.4a   Cannabis and Psychosis 
Cannabis, the most widely used recreational drug, has also been consistently 
associated with psychosis in both experimental and epidemiological studies (Paparelli 
et al., 2011). Cannabis has been linked to the development of psychotic symptoms for 
a very long time. The world’s oldest pharmacopeia, the Pen-Ts’ao Chin, traditionally 
attributed to the Chinese Emperor Shen Nung (2737 a.c.), suggests cannabis use as a 
remedy for rheumatic pain, intestinal constipation, disorders of the female 
reproductive system, and malaria, but adds that “if taken in excess will produce 
visions of devils … over a long term, it makes one communicate with spirits and 
lightens one’s body…” (Zuardi, 2006). In the mid-nineteenth century, the French 
psychiatrist Moreau de Tour noted the phenomenological similarities between drug-
induced states and psychosis. Indeed, he proposed the use of hashish to study 
madness a full century before the LSD model of psychosis (Beringer, 1927; 
Hofmann, 1980). 
The first convincing evidence that cannabis might be a risk factor for psychosis came 
from the Swedish Conscripts Study in which 45,570 inductees into the military were 
followed-up for 15 years. This!study reported a risk for schizophrenia 2.4 times 
higher among those who had used cannabis by 18 years than among non-users. 
Moreover, there was a dose–response relationship in that risk for schizophrenia rose 
to 6.0 times in heavy cannabis smokers (use of cannabis more than 50 times at initial 
interview; Andreasson et al., 1987). After 15 years of silence, other epidemiological 
studies on cannabis use and schizophrenia started to be published (Arseneault et al., 
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2002; Van Os et al., 2002; Zammit et al., 2002; Fergusson et al., 2003). Today 
consistent evidence supports an association between heavy cannabis use and the risk 
of psychotic symptoms and illness (Green et al., 2005; Henquet et al., 2005; 
Fergusson et al., 2006; Barnett et al., 2007; Di Forti et al., 2007b; Moore et al., 2007; 
Mc Grath et al., 2010) even if the strength and nature of that association is still an 
object of discussion (D’Souza et al., 2004) (FIGURE 1.4). 
 
 
FIGURE 1.4   Studies Suggesting an Association Between Cannabis Use and Psychosis. Taken 
from Paparelli et al., 2011. 
 
Recent meta-analyses reported an increase in risk between 1.4 and 1.9 times in people 
using cannabis that might account for 8–14% of cases of schizophrenia in different 
countries (Moore et al., 2007). Furthermore, Di Forti et al. (2009) showed a positive 
association between the potency and frequency of cannabis use and the risk of 
psychotic illness (Di Forti et al., 2009). 
1.5.5     The Contribution of Genes to Schizophrenia 
1.5.5a   Family Studies 
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A family history of psychotic disorders in first-degree relatives is the strongest and 
most replicated risk factor for schizophrenia and for psychosis in general (Gottesman, 
1991).  
Back in 1916 Ernst Rüdin, who later became involved with Nazi eugenics, conducted 
the first systematic family study of what we call now schizophrenia (Rüdin, 1916). 
He found that the rate of illness was higher in the biological relatives of his cases and 
the mode of transmission didn’t follow simple Mendelian patterns. He then postulated 
a possible two-gene recessive model (Rüdin, 1916).  
Since then more sophisticated studies have been conducted in order to examine the 
morbid risk of schizophrenia within the same family. Those studies show a higher 
mrbid risk  of psychosis in the relatives of patients than the relatives of general 
population controls (Gottesman, 1991). In addition the risk increases with the degree 
of biological relatedness and if more than one relative was affected (Gottesman, 
1991) (FIGURE 1.5).  
Kendler et al. (1993) carried out a large family study on three proband groups, 
schizophrenic patients, affective psychosis patients and matched randomized healthy 
controls, revealing a risk of schizophrenia among first-degree relatives of 6.5% and 




FIGURE 1.5   Risk of Developing Schizophrenia. Taken from Gottesman 1991. 
 
1.5.5b   Twin Studies 
Heritability estimates are derived mostly from twin studies (Gottesman, 1991). The 
first twin study dates from 1928 and was carried out by Luxenberger (Luxenberger, 
1928). He found a high concordance in monozygotic twins (MZ) and none in 
dizygotic twins (DZ) (Luxenberger, 1928). 
Subsequent studies reporting probandwise rates for schizophrenia, confirmed that 
concordance among MZ was higher than DZ pairs (Kallmann, 1946; Slater, 1953; 
Kendler, 1983; McGuffin et al., 1984; Onstad et al., 1991; Cardno and Gottesman, 
2000). In this regard, the concordance rates between MZ twins (almost 50%) provides 
strong evidence for the involvement of genes but also raises the question of what 
other factors may be involved in the aetiology of schizophrenia (Cardno et al., 1999). 
A large twin studies carried out at the Maudsley Hospital to estimate the variance for 
genetic and environmental contribution to liability to schizophrenia, demonstrated 
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that 83% of the variance in the liability to schizophrenia was due to genetic effects 
(Cannon et al., 1998; Cardno et al., 1999).   
 In other studies, the heritability for schizophrenia has been variously calculated as 
between 66% and 85% (Cardno, et al. 1999). Its mode of transmission is still unclear 
but most likely to be polygenic and non-Mendelian (Owen and Cardno, 1999). 
1.5.5c   Adoption Studies 
In order to further examine the contribution of genes and environment in the 
transmission of schizophrenia, Kety et al. (1976) carried out a study among biological 
and adoptive children (Kety et al., 1976). Almost 20% of adoptees with a biological 
parent with schizophrenia developed a schizophrenia spectrum illness themselves, 
compared to 5.8% of adoptees with healthy biological fathers (Kety et al., 1976). In 
1981 Kendler et al. confirmed this finding using operational criteria, providing a 
strong evidence for a genetic component to schizophrenia (Kendler et al., 1981). 
Thus, shared genes rather than shared environments seem to explain the increased 
risk in biological relatives of schizophrenia probands (Owen et al., 2004).  
1.5.5d   Molecular Genetic Studies 
Hypothesis-driven candidate gene studies have been a key approach to the genetics of 
schizophrenia; since 1965 more than 1700 studies, 150 published each year, and 1008 
different genes have been tested so far for association (Allen et a., 2008; Collins et 
al., 2011). 
Those studies target genes selected on the basis of plausible pathophysiology (i.e. 
schizophrenia as a synaptic or a neurodevelopmental disorder) or suggested by a 
linkage study (Cichon et al., 2009). In the last decade, they have contributed to a list 




TABLE 1.1   Top 30 Genetic Loci With at Least One Nominally Significant Meta-Analysis 
Result. Adapted from SZGene, last update 2011.  
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The most well known genetic variants associated with schizophrenia have included 
genes such as NRG1 (Neuregulin 1), DTNBP1 (Dystrobrevin-Binding Protein 1) and 
DISC1 (Disrupted in Schizophrenia 1) involved in the regulation of 
neurodevelopmental processes, or genes such as COMT (Catecol-O-Metil-
Trasferasi), DAT1 (Dopamine Transporter), BDNF (Brain-Derived Neurotrophic 
Factor) and others involved in the regulation of the dopamine system (Harrison and 
Owen, 2003).  
So far only a few studies have shown similar results between each other and 
according to a meta-analysis done by Allen et al. (2008), four genes, namely 
Dopamine Receptor D1 (DRD1), DTNBP1, Methylenetetrahydrofolate Reductase 
(MTHFR) and Tryptophan Hydroxylase (TPH) seemed to be the best candidate genes 
in increasing the risk for schizophrenia (Allen et al., 2008).  
1.5.5e   Genome-wide Association Studies 
Up to 5 years ago genetic studies could only investigate an extremely small 
proportion of the genome, but now genotyping and cost improvements permit us to 
conduct studies as Genome-wide association studies (GWAS), equipped to assess a 
million genetic variants in huge sample (Stone et al., The International Schizophrenia 
Consortium, 2008). Since 2008 more than ten GWAS for schizophrenia have been 




TABLE 1.2   Genome-Wide Association Studies. Adapted from SZGene, last update 2010. 
 
Unfortunately, reports suggesting particular candidate genes as risk factors of 
schizophrenia have not been consistently replicated or confirmed by GWAS. Collins 
et al. (2011) compared the top 5% genes listed in SzGene (Allen et al. 2008) with the 
largest schizophrenia GWAS published to date (Stone et al., The International 
Schizophrenia Consortium, 2008; Purcell et al. 2009) looking for an overlap between 
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the two tpyes of studies. They found no evidence for over-representation between the 
best findings from GWAS and the results driven from the “first generation” candidate 
genes studies (Collins et al., 2011). They also demonstrated that poor choices of 
candidate genes or inadequate assessment (i.e. small samples or incomplete coverage 
of common genetic variation) could possibly play a role for inconsistent or confusing 
results (Collins et al., 2011).  
Nevertheless the large GWAS collaborations have demonstrated that the strength of 
the association between individual genes and psychiatric disorders is weak and often 
non-specific.  
More recently, in a joint analysis with a bipolar disorder sample, a GWAS identified 
8 new schizophrenia loci (Schizophrenia Psychiatric Genome-Wide Association 
Study (GWAS) Consortium, 2011) (FIGURE 1.6).  
 
FIGURE 1.6   Top Genome-Wide Association Results for Schizophrenia. Taken from The 
Schizophrenia Psychiatric GWAS Consortium, 2011!
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The strongest new finding was with rs1625579 within an intron of a putative primary 
transcript for MIR137 (microRNA 137). Four other schizophrenia loci (TCF4, 
CACNA1C, CSMD1 and C10orf26) contained predicted targets of MIR137, 
suggesting MIR137-mediated dysregulation as a previously unknown etiologic 
mechanism in schizophrenia (GWAS, 2011). 
Moreover these results, together with previously published data, suggest that the 
genetic susceptibility to bipolar disorder and schizophrenia partially overlaps and is 
likely to be mediated by several common genetic variants of small effect rather than 
by a single rare gene mutation (Sullivan et al., 2008; Kirov et al., 2009). 
1.5.5f   Rare Structural Variants 
Another approach to studying the genetic contribution to psychosis is to examine rare 
structural variants. Recent findings have established that both rare mutations of large 
effect and common variants of modest effect contribute to genetic risk for 
schizophrenia (Sebat et al., 2009) (FIGURE 1.7).  
 
 
FIGURE 1.7   Genomic Regions Implicated by Rare Structural Variants in Schizophrenia. Taken 
from Sebat et al., 2009. 
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Walsh et al. (2008) found that novel deletions and duplications of genes were present 
in 5% of controls compared with 15% of schizophrenic patients and 25% of subjects 
with early-onset schizophrenia (Walsh et al., 2008).  Moreover subjects with 
schizophrenia were 1.15 times more likely to have a higher frequency of copy number 
variants (CNVs) than controls (Stone et al., The International Schizophrenia 
Consortium, 2008).  
The best-supported loci are deletions at 1q21, 2p53, 3q29, 15p11.2, 15q11.3, 17q12, 
22q11.2 and Neurexin 1 (NRXN1), and duplications at 7q36.3, 25q11–13, 16p11.2 
and 16p13.1 (Rapoport et al., 2012). The majority of genes identified are important 
for brain development, including synaptic long-term transmission, NRG signaling, 
axonal guidance, and integrin signalling (Fatemi et al., 2009).  
Mutations at 16p11.2 confer high risk for schizophrenia and for other 
neuropsychiatric disorders, and at the same time, duplication of this region, confers 
substantial risk to the individuals who carry it (McCarthy et al, 2009). In addition, 
16p11.2 microdeletion both predisposes to neuropsychiatric phenotypes as a single 
event and exacerbates neurodevelopmental phenotypes in association with other large 
deletions or duplications (Girirajan et al., 2010). Therefore a ‘two-hit’ model has been 
proposed, where the ‘second hit’ could be another CNV, a disruptive single base pair 
mutation, or an environmental event influencing the phenotype (Girirajan et al., 
2010).  
In conclusion, although GWAS have identified a substantial number of 
polymorphisms associated with schizophrenia, these findings are characterized by 
small effect sizes (Pidsley and Mill, 2011). It is unlikely that common genetic 
variants cumulatively account for all the population variance in risk for psychosis 
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(O’Donovan et al., 2009). CNVs have also been implicated, but these de novo events 
are extremely rare and only found in a small number of patients (Merikangas et al., 
2009). Thus, the genetics of psychosis seems to comprise the cumulative effects of a 
large number of genes of small effects in the majority of cases plus the effects of 
CNVs in minority of cases. Moreover, it is likely that the effect of genes on the 
disease causal path might partly depend on environmental exposures. 
 
 
1.6     Summary 
Characterized by hallucinations, delusions and thought disorder, schizophrenia is the 
most severe of the functional psychotic disorders. In recent years much evidence has 
suggested that multiple factors seem to be involved in the development of the illness: 
liability to psychosis in general, and to schizophrenia in particular, involves genetic 
predisposition which is then compounded by exposure to a range of environmental 
factors including neonatal hypoxia, urbanicity, migration, and certain types of social 
adversity (Stilo and Murray, 2011).  
Genetic and environmental factors and their interaction seem to be one of the most 








Early Environmental Hazards 
 
 
2.1 Prenatal Risk Factors for Schizophrenia 
Over the past three decades much research effort has focused on the identification of 
prenatal risk factors for schizophrenia.  These factors include winter birth, parental 




FIGURE 2.1   Pre- and Peri-natal Factors for Schizophrenia. Taken from Sullivan, 2005. 
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2.1.1     Time and Place of Birth 
2.1.1a   Season of Birth 
Reported for the first time in 1929, winter birth is one of the most firmly established 
environmental risk factors for schizophrenia (Tramer, 1929). Compared to the general 
population, schizophrenic patients show an excess of birth in winter and early spring 
of 5%- 8% (Torrey et al., 1997). This has been observed more consistently in the 
northern hemisphere (Hare, 1975; Kendell and Adams, 1991; Mortensen et al., 1999) 
possibly because of little variation in seasonal temperatures found in equatorial 
regions and because relatively few studies have been carried out in the southern 
hemisphere (King et al., 2010). There could be differential fertility and seasonal 
patterns of procreation in the parents of individuals with schizophrenia (Hare, 1976; 
Suvisaari et al., 2001). Seasonally fluctuating factors have also been suggested 
including nutrition, hormones, maternal exposure to viral infections (Torrey et al., 
1997), and certain meteorological factors (e.g., sunlight exposure and vitamin D, 
temperature, or severe weather) (Susser et al., 1996; Cannon et al., 2003; reviewed by 
Tochigi et al., 2004). 
2.1.1b   Urbanicity 
It has been known for many years that living in urban areas increases the risk of 
psychosis at least 2 fold (Faris and Dunham, 1939; Hare, 1956; Lewis et al., 1992; 
Marcelis et al., 1998). This has been interpreted in terms of socio -economic and 
behavioural factors such as stress, anonymous lifestyle (Hare, 1955; Ventura et al., 
1989; Malla et al., 1990; Castle et al., 1993; Thornicroft et al., 1993) or due to the 
greater exposure to chemical factors and infections (Brown et al., 2000; Torrey et al., 
2001). Lewis et al. in 1992 and then Pedersen in 2001 showed that larger the town 
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and longer the individual has lived in the city, the greater the risk (Lewis et al., 1992; 
Pedersen and Mortensen, 2001).  Some have pointed out the possible role played by 
“neighborhood social capital”, understood as a set of characteristics of the social 
structure in which the subject lives (McKenzie et al., 2002). McKenzie et al. (2002) 
claimed that the absence or lack of proper “neighborhood social capital” can 
participate significantly in the development of psychosis (McKenzie et al., 2002). In 
2006, the Aetiology and Ethnicity of Schizophrenia and Other Psychoses (AESOP) 
study demonstrated that even within one city there were wide variation in rates and 
the highest rates were found in the area with least social cohesion (Fearon et al., 
2006; Kirkbride et al., 2006). 
2.1.1c   Immigration 
Ethnic factors are responsible for discrepancies in incidence inside the same country; 
some immigrant populations, such as African-Caribbeans in the UK (Harrison et al., 
1997) and the Surinamese in the Netherlands (Selten et al., 1997) show higher 
incidence rates of schizophrenia, with a meta-analysis showing a mean weighted 
relative risk among migrants (first and second generation) of 2.7 (95% CI 2.3-3.2) 
(Cantor-Graae and Selten, 2005). 
This is true not only in immigrants, but also in the children of immigrants born in 
these countries (Boydell et al., 2003). Selective migration, obstetric complications, 
neurological diseases, previous infections, and substance abuse have been 
hypothesized to be the cause (Boydell et al., 2003).  Other studies have also pointed 
out that the immigration is a possible risk factor for being more often on the margins 
of social life and more easily exposed to stressful situations and also the subject of 
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racial discrimination (Hutchinson et al., 1999). This, in susceptible individuals, could 
result in a greater chance of developing paranoid attitudes (van Os et al., 2002). 
2.1.2     Parental Age at Birth 
Advanced parental age has been cited as a risk factor for schizophrenia among 
offspring for more than half a century (Barry, 1945; Johanson, 1958; El-Saadi et al., 
2004) (FIGURE 2.2).  
 
FIGURE 2.2   Odds Ratios for Psychotic Disorders for Parental Age. Taken from Lopez-
Castroman et al., 2010. 
2.1.2a   Paternal Age 
Back in 1958 Johanson reported an association between paternal age and 
schizophrenia (Johanson, 1958).  Since then other studies have replicated the same 
finding (Hare and Moran, 1979; Raschka, 1998; Malaspina et al, 2001; Brown et al, 
2002; Dalman and Allebeck, 2002; Zammit et al., 2003). Children of fathers over 45 
years of age have a doubled relative risk (RR=2.02; 95% CI, 1.17-3.51) to develop 
schizophrenia than children of younger fathers (Malaspina, et al. 2001; Sipos and 
Rasmussen, 2004). 
Advanced paternal age has been associated with major congenital malformation 
syndromes and isolated birth defects known to be caused by autosomal dominant 
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mutations (Brown et al., 2002). It is still controversial what causes such association. 
One possibility proposed by Penrose was the “copy error” hypothesis as a mechanism 
underlying these congenital anomalies (Penrose, 1955). After puberty, spermatocytes 
divide every 16 days; de novo genetic mutations resulting from replication errors and 
defective DNA repair mechanisms are believed to propagate in successive clones of 
spermatocytes; as a result de-novo mutations increasing the risk of schizophrenia are 
more likely to occur (Malaspina, 2001; Byrne et al., 2003) in aging sperm. However, 
in paper by Petersen et al. (2011) showed that the association between paternal age 
and risk of schizophrenia was accounted for by the father’s greater age when his first 
child was born, and not by the father’s age when later children were conceived; such 
results do not support the de-novo mutation hypothesis but raise the possibility of 
fathers marrying late because of some personality characteristic (Petersen et al., 
2011).  
More recent Miller et al. (2011) found a significant increase in risk of schizophrenia 
in the offspring of fathers older than 30 years of age, but they also found a significant 
increase in risk of schizophrenia in the offspring of younger fathers (<25 years of 
age) (Miller et al., 2011). 
2.1.2b   Maternal Age 
The literature on perinatal complications supports an independent role for maternal 
age in increasing risk of psychotic disorders (McNeil, 1995; Cantor-Graae et al., 
1997; Preti et al., 2000). Recently Lopez- Castroman et al. (2010) found a positive 
linear increase in risk for psychotic disorders both with maternal and paternal age, but 
the correlation was only significant for increasing maternal age (Lopez-Castroman et 
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al., 2010). Late maternal age (>34 years) tends to increase the risk of schizophrenia 
due to higher maternal morbidity for obstetric complications (Ekeus et al., 2006). 
Advanced maternal age is a risk factor for antepartum haemorrhage, abnormalities of 
placentation, and certain types of chromosomal anomalies (Turnbull and 
Chamberlain, 1989).  Obstetric complications are also common in younger mothers 
(<20 years) (Cantor- Graae et al., 1997); a younger age confers an increased risk of 
adverse pregnancy outcomes such as delivering low-birth weight, premature, and 
small-for-gestational-age infants (Fraser et al., 1995; Ip et al., 2010). Moreover the 
risk of anaemia during pregnancy increases significantly with lower maternal age 
(Jolly et al., 2000; Menacker et al., 2004; Conde-Agudelo et al., 2005; de Vienne et 
al., 2009). In 2004 El-Saadi et al. used data from three sources examining psychosis: 
a population-based cohort study (Denmark), and two case-control studies (Sweden 
and Australia) (El-Saadi et al., 2004). Looking at the association between maternal 
age and risk of psychosis, they found that when adjusted for paternal age, the Danish 
study (cohort study) showed that the offspring of younger mothers had a small but 
significant increased risk of psychosis (RR = 1.12) (El-Saadi et al., 2004). The two 
case-control studies both found the highest Odds Ratio for psychosis in younger 
mothers; however this was not statistically significant (El-Saadi et al., 2004). The 
offspring of younger mothers are at increased risk of developing psychosis possibly 
because such women are more likely to suffer obstetric complications, well known to 
be involved in increasing the risk of schizophrenia (Cannon et al., 2002). The 
literature on OCs suggests an independent role for maternal age in increasing the risk 
of psychotic disorders (Preti et al., 2000), and early-onset schizophrenia (Byrne et al., 
2007).  
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2.1.3   Maternal Infection 
Epidemiological studies linked influenza epidemics to an increase in population 
levels of schizophrenia (Mednick, 1988) mainly if occurring during the 2nd trimester 
of pregnancy, particularly the 5th or 6th month (McGrath et al., 1994; Wright et al., 
1999). Late in 2004 Brown et al. found that the risk for schizophrenia increased 7 fold 
if the infection occurred in the 1st trimester and prenatal exposure to influenza 
accounted for 14% of all schizophrenia cases (Brown et al, 2004). Prenatal infections 
that have been repetedly associated with schizophrenia include toxoplasmosis (2.6-
fold increase), influenza (3-fold increase), or genital or reproductive infection (5-fold 
increase) (Brown and Derkits, 2010). Proposed mechanisms include the direct effects 
of the pathogen on the fetal brain, maternal immune reaction, fever, stress, and use of 
analgesics and anti-inflammatory drugs (Boksa, 2008).   
2.1.4     Other Risk Factors  
2.1.4a   Maternal Nutrition 
Both under eating and overeating during pregnancy may increase schizophrenia risk 
in the offspring (King et al., 2010). Epidemiological studies show a twofold increase 
in risk for schizophrenia among individuals who were exposed to famine in their first 
trimester of gestation (Susser and Lin, 1992; Susser and Lin, 1994). It has been 
suggested that nutritional insufficiencies (e.g., folic acid, essential fatty acids, iron, 
vitamin A) increase the risk of spontaneous genetic mutations and/or disrupt proper 
neurodevelopment, ultimately resulting in schizophrenia (King et al., 2010). 
Additionally, high maternal pre and early pregnancy body mass index (BMI) is 
associated with a 2.8-fold increase in risk for schizophrenia in offspring (Schaefer et 
al., 2000). This it may be explained by metabolic problems (e.g., diabetes), dietary 
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restrictions, or poor maternal care, all of which may affect neurodevelopment and/or 
increase the risk of obstetric complications (King et al., 2010). 
2.1.4b   Maternal Stress 
Stressful events occurring during pregnancy are claimed to result in increased risk for 
schizophrenia for the offspring later in adulthood (King et al., 2010). The stressors 
studied to date have ranged from military invasion (Van Os and Selten, 1998) to 
tornados (Kinney et al., 1999) to personal loss (Huttenen and Niskanen, 1978), 
unwanted pregnancy (Myhrman et al., 1996) and maternal depression during 
pregnancy (Jones et al., 1998). In 1978 Huttenen and Niskanen (1978) showed a 
significant increase in risk in individuals whose fathers had died while they were in 
utero compared with those whose father died during their first year of life (Huttenen 
and Niskanen, 1978). More recently, a study concluded that the death of a close 
relative during the first trimester of pregnancy increases risk for schizophrenia in the 
child by 67% (Khashan et al., 2008). 
Animal studies demonstrate that externally generated stressors to the pregnant female 
(i.e. loud noise, social isolation, or pain) result in a surge of stress hormones passing 
through the placenta to the fetus (Beydoun and Saftlas, 2008). These changes in 
maternal hormones result in permanent changes to parts of the fetal brain that are 
associated with schizophrenia (King et al., 2010). Prenatal stress may increase risk for 
schizophrenia directly, by influencing brain development, or indirectly, by increasing 
the likelihood of other risk factors such as obstetric complications (Beydoun and 




2.2     Obstetric Complications  
Obstetric complications are among the best documented environmental risk factors 
for schizophrenia. This term is used to cover both pre- and perinatal adverse events. 
OCs occur in approximately 25-30% of the general population (Cannon et al., 2002) 
(FIGURE 2.3).   
 
 
FIGURE 2.3   Meta-Analysis of Eight Prospective Population-Based Studies of the Association 
Between Obstetric Complications and Schizophrenia. Taken from Cannon et al., 2002. 
 
An association between OCs and schizophrenia was first mentioned in 1934. 
Rosanoff et al. (1934) in “The Etiology of So-Called Schizophrenic Psychoses” 
suggested that schizophrenia could be regarded at least in part as a “decerebration 
syndrome which may result from birth trauma” (Rosanoff et al., 1934). Since then, 
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according to Cannon et al. (2002), research into OCs as a risk factor for schizophrenia 
has gone through different phases (Cannon et al., 2002). Following the time line 
proposed by Cannon et al. (2002), surprisingly it was not until several decades later 
that first reports of significant association between prematurity, toxaemia, bleeding, 
and maternal illness were published (Terris et al., 1964). In the early ‘50s it had been 
noted that complications of pregnancy and delivery as well as prematurity were 
associated with brain injury resulting in death of the baby. Depending upon the 
severity, type, and localization of damage, Pasamanick et al. (1956) proposed that 
children who were not killed by their traumatic experiences could have developed 
various sequel of brain injury as a “continuum of reproductive casualty” (Pasamanick 
et al., 1956). 
 In 1966 attention shifted to the weight at birth when Lane and Albee reported a 
significant correlation between low weight at birth (<2500 g) and schizophrenia 
(Lane et al., 1966). There appeared to be a “shift in distribution” of birth weight 
within a population of cases compared with controls (Cannon et al., 2002). In 1987, 
Lewis and Murray did a case-control study finding that patients with schizophrenia 
were more likely to have a history of OCs than patients with other psychiatric 
disorders (Lewis and Murray, 1987). They introduced the “Lewis-Murray” scale for 
rating retrospective information on OCs (Lewis et al., 1989). To examine specific 
complications, in 1999 Geddes et al. conduced a meta-analysis on 12 case-control 
studies that had used the Lewis-Murray scale.  They found that the following OCs 
were significantly associated with schizophrenia: premature rupture of membranes, 
prematurity, use of resuscitation or incubator, birth weight <2500 g, pre-eclampsia, 
and forceps delivery (Geddes et al., 1999). 
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Thus, the risk of developing schizophrenia is increased in individuals who were 
exposed to various complications during pregnancy. Cannon et al. (2002) concluded 
that there are three major categories of complications: (a) complications of pregnancy 
(bleeding, preeclampsia, diabetes and rhesus incompatibility), (b) abnormal fetal 
growth and development (low birth weight, congenital malformations and small head 
circumference), and (c) delivery complications (asphyxia, uterine atony and 
emergency caesarean sections) (Cannon et al., 2002). Many obstetric complications 
seem to compromise neurodevelopment inducing the oxygen deprivation (Hypoxia) 
in the foetus (McGrath and Murray, 2003).  
Recent epidemiological studies further document the relationship between obstetric 
complications and psychosis-like symptoms or deficit in cognitive function (Zammit 
et al., 2009) and fetal hypoxia has been proposed as a common denominator for most 
of these pre- and perinatal events (van Os et al., 2010). 
Perinatal hypoxia models in rats and mice have revealed several behavioral, 
pharmacological, neurochemical and neuroanatomical abnormalities in adulthood 
with relevance to schizophrenia (Brake et al., 1997; Brake et al., 2000; El-Khodor and 
Boksa, 2000; Wakuda et al., 2008). Rat models of perinatal hypoxia include (1) 
unilateral carotid artery ligation combined with exposure to a hypoxic atmosphere in 
the postnatal rat (Rice et al., 1981) (2) exposure of rat pups to global anoxia during a 
Caesarean-section (C-Section) birth, by immersion of the isolated intact uterus into a 
saline bath (Bjelke et al., 1991) and (3) exposure of postnatal rats to anoxic or 
hypoxic atmospheres (Boksa, 2004). In rats C-section birth alone is sufficient insult 
to produce long-term enhancement of AMPH-induced locomotor responses, in 
comparison to vaginal birth (Boksa and El-Khodor, 2003).  
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2.3   Summary 
There is no doubt a strong genetic component to schizophrenia. However it is now 
clear that neither environmental risk factors nor candidate genes alone play a 
necessary or sufficient role in the onset of psychosis. Different varieties of 
environmental insults can act early, during the most critical phase of the formation of 
the CNS, but also later in childhood or adolescence, in an individual genetically 
vulnerable (Murray et al., 2002). The neurodevelopmental impairment resulting 



















Genetic Predisposition and Environmental Risk Factors 
 
 
3.1     Gene X Environment Interaction 
Back in 1986 Carpenter suggested that schizophrenia is an illness that requires the 
development of a vulnerable personality resulting from the combination of genetic 
and environmental influences (Carpenter, 1986). The mode of transmission is most 
likely complex and non-Mendelian (Owen and Cardno, 1999). We now know that the 
heritability of schizophrenia is approximately 80% (Cannon et al., 1998; Cardno et 
al., 1999). However, concordance between MZ twins (almost 50%) not only provides 
strong evidence for the involvement of genes but also raise the question of what other 
factors may be involved in the aetiology of schizophrenia (Cardno et al., 1999). The 
stress-vulnerability model suggests that genetic sensitivity to adverse environmental 
circumstances explains why some individuals are more likely to develop symptoms 
when exposed to specific environmental factors than others (Zubin and Spring, 1977). 
Biological interaction refers to a casual mechanism in which two casual factors (e.g., 
a genetic variant and environmental exposure) contribute to an outcome (e.g., mental 
illness) but neither of them is a sufficient cause in itself (Rothman et al., 2008; Uher, 
2011). Thus, a genetically transmitted predisposition to schizophrenia is a condition 
necessary but not sufficient for the development of the disease; for this to happen the 
individual must be exposed to the action of environmental stimuli. Thus, one does not 
inherit the disease itself but a greater susceptibility to it.  
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In statistical terms, as defined by Greenland et al. (2009), a Gene x Environment 
(GxE) interaction occurs when: “the risk of disease if exposed to both the gene (G) 
and the environmental exposure (E) is significantly different from that predicted by 
the statistical model being used” (Greenland, 2009). 
In GxE studies, a family history for the outcome illness has been often used as a 
proxy variable for the genetic risk. Now schizophrenia research is moving toward 
studies that consider direct molecular genetic information to explain how various risk 
factors work together to increase risk of the illness. 
3.1.1   MAOA x Child Maltreatment 
The first important GxE findings in psychiatry came from the Dunedin 
Multidisciplinary Health and Development Study also known as the Dunedin study 
(Caspi et al., 2002). The Dunedin Study comprises 1037 babies born in Dunedin, 
New Zealand between 1 April 1972 and 31 March 1973 at the Queen Mary Maternity 
Hospital. Numerous measures of exposure to environmental risks factor were 
collected along with DNA samples at several follow-up points. The babies were first 
followed up at the age of 3, and then at 5, 7, 9, 11, 13, 15, 18, 21, 26 and 32.  The 
investigators examined if a functional polymorphism in the promoter region of the 
gene encoding the neurotransmitter-metabolizing enzyme monoamine oxidase A 
(MAOA) would increase the likelihood of violent behavior in maltreated children. 
The first Dunedin cohort findings showed that maltreated children, carrying the 
genotype coding for the low-activity MAOA enzyme, were more likely to develop 
conduct disorder, antisocial personality and adult violent crime than children carrying 
the genotype for the high-activity MAOA enzyme (Caspi et al., 2002).  An important 
replication of these findings was published in 2006 (Kim-Cohen et al., 2006). In a 
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cohort of 975 seven year old children they found that among those with a history of 
physical maltreatment, boys carrying the low-activity MAOA allele had significantly 
higher mental health problems compared to high- activity MAOA (Kim-Cohen et al., 
2006). This finding suggests that maltreatment early in life might increase risk of the 
development of psychopathology conditionally to the child’s MAOA genotype and 
ultimately to the enzyme functioning. Recently Fergusson et al. (2011) attempted to 
replicate the GxE interaction effects between MAOA, childhood maltreatment and 
the development of antisocial behaviour.  Their findings add to the evidence 
suggesting that there is a stable GxE interaction involving MAOA, abuse exposure 
and antisocial behaviour across the life course (Fergusson et al., 2011). 
3.1.2   HTTLPR X Stress 
The first report testing the interaction between the serotonin transporter gene 
promoter region (5- HTTLPR) and stress on the risk of depression came in the 
1990’s; individuals carrying one or two copies of the 5- HTTLPR short allele had 
higher personality traits linked to propensity to depression (Lesch, et al., 1996).  But 
it was not until 2003 that the Dunedin study published the first evidence suggesting a 
GXE interaction between 5- HTTLPR and stress (Caspi et al., 2003). Carriers of the 
5- HTTLPR short allele were more likely to develop depression following stressful 
life events compared to individuals with two copies of the ‘long’ allele (Caspi et al., 
2003).  
The Dunedin findings on the 5- HTTLPR generated a huge interest in GXE research 
and over 50 studies followed attempting to replicate this interaction. Ten of these 
replication studies were analyzed in a meta-analysis done by Risch et al. (2009). They 
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concluded there were no convincing evidences of a 5- HTTLPR genotype x Stress 
interaction on the risk of depression (Risch et al., 2009). 
In contrast, a more recent meta-analyses on 54 studies confirmed once again  
evidence of the 5-HTTLPR genotype x Stress interaction on depression showing how 
the quality of the studies included in a meta-analysis could influence the direction of 
its results (Karg et al., 2011). Indeed they investigated whether different measures of 
exposure to stress across studies could affect the overall result leading to contrasting 
finding among meta-analysis. Studies using self-report questionnaire (p=0.042) 
showed less striking results when compared to the ones using objective measures 
(p=0.000003) and interview assessment (p=0.0002). 
This may explain why in the meta- analysis done by Risch et al. (2009), in which 
most of studies included used self report measures of exposure to stress, the 
association was not significant (Risch et al., 2009).   
3.1.3   COMT x Stress 
In line with this strategy, Stefanis et al. (2007) investigated how exposure to stress 
could lead to psychosis due to different genetic make up (Stefanis et al., 2007).  
Dopamine plays an important role in the biological processes that mediate stress 
responses (Adler et al., 2000). A popular candidate gene in psychiatric genetics is 
COMT, which codes for the enzyme that catabolizes dopamine, norepinephrine and 
epinephrine in the prefrontal cortex. The COMT gene contains a G to A missense 
polymorphism that generates a valine (Val) to methionine (Met) substitution at the 
codon 158 (Val 158 Met). This results in a different pattern of enzymatic activity with 
COMT Val-Val carriers having the greater activity with a consequent faster break 
down of dopamine in the prefrontal cortex. 
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Stefanis et al. (2007) tested whether exposure to stress was associated with an 
increased risk of psychotic symptoms in interaction with a particular polymorphism 
in COMT genotype (Stefanis et al., 2007); carriers of the COMT Val allele were more 
likely to report psychotic symptoms following a stressful event compared to those 
with COMT Met/Met genotype (Stefanis et al., 2007). Thus, it is very likely that the 
effect of environment might be influenced by the interaction with several genetic 
variants as a risk factor for psychosis.  
3.1.4   Genes X Cannabis 
3.1.4a   COMT x Cannabis 
The role of COMT in the breakdown of dopamine and the evidence suggesting that 
exposure to the cannabis active ingredient, D9-THC, affects striatal dopamine 
transmission, made COMT and cannabis plausible candidates for a GxE model of 
liability to psychotic disorders. 
Once more the Dunedin Study showed a GxE interaction between environment and 
genes: in adolescent cannabis users the risk of developing psychosis later in life was 
moderated by the functional polymorphism in COMT gene (Caspi et al., 2005). This 
association showed an increased risk of psychosis of around 10-fold in the COMT 
Val-Val carriers who had used cannabis. Indeed, Cannabis users carrying the COMT 
Val allele were more likely to develop psychotic symptoms compare to the ones 
carrying two copies of the COMT Met allele. In line with this finding in 2009 
Henquet et al. showed that COMT Val Val genotype were significantly more likely to 
experience hallucinations than those with COMT Met-Met following cannabis use 
(Henquet et al., 2009).  
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However, other studies have failed to support this finding (Zammit et al., 2007; 
Costas et al., 2011; van Winkel, 2011). One of the first attempts to replicate the above 
findings came from Zammit et al. in 2007. They investigated if the individual risk of 
psychotic disorders was conditional on the genotype of COMT and another plausible 
candidate gene Cannabinoid Receptor Gene 1 (CNR1). They fail to show any 
evidence for a differential effect of cannabis use on psychosis risk according to 
variation in either of the genes (Zammit et al., 2007). But it was not until 2011 that 
Zammit et al. were able to replicate the Dunedin study on the relationship between 
cannabis and COMT as originally described.  Once again they didn’t report any 
association between any of the COMT single-nucleotide polymorphisms (SNPs) or 
haplotypes examined and cannabis use in the onset of psychosis; Cannabis increased 
risk of psychosis irrespective of underlying COMT genotypes (Zammit et al., 2011).  
In conclusion, results from the Dunedin study found no evidence that risk of 
psychosis was increased by cannabis use in individuals who were methionine 
homozygotes while Zammit et al. (2011) indicate that cannabis use is likely to 
increase the risk of individuals developing psychotic experiences irrespective of 
underlying COMT genotypes (Zammit et al., 2011). It would then be incorrect to 
state that methionine homozygotes can use cannabis with impunity in relation to risk 
of psychosis (Zammit et al., 2011).  
3.1.4b   BDNF x Cannabis 
Some studies have also suggested interactions between cannabinoids and BDNF, with 
increased levels of serum BDNF in humans following injection of Delta-9-TCH 
(Jockers-Scherubl et al., 2004). 
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Van Winkel et al. (2009) showed that psychotic patients who were BDNF Met-
carriers were significantly more likely to have smoked cannabis in adolescence (van 
Winkel et al, 2009). They tested for an interaction between BDNF, Cannabis use and 
seven polymorphisms of the COMT gene on risk of schizophrenia.  Four of these 
polymorphisms constitute its three common functional haplotypes, named after their 
capacity to influence sensitivity to experimental pain: low pain sensitivity (LPS) 
haplotype, associated with the highest COMT enzymatic activity, the high pain 
sensitivity (HPS) haplotype, associated with an 18-fold lower enzyme activity 
compared to LPS and finally the average pain sensitivity (APS) haplotype, associated 
with intermediate enzymatic activity.  
They found that the effect of BDNF Met was greater for COMT non-LPS 
homozygotes, and the effect of COMT LPS homozygosity was greater for BDNF 
Val/Val carriers suggesting that that both these genetic variants play a role in the 
developing brain sensitivity to cannabis (van Winkel et al, 2009).  These complex 
findings require replication.  
3.1.4c   AKT1 x Cannabis 
More recently the V-Akt Murine Thymoma Viral Oncogene Homolog 1 (AKT1) gene 
has become an attractive candidate to be tested for an interaction with cannabis use on 
psychotic disorders. AKT1 gene codes for a protein kinase (Protein kinase 
B, PKB), that forms an integral part of a signaling cascade mediating transmission of 
striatal dopamine. Moreover, cannabinoids are able to activate the AKT1 pathway by 
acting on Cannabinoid receptors 1 and 2 (CB1 and CB2).  
In a study of 740 unaffected siblings of 801 patients with psychosis and 419 controls, 
van Winkel et al. (2011) examined the interactions between cannabis use and 152 
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single-nucleotide polymorphisms in 42 genes, including two polymorphisms of the 
AKT1 gene (rs2494732 and rs1130233) (van Winkel et al., 2011). Among those who 
used cannabis, carriers of the AKT1 rs2494732 C/C genotype had a significant two 
fold increased risk of schizophrenia compared to the AKT1 rs2494732 T/T carriers. 
Most recently, Di Forti et al. (2012) confirmed that the AKT1 genotype influences the 
risk of psychosis in cannabis users (Di Forti et al., 2012). 
 
 
3.2     Genes x Obstetric Complications 
The OCs I have discussed in the previous chapter explain a small, but significant, 
increase in risk for schizophrenia (Cannon et al., 2002).  
For several labour and delivery complications associated with increased incidence of 
schizophrenia, perinatal hypoxia is highly likely to be a common factor and the 
incidence of schizophrenia increases linearly with the number of hypoxia-associated 
birth complications (Cannon et al., 2000).  Back in 1968 the Copenhagen High-Risk 
Study, examining the characteristics of a group of offspring of schizophrenic parents, 
found that the “high-risk” children who were psychiatrically ill by their early 20s 
were more likely to have suffered one or more serious OCs than the comparison 
group (Mednick and Schulsinger, 1968). Mednick’s explanation was that people with 
genetic predisposition would become schizophrenic only if the hippocampus was 
selectively injured by anoxia at birth (Mednick, 1970). The hippocampus is especially 
sensitive to hypoxic injury. There have been several findings of hippocampal 
abnormalities in individuals with schizophrenia particularly in those who experienced 
OCs (Stefanis et al., 1999; van Erp et al., 2002). It has therefore been hypothesized 
! 82 
that hypoxia in the prenatal and perinatal period contributes to the 
neurodevelopmental alterations that later in life are involved in the onset of 
schizophrenia (Buka et al., 1993; Zornberg et al., 2000; Dalman et al., 2001; Van Erp 
et al., 2002; Murray et al., 2004).  
A recent systematic review suggested that more than 50% of genes potentially 
associated with schizophrenia are subject to regulation by hypoxia and/or are 
expressed in the vasculature (Schmidt-Kastner et al., 2006; Schmidt-Kastner et al., 
2012). It seems that the hypoxic regulation of expression of some of these genes 
could be a potential key player in the aetiopathogenesis of schizophrenia.  Vice-versa, 
gene variants can also influence the reaction to hypoxia (Schmidt-Kastner et al., 
2012).  
In a sample of 116 family-trios (affected individuals and their unaffected parents), 
Nicodemus et al. (2008) examined 13 genes SNPs, known to regulate neurovascular 
processes (Nicodemus et al., 2008). Three SNPs of the AKT1 gene, two of BDNF 
gene, one of DTNBP1 and finally one of Glutamate Receptor Metabotropic 3 
(GRM3) gene showed evidence for a significant interaction with obstetric 
complications in increasing the risk of schizophrenia (LRT P-values ranged from 




FIGURE 3.1   Odds Ratios for Serious OCs and Minor Allele Carrier Status. Taken from 
Nicodemus et al., 2008 
 
All of these genes have been shown to play a neuroprotective role in response to 
hypoxic/ischemic insults during neurodevelopment so they could explain the toxic 
effect of obstetric complications on brain development (Nicodemus et al., 2008). Two 
other studies purported to confirm the significance of particular SNPs within the 
AKT1 locus (Joo et al., 2009); however the analyses in these two studies are obscure.  
More recent, Forsyth et al. (2012) using familial liability (family history of 
psychiatric illnesses) as a proxy measure of genetic risk, tested if this mediated the 
effect of OCs to affect development  (Forsyth et al., 2012). They hypothesized that 
the presence of OCs would differentially predict neurobehavioral outcomes in 
individuals at high risk (HR) for the illness (ie, having 1 or 2 parents with 
schizophrenia) vs those at low risk (LR; ie, having parents with no psychiatric 
illnesses). Early studies reported that OCs predicted motor impairments in HR 
individuals but not in LR individuals and they also interacted with genetic risk to 
predict ventricular enlargement (Cannon et al., 1989; Fish et al., 1992; Cannon et al., 
1993). Moreover Clarke et al. (2009) reported that siblings exposed to prenatal 
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infection had a 5-fold increased risk to schizophrenia in HR compared with LR 
offspring (Clarke et al., 2009).  
Forsyth et al. (2012) obtained data on OCs and school records in individuals born in 
Finland between January 2, 1987 and December 31, 1993 at HR vs LR for 
schizophrenia. This resulted in the identification of 373 HR offspring and 1070 LR 
offspring from 107 schools in the Helsinki area. Thus, they examined the interaction 
of Low Birth Weight (LBW) and hypoxia in relation to school outcome at 15–16 
years.  
HR offspring performed worse than LR offspring across academic, nonacademic, and 
physical education domains. LBW predicted poorer academic and physical education 
performance in HR offspring, but not in LR offspring. Hypoxia predicted poorer 
physical education score across risk groups. Rates of LBW and hypoxia were similar 
for LR and HR offspring.  
It is very likely that the effect of the OCs confers augmented vulnerability of the 
developing brain influenced by the interaction with several genetic variants. 
Therefore, although this study does not use a specific “biological plausible” 
polymorphism as a marker of genetic risk, its findings are suggestive of a gene x 
environment interaction between shared genes (familial liability) and the environment 
in influencing the risk of psychosis, possibly via epigenetic mechanisms. 
Results from several GWAS in schizophrenia show several interesting matches 
between genes and ischemia– hypoxia or vascular factors but unfortunately 
differences in design and data presentation in different GWAS studies preclude a 
quantitative analysis (Schmidt-Kastner et al., 2012).   
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Epigenetic regulation of gene expression (for example, through histone alterations, 
DNA methylation or microRNAs (miRNAs)) could possible explain the effects of 
pre-and perinatal exposure to hypoxia–ischemia on gene expression and aberrant 
neurodevelopmental processes (Schmidt-Kastner et al., 2012). In particular a recent 
GWAS study showed a significant association with miRNA137 and schizophrenia. 
Elevated levels of miRNAs were found in the prefrontal cortex of patients afflicted by 
schizophrenia and have been also documented to regulate the response to hypoxia.  
No studies have yet provided direct evidence for epigenetic mediation of hypoxia–
ischemia during pre- and perinatal life in schizophrenia so further research is 
warranted to identify direct links between hypoxia, epigenetic alterations and 
schizophrenia (Schmidt-Kastner et al., 2012). 
 
 
3.3     Summary 
There is no doubt a strong genetic component to schizophrenia. However twin studies 
have shown that simple genetic transmission is far from the whole story. Variability 
in people’s responses to environmental risk factors suggests that genes and 
environments operate together to produce psychosis. Liability to psychosis in general, 
and to schizophrenia in particular, is distributed though the general population in a 
similar continuous way to liability to medical disorders such as hypertension and 
diabetes. As with these disorders, some people show a high liability to the condition 
and as blood pressure can be increased by obesity, lack of exercise, and cigarette 
smoking, so exposure to a range of environmental factors including neonatal hypoxia, 
urbanicity, migration, and certain types of social adversity, can increase an 
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individual’s likelihood of expressing psychotic symptoms. Thus it appears that 
multiple genetic and environmental factors operate together to push individuals over a 
threshold into expressing the characteristic clinical picture (Tsuang et al., 2004; Di 























Epigenetics and Early Environmental Influences 
 
 
4.1     Introduction 
Despite sharing the same DNA sequence, the concordance rate between MZ twins for 
schizophrenia is estimated to be less than 50% (Gottesman, 1991). This could reflect 
environmentally or stochastically mediated epigenetic variation (Dempster et al., 
2013). Thus, recent research has raised the notion that epigenetic mechanisms are 
involved in the pathogenesis of schizophrenia and psychosis in general (Tsankova et 
al., 2007; Mill et al., 2008).  
Conrad Waddington first defined Epigenetics in 1940 as “…the interactions of genes 
with their environment which bring the phenotype into being” (Waddington, 1940).  
Epigenetics is the study of the changes in gene expression not encoded by the DNA 
sequence. These changes comprise molecular modifications to both DNA and 
chromatin, the most extensively investigated of which are DNA methylation and 
histone modifications (Jirtle and Skinner, 2007). Other epigenetic mechanisms of 
gene-expression control include regulation by microRNAs (miRNAs) and 
mechanisms that control the higher-level organization of chromatin within the 
nucleus (Jirtle and Skinner, 2007).  
Epigenetic modifications are essential for normal development and the maintenance 
of gene expression patterns in mammalian cells. In particular DNA methylation is 
involved in normal cellular control of expression, histone modifications control the 
accessibility of the chromatin and transcriptional activities inside a cell, and miRNAs 
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are small RNA molecules that can negatively control their target gene expression 
post-transcriptionally (Jirtle and Skinner, 2007).  
Importantly, epigenetic changes can be inherited mitotically in somatic cells, 
providing a potential mechanism by which environmental effects on the epigenome 
can have long-term effects on gene expression (Jirtle and Skinner, 2007).!In addition 
increasing evidence suggests that epigenetic alterations might also be inherited 
transgenerationally, thereby potentially affecting the health of future generations 
(Jirtle and Skinner, 2007). 
 
 
4.2    Epigenetic Studies on Psychosis 
Epigenetic processes are known to regulate key neurobiological and cognitive 
processes in the brain and, through regulation of gene expression, have been widely 
acclaimed as the “missing piece” of the etiological puzzle for complex disease such 
as schizophrenia (Dempster et al., 2013).  Some researchers have therefore suggested 
that schizophrenia may arise from alterations in how some genes are ‘‘turned on or 
off’’ due to exposure to nongenetic factors (Rutten and Mill, 2009).  
Initial studies were investigating methylation in candidate genes using postmortem 
brains and peripheral blood samples including genes involved in neurotransmitter 
systems, synaptic plasticity, oxidative stress and oligodendrocyte viability and 
myelination (reviewed by Pishva et al., 2014). Although these studies on candidate 
genes have provided important first insights into possible epigenetic dysregulation in 
the psychotic disorders were not always replicated (Labrie et al., 2012).  
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The first epigenome-wide study characterizing DNA methylation in major psychosis 
surveyed 12,000 GC-rich regions, including CpG islands, in the prefrontal cortex of 
the brain (Mill et al., 2008). This study identified several sites with significant 
epigenetic differences between affected individuals and controls, which contained 
genes involved in brain development and neurotransmitter pathways, particularly 
genes involved in glutamatergic and GABAergic neurotransmission, and which had 
previously been associated with major psychosis (Mill et al., 2008).  
Dempster et al. (2011) performed a genome-wide analysis of DNA methylation on 
peripheral blood DNA samples obtained from a MZ twin pairs discordant for major 
psychosis (Dempster et al., 2011). They found numerous disease-associated 
differences in DNA methylation, many located in the vicinity of genes previously 
implicated in psychosis, supporting the hypothesis that epigenetic alterations play an 
important role in the etiology of psychosis (Dempster et al., 2011). Overall, the top 
differentially methylated psychosis-associated site was located in the promoter region 
of the gene encoding alpha-N-acetylgalacto saminide alpha-2,6-sialyltransferase 1 
(ST6GALNAC1), which was hypomethylated in affected individuals compared with 
their unaffected co-twins (mean Δβ = 0.06, P= 4.03E − 04) (Dempster et al., 2011).  
Another methylome-wide association study of patients with schizophrenia and 
controls showed differentially methylated regions in the promoter region of several 
genes associated with schizophrenia, such as beta-1,3-glucuronyltransferase 2 
(B3GAT2), histone deacetylase 4 (HDAC4) and diacylglycerol kinase (DGKI) 
(Kinoshita et al., 2013). 
Recently a large study on 1479 schizophrenic patients and controls examining DNA 
from peripheral blood cells found additional evidence for differential methylation in 
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the loci of several genes previously already been linked to the pathogenesis of 
schizophrenia (Aberg et al., 2014). 
Perturbations of DNA methylation in major psychosis may also result from the 
abnormal activity of DNA methyltransferases (DNMTs) or changes in the levels of 
methyl-group donors and co-factors affecting DNA methylation (Labrie et al., 2012).  
In particular as reviewed by Pishva et al. (2014) schizophrenic patients express higher 
levels of DNMTs on peripheral lymphocytes (Pishva et al., 2014).  On the other hand, 
investigations on the levels of methyl-group donors and cofactors affecting DNA 
methylation have detected differences in the levels of S-adenosyl methionine, a 
methyl donor, and other molecules such as homocysteine and folate in patients with 
major psychosis (reviewed by Pishva et al., 2014).  
Differences in patterns of histone modifications have also been found in major 
psychosis (Labrie et al., 2012). In particular gene expression studies on histone 
modifying enzymes have provided further evidence for involvement of histone tail 
alterations in psychosis (reviewed by Pishva et al., 2014). 
Although these findings provide some support for the role of epigenetic dysfunction 
in the etiology of schizophrenia, they represent a fairly crude initial snapshot of the 
regulatory changes involved in pathogenesis and indicate that a more systematic 




4.3     Epigenome and Early Environmental Influences  
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Increasing evidence from animal studies indicates that both prenatal and early 
postnatal environmental factors can result in altered epigenetic programming and 
subsequent changes in the risk of developing disease (Jirtle and Skinner, 2007).  
The results of these studies support the hypothesis known as the fetal basis or 
developmental origins of adult-onset disease (Jirtle and Skinner, 2007). Thus, the 
evolution of developmental plasticity, which empower an organism to adapt to 
enviroment during early life, can also increase the risk of diseases when there is a 
mismatch between the perceived environment and that which is encountered in 
adulthood (Jirtle and Skinner, 2007).  
Growing evidence seems to suggest that early environmental factors are linked to 
disease phenotypes through modifications of the epigenome (Jirtle and Skinner, 
2007). Particularly in psychosis findings from both animal and human studies 
together suggest that adversity in early life may lead to persistent epigenetic marks on 
specific genes associated whit psychotic disorders (reviewed by Pishva et al., 2014). 
Inherited genetic and epigenetic profiles constitute the molecular basis of an 
individual; during life course environmental factors seem to interact with genetic and 
epigenetic profiles leading to long-term alterations of the epigenome (Pishva et al., 
2014). The possible alteration of gene expression resulting may influence behavioral 
and experiential phenotypes of individuals (Pishva et al., 2014). Additional evidence 
suggests the existence of allele-specific epigenetic differences in genes associated 
with psychosis constituting a further element in the dynamic interplay between the 
environment, genome and epigenome (Pishva et al., 2014). 
Despite considerable speculation about the role of epigenetics in psychosis this is a 
relatively nascent area of research and although publications in the field are growing, 
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they account mainly of non-research articles and animal studies (Dempster et al., 
2013). Epigenetic processes are influenced by a spectrum of external environmental 
factors, including early environmental factors, diet, toxins, drugs, and stress. 
Moreover polymorphisms can also exert an effect on gene function via epigenetic 
processes (Gamazon et al., 2013).  These suggest a common pathway behind both 
genetic and environmental effects possibly through gene–environment interaction 
(Dempster et al., 2013).  
 
 
4.4     Conclusion 
Progress in understanding the pathways through which various etiologic factors 
disrupt brain development in schizophrenia is necessary. A growing number of 
studies are attempting to measure both genes and environments to explain why people 
respond differently to the same environment (Van Os et al., 2008).  
GxE research represents an important approach to explain the occurrence of 
psychosis. Nevertheless exposure to certain environmental factors could also 
contribute to spontaneous genetic mutations that give rise to vulnerability for the 
illness.  
Despite considerable interest on epigenetic mediation of environmental factors in the 
development of psychosis, little evidence is currently available. No studies have yet 
provided direct evidence for epigenetic mediation of hypoxia–ischemia during pre- 
and perinatal life in schizophrenia so further research is warranted to identify direct 
links between hypoxia, epigenetic alterations and schizophrenia (Schmidt-Kastner et 
al., 2012). 
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In the context of this Thesis, which focuses on obstetric complications and psychosis, 
the major aim is to address the question of whether or not selected genes interact with 
the presence of OCs in the aetiology of psychosis. In particular two different 
approaches will be described, one human and one animal. In humans, firstly I 
attempted to replicate the findings coming from Nicodemus et al. (2008) looking at 
different gene polymorphisms of AKT1, BDNF, DTNBP1 and GRM3 (CHAPTER 7 
and 9); then I looked at 25 SNPs selected from the GWAS findings published so far 
(CHAPTER 8). In animals, I attempted to explore epigenetic mediation of hypoxia–


















Aims and Methods  
 
 
5.1     Introduction  
Following the description of the aims and hypothesis of my thesis, in this chapter I 
now outline the study design and the recruitment strategy for participants. This 
includes the power calculation applied to select the appropriate sample size. 
I then describe the main assessment tools used to gather the clinical and socio-
demographic data and the history of any Obstetric Complications (OCs) relevant for 
the analyses.  
A separate section of the methods describes the collection and processing of DNA 
samples. 
Finally, I present a summary of the statistical analyses applied to test the Thesis 
hypotheses and my personal contribution to the collection and processing of the data.  
 
 
5.2     Aims  
In a case-control design, I investigated how exposure to OCs influenced the risk of 
psychotic disorder, by employing a GxE causation model. 
Specifically the principal aims of this project are to: - 
1. Investigate obstetric history in psychotic patients, their unaffected siblings 
and healthy controls (CHAPTER 6). 
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2. Test, under a multiplicative model, the hypothesis that a range of genetic 
variants interacted with OCs in increasing the risk of psychotic disorder: 
a) Examine whether the following genes, selected on the basis of their 
pathophysiologic mechanism, play a role in the onset of psychotic 
disorders in interaction with OCs as seen in a previous study 
conducted by Nicodemus et al (2008): AKT1 rs 2494753, rs1130233, 
rs3803300; BDNF rs2049046, rs56164415; DNMBP1 rs875462 and 
GRM3 rs7808623 (CHAPTER 7 and CHAPTER 9);  
b) Examine whether the following susceptibility genes, deriving from 
the most recently available GWAS studies, play a role in the onset of 
psychotic disorders in interaction with OCs: AK573765-TWIST2 
(intergenic) rs9751357; CACNA1C rs4765905; CEACAM21 
rs4803480; CNNM2 rs7914558; CSMD1 rs10503253; Erbb4 
rs1851196; ITIH3/4 rs2239547; LOC645434-NMBR rs2066036; 
LRRFIP1 rs12052937; MIR137 rs1625579; MMP16 rs7004633; 
NKAPL rs1635; NRG rs12807809; NT5C2 rs11191580; PCLO 
rs6979348; PLXNA2 rs752016; PGBD1 rs2142731; PCGEM1 
rs17662626; RELN rs7341475; SDCCAG8 rs6703335; STT3A 
rs548181; TCF4 rs17512836; UGT1A1 HJURP(intergenic)rs741160; 
rs10489202; rs16887244 (CHAPTER 8). 
3.  Examine whether rats that had experienced perinatal asphyxia during birth 
show any abnormality in gene expression and consequently in methylation 
status in Prefrontal Cortex (PFC), Hippocampus (HiP) and Striatum (STR) at 
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three developmental periods, post natal day (PND) (T1: 0 week), adolescence 
(T2: 5 weeks old) and adulthood (T3: 12 weeks old) (CHAPTER 10). 
 
 
5.3     Hypotheses 
 I will test the following hypotheses: 
1. Psychotic patients to be more likely than controls to have experienced a 
definite OC. 
2. The effect of OCs on odds of psychotic disorder to be conditional on the 
individual’s genotype. 
3. The hypoxic rats to show abnormal gene expression and methylation status 




TABLE 5.1   Summary of Main Investigations and Related Hypotheses and Statistical Analysis 
 
 
5.4     Study Design  
The project is a case-control study design; the majority of subjects have been 
recruited as part of the Maudsley Family Study (MFS), London. This large study has 
been running under the overall supervision of Professor Robin Murray since the early 
1990’s and includes data for over 1000 subjects comprising patients with psychotic 
illness, their unaffected first-degree relatives and controls. The families were 
recruited by self-referral in response to advertisements, through voluntary 
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organizations, or by direct referral from their local psychiatric service. All 
partecipants were Caucasian. 
The major aim of the study is to identify neurobiological deviations associated with 
psychosis that are linked to genetic susceptibility (Frangou et al., 1997; Frangou et 
al., 1997b; Sharma et al., 1997; Crawford et al., 1998; Griffiths et al., 1998; Sharma 
et al., 1998; Sharma et al. 1999; Birkett et al., 2008).  
I increased the available sample of patients as part of the Genetic and Psychosis 
(GAP) study, London – active since 2004. Under the overall supervision of Professor 
Robin Murray and Dr Marta Di Forti, the study includes patients (age 18-65 yrs) 
presenting with their first episode of psychosis to the Lambeth, Southwark, Croydon 
and Lewisham adult in-patient units of the South London and Maudsley Foundation 
NHS trust and healthy matched controls (Di Forti et al., 2009).  
These projects used similar diagnostic criteria and recruitment strategy to collect OCs 
data. Although the GAP study is a multiethnic project only Caucasian patients 
recruited in the South London and Maudsley Hospital Trust were included in the 




5.5     Ethics 
All studies involving human subjects were approved by the South London and 
Maudsley NHS Trust and the Institute of Psychiatry Ethical Committee. My measures 
didn’t fall within the GAP study’s ethical approval (REC reference number 
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05/Q0706/158) and so I had to amend the ethics application and forms in order to 
assess the relatives (Amendment numbers 8, 9, and 11). Written informed consent 
was obtained after a full explanation of the study was given to participants. 
 
5.6     Recruitment  
5.6.1   Patients 
The sample comprised individuals who are participants in the Maudsley Family Study 
of Psychosis, comprising patients with psychotic illness, their unaffected first-degree 
relatives and controls. The families were recruited by self-referral in response to 
advertisements, through voluntary organizations, or by direct referral from their local 
psychiatry services. They were chosen on the basis that the index patient had a 
lifetime DSM-IV diagnosis of schizophrenia or schizoaffective disorder. All 
partecipants were Caucasian. 
As part of the GAP study, my colleagues and I approached all patients aged 18 to 65 
years presenting with their first episode of psychosis to the Lambeth, Southwark, 
Croydon and Lewisham adult in-patient units of the South London and Maudsley 
Foundation NHS Trust (SLAM) between December 2005 and October 2011. 
A weekly screening through the electronic-Patient Journey System of SLAM was 
done in order to identify new admissions of first episode of psychosis patients in the 
psychiatric wards from the catchment area.  
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All patients who met ICD10 criteria for a diagnosis of nonorganic psychosis (F20-
F29 and F30-F33), validated by administering the Schedules for Clinical Assessment 
in Neuropsychiatry (SCAN), were invited to participate in the study.  
Of the total (n=745) approached, 20% (n=149) refused to participate. The two most 
common reasons for refusal were lack of interest in the research and the length of our 
study assessment (Woodal et al., 2011). If patients were too unwell to cooperate, they 
were re-contacted following improvement. 
5.6.1a   Inclusion and Exclusion Criteria 
The following inclusion criteria were applied: contact with psychiatric services for 
psychosis, Caucasian, fluent speaker of English, aged between 18 and 65 years old. 
Exclusion criteria: organic psychosis (as defined by ICD-10, WHO, 1992) and IQ 
below 70.  
5.6.2     Siblings 
Siblings were recruited as part of the Maudsley Family Study of Psychosis. They 
were chosen among first-degree relatives on the basis that the index patient had a 
lifetime DSM-IV diagnosis of schizophrenia or schizoaffective disorder. All 
partecipants were Caucasian. 
5.6.2a   Inclusion and Exclusion Criteria 
Siblings were all Caucasian aged 16-69.  
Exclusion criteria: not fluent speaker of English, history of organic brain disease, 
history of head trauma resulting in loss of consciousness for more than 5 minutes, 
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fulfilled DSM-IV criteria for substance or alcohol dependence in the 12 months prior 
the assessment. 
5.6.3   Controls  
Over the same time frame, from the area served by the same mental health units, I 
obtained a healthy control sample, aged 18 to 65 years, which was broadly similar to 
the local population in terms of ethnicity, educational attainment and employment 
status (www.statistics.gov.uk/census 2001), using internet and newspaper adverts and 
distribution of leaflets at train stations, shops and job centres.  
Volunteers willing to take part in the study were administered the Psychosis 
Screening Questionnaire, and excluded if they met criteria for a psychotic disorder or 
if they reported a previous diagnosis of psychotic illness (Bebbington and Nayani 
1995).  
5.6.3a   Inclusion and Exclusion Criteria 
Control participants are recruited from the local population living in the area served 
by SLAM mental health services. All partecipants were Caucasian.  
Exclusion criteria: not fluent speaker of English, current or past diagnosis of 
psychotic disorders and IQ below 70.  
5.6.4   Mothers 
The sample comprised firstly 252 individuals who are participants in the MFS. All 
partecipants were Caucasian. 
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Furthermore I contacted all Caucasian patients who had already been assessed as part 
of the GAP study. Of a total of 596 who agreed to participate in the GAP study since 
2005, 196 were Caucasian (35.7%). Among them only 56 individuals supplied 
informed consent for maternal interview. Of the remaining 140, 69 individuals 
refused to participate, 46 were ineligible (4 patients died, 17 patients withdrawn from 
GAP in general, 16 mothers were dead, 9 mother non-English-speaking or living 
abroad); 25 could not be contacted.  
After informed consent was obtained, the mother of each participant was identified 
wherever possible and invited either to attend for interview or to take part in a 
telephone interview (depending on their preference). Of the 56 individuals who had 
given permission to contact their mother and who had completed the proband 
interview, 23 were not included because their mother subsequently refused or could 
not be contacted. Finally I collected a total of 33 cases and 28 controls.  
5.6.4a   Inclusion and Exclusion Criteria 
The following inclusion criteria were applied: Caucasian and fluent speaker of 
English. 
Exclusion criteria: women over the age of 70 were not included in the study as 
evidence suggests that a decline occurs on tests of episodic memory in women after 
this age (Herlitz et al., 1997). 
 
5.7    Assessment  
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In the GAP study, subjects were given a wide range of assessments, including blood 
and/or cheek swabs for genetic analysis, structural and functional MRI, biological 
measures, wide clinical and socio-demographical interview, substance use, a 
neuropsychological battery and other questionnaires.  
As part of the GAP study, I also contributed to the collection of socio- demographic 
data (age; gender; ethnicity; level of education attainment and employment status) on 
both patients and controls using a modified version of the Medical Research Council 
(MRC) socio-demographic scale (Mallett et al., 2002). Ethnicity was assessed by 
asking participants to select the ethnic group that most closely described their 
ethnicity from a list used in the last UK census (www.statistics.gov.uk/census 2001). 
5.7.1   Obstetric History 
Each participant’s history of OCs was assessed in the same way. Consenting mothers 
of subjects were interviewed using the Maternal Interview Schedule (MIS) elicited 
using a standard questionnaire developed from other published reports (Lewis and 
Murray, 1987; McCreadie et al, 1992; McNeil et al., 1995; Cannon et al., 2002) 
(APPENDIX).  
The MIS includes the following questionnaires:  
1. Sociodemographic Schedule  
2. Obstetric Complications Questionnaire 
3. Family History for Genetic Study 
In detail the Obstetric Complications Questionnaire includes the following data: 
⋅  Maternal health in brief 
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⋅  Place of birth 
⋅  Paternal age at birth 
⋅  Maternal age at birth 
⋅  Pregnancy complications 
⋅  Gestational infections 
⋅  Maternal substance use during pregnancy and breast feeding  
⋅  Labour and delivery complications 
⋅  Neonatal complication 
5.7.2   Lewis-Murray Scale 
The Lewis-Murray Scale (Lewis and Murray, 1987) was used as the principal 
measure of OCs as it includes the greatest number of complications of potential 
relevance to the aetiology of schizophrenia (FIGURE 5.1). 
 
FIGURE 5.1   The Lewis-Murray Scale. Taken from Lewis et al., 1989. 
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The Lewis-Murray Scale consists of 17 individual items including information about 
rubella, syphilis, Rh incompatibility, pregnancy-induced hypertension, obstetric 
bleeding, premature membrane rupture, labour duration, twin birth, cord prolapse, 
gestational age, Caesarean section, breech or abnormal presentation, instrumental 
delivery, birth weight, foetal distress, and gross physical anomaly. Lewis-Murray 
Scale includes several items of potential hypoxic harm to the foetus such as maternal 
preeclampsia; neonatal cyanosis; emergency caesarean section; umbilical cord 
wrapped around the neck; requiring incubator care for more than 1 week in the 
neonatal period; requiring neonatal resuscitation (Lewis et al., 1989). 
Each item was evaluated as definite (score 1), or absent (score 0). Subjects were rated 
as having a “definite” (score 1) complication if they had suffered at least one 
significant complication (Lewis et al., 1989). I did not rate labour of less than 3 h as a 
definite complication (O'Callaghan et al., 1990). Other items on the scale were rated 
as unknown if the record could not be used to determine whether an event had or had 
not occurred. Maternity records were not used if they could not supply information 
for at least 10 items from the Lewis-Murray Scale. 
 
5.8      DNA Samples Collection and Storage 
A blood sample was also collected from both patients and controls (two 6 
mls EDTA tubes) in the GAP study. This was used to obtain DNA samples. 
Participants who refused venopuncture (25%) were asked to provide a DNA sample 
using a cheek swab kit, provided by the laboratory of the MRC Social, Genetic and 
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Developmental Psychiatry Centre (SGDP). The DNA was extracted from both blood 
samples and cheek swabs, following standard procedures. All samples were bar-
coded to preserve confidentiality and blindness to clinical status and appropriately 
stored in the SGDP -80 ° C degree freezer for later analysis. Similar proceedures had 
been followed in the Maudsley Family Study.  
The genotyping of selected genetic polymorphisms was carried out under the overall 
supervision of my supervisor Dr John Powell. In particular I have been working at the 
Institute of Psychiatry Neuroscience Department laboratory under the supervision of 
Dr Conrad Iyedgbe and at the Social, Genetic and Developmental Psychiatry Centre 
(SGDP) under Dr Rebecca Smith supervision. The procedures followed for the 
genotyping are described in the CHAPTER 7 and 8.  
 
 
5.9     Sample Size 
Overall OCs data was available on 313 subjects. A total of 145 psychotic patients, 65 
controls and 103 unaffected siblings were available for my project. Variations on 
sample size are present across the different statistical analyses carried out in this PhD. 
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112 33 145 
103 - 103 
37 28 65 
 
105 22 127 
95 - 95 
33 7 40 
 





252 61 313 
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TABLE 5.2   Sample Size. Sample size for each experiment * DNA material was obtained from 290 
subjects in total. 
 
Assuming an exposure of OCs of 30% among the general population (Cannon et al., 
2002), I have the 80% power and a significance level of 0.05% (two-tailed) of 
detecting an OR of 2.0 with 95% confidence in our population.  
For a G×E interaction purpose in a case-control design in order to have 80% power 
and a significance level of 0.05% (two-tailed) a sample of 355 case-control pairs is 
required. In a case-only design in order to have 80% power and a significance level of 
0.05% (two-tailed) a sample of 140 cases is required. This assumes an exposure of 
30% among the general population (Cannon et al., 2002) and with a mean allele 
frequency of 0.5.  
Power Calculations were made using the Quanto 1.2.4 software using the gene-
environment module (John Morrison and W. James Gauderman at the University of 
Southern California). 
QUANTO is a program for computing either power or required sample size for 
association studies of genes, environmental factors, gene-environment (G×E) 
interaction, or gene-gene (G×G) interaction.  
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5.10     Statistical Analysis  
All the data collected, including the genotyping results, were recorded and analyzed 
in SPSS version 20.  
As presented in more detail in the results chapters, χ2 tests and t-tests (or Mann-
Whitney U tests) were used: 
1. To test for associations between the presence of psychotic disorder, 
exposure to OCs, and genotype. 
2. To establish whether OCs were more likely to occur in individual carriers 
of a particular genotype class (a GxE correlation). 
Logistic regression was then used, as illustrated in the Chapters detailing the results: 
1. To analyse the association between the exposure to OCs and risk of 
psychotic disorders. 
2. To analyse the association between candidate genotype and presence of a 
psychotic disorder along with any history of OCs. 
3. To test in separate analyses for an interaction between exposure and 
genotypes. The interaction term was used to identify the effect of genotype on 
presence of psychosis, conditional on history of OCs. 
ANOVA 
1.To analyse the abnormality in gene expression in different brain regions at 
three developmental periods in hypoxic rats. 
2.To measure DNA methyltransferase expression in different brain regions at 









6.1     Introduction 
OCs are among the best documented environmental risk factors for schizophrenia 
with an increased risk of about 2.0 (Cannon et al., 2002). OCs occur in approximately 
25-30% of the general population, and individuals with schizophrenia are about twice 
as likely to have experienced obstetric complications compared with healthy controls 
(Geddes et al., 1999; Cannon et al., 2002).  
 
 
6.2    Aim  
My aim is to investigate the rate of OCs in Psychotic Patients, Unaffected Siblings 
and Healthy Controls.  
 
 
6.3     Hypothesis 
I expect psychotic patients to be more likely than controls and siblings to have 
suffered an OC. 
 
 
6.4     Methodology 
6.4.1     Recruitment and Assessment  
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As discussed more in detail in CHAPTER 5, all data on OCs were retrospectively 
collected from mother and scored using the Lewis-Murray Scale.  In brief each item 
is evaluated as definite (score 1), or absent (score 0). Subjects were rated as having a 
“definite” (score 1) complication if they had suffered at least one significant 
complication (Lewis et al., 1989).  
6.4.2     Sample size and Power calculation 
Overall OC data was available on 313 Caucasian subjects, comprising 145 psychotic 
cases, 103 unaffected siblings and 65 healthy controls. Assuming an exposure of OCs 
of 30% among the general population (Cannon et al., 2002), I have 80% power of 
detecting an OR of 2.0 with 95% confidence in our population. This calculation has 
been made using the Quanto 1.2.4 software using the environment module (John 
Morrison and W. James Gauderman at the University of Southern California). 
6.4.3     Statistical Analysis  
The one-way Analysis of Variance (ANOVA) and post hoc comparisons with 
Hochberg’s GT2 (due to the sample size differences among groups) were used to 
analyze difference in the mean for age, gestational age, weight at birth and labour 
duration in the three groups, cases, siblings and controls.  
Logistic regression was used to analyse the associations between the occurrence of 
OCs and case–control status, and to test for interaction effects while controlling for 
potential confounders.   
Confounders were selected after testing, using χ2 tests and t-tests (or Mann-Whitney 
tests), for their association with the presence of history of OCs and of psychotic 
disorders. 
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6.5     Results 
6.5.1     Description of the Whole Sample 
6.5.1a   Clinical Characteristics of the Sample  
Subjects included in the study consisted in 145 subjects who met ICD10 criteria for a 
diagnosis of non-organic psychosis (F20-F29 and F30-F33), 103 of their unaffected 
siblings and 65 healthy controls.  
6.5.1b   Demographic Characteristic of the Sample  
The demographic characteristics for the three groups are shown in TABLE 6.1.  
 








  Mean (SD) Mean (SD) Mean (SD)  




 26.98 (4.5) 27.55 (4.4) 28.35 (4.8) p=0.13 







31 (47.7%)  
 
p=0.04 
TABLE 6.1   Demographic Characteristics of the Sample.  P values from t-tests and χ2 tests. 
 
The mean age of the whole sample is 27.68 years (SD 8.33); among the groups, 
patients were the youngest (23.11 years old, SD 4.86, 95% CI 22.28-23.94, F (2, 
298)= 54.88; p<0.001). There was a significant group difference for gender with an 
excess of males in the patients’ group (χ2=11.09 p =0.004). Regarding ethnicity, only 
Caucasian people were included. 
6.5.1c   Maternal Characteristics of the Sample  
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The demographic characteristics for the three groups are shown in TABLE 6.1. The 
mean age of the mother at the time of the interview was 59.14 years (SD 8.07). The 
groups did not significantly differ in the measure of maternal age at delivery (mean 
age 27.45 years, SD 4.52; 95% CI 26.94-27.95, F (2-308) = 2.08, p=0.127).  
6.5.2     Obstetric Complications  
The rate of definite OCs, mean of gestational ages and mean birth weights for each 










 n (%) n (%) n (%)  
Definite OCs  56 (38.9%) 22 (21.4%) 22 (34.4%) p=0.01 
 Mean (SD) Mean (SD) Mean (SD)  
Gestational age 
in weeks 
40 (1.8) 40 (1.5) 40 (1.7) p=0.71 
















13 (14.4)  
 
p=0.37 
TABLE 6.2   Rates of OCs, Mean of Gestational Ages, Mean Birth Weights and Labour 
Duration in Each Subject Group.  P values from t-tests and χ2 tests. 
 
38.9% of psychotic patients had a positive history for OCs compared to 34.4% of the 
controls and to 21.4% of siblings (χ2=8.64, p=0.013). There was no significant 
difference among the three groups for gestational age (mean age 39.9 weeks, SD 
1.69, 95% CI 39.71- 40.09, F (2-302)=0.34, p=0.71) and weight at birth (mean weight 
3370 gr, SD 540.4, 95% CI 3308- 3430, F (2-303)= 2, p=0.137).  
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Moreover the three groups did not significantly differ on labour duration at time of 





 n (%) n (%) n (%) 
Rubella - - - 
Syphilis  - - - 
Rhesus 
incompatibility 
- - - 
Antepartum 
hemorrhage 
6 (4.1%) 5 (4.9%) 5 (7.7%) 
Severe  
Pre-eclampsia 
16 (11%) 6 (5.8%) 4 (6.2%) 
Premature rupture of 
membrane 
- - 1 (3.6%) 
Labour > 36 hours 9 (6.3%) 3 (3%) 4 (6.3%) 
Birth weight 2000 gr 
or less 
2 (1.4%) 3 (3%) - 
Complicated twin 
birth 
- - - 
Cord prolapse - 1 (1%) - 
Gestational age <37 
weeks 
9 (6.2%) 3 (3%) 4 (6.5%) 
Gestational age >42 
weeks 
5 (3.5%) 2 (2%) 1 (1.6%) 
Emergency Caesarian 
Section 
5 (3.1%) - 2 (3.5%) 
Breech or abnormal 
presentation 
7 (4.9%) 3 (2.9%) 7 (5.2%) 
Mid to high forceps 19(13.2%) 14 (13.7%) 14 (22.6%) 
Incubator > 4 weeks 3 (2.1%) 1 (1%) 3 (4.7%) 
TABLE 6.3   Individual Obstetric Events on Lewis-Murray Scale.  I did not rate as a “Definite” 
OCs labour lasting less than 3 hours. 
 
6.5.3     Case- Control Prediction Analyses 
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I applied logistic regression to analyse if OCs significantly increased the risk of 
psychosis, while controlling for potential confounders such as age and gender 
(FIGURE 5.1).  To maximise statistical power siblings and the healthy controls were 
collapsed into one group of “controls/siblings”  
 
FIGURE 6.1   Adjusted OR of Psychosis for Subjects with OCs. 
 
As expected there was a statistical difference in the rate of definite complications in 
the patient group when compared to the “controls/siblings” group: patients were 2 
times more likely to have had an OC (Adj OR = 1.88; 95% CI 1.36 -3.41; p=0.038).  
 
 
6.6     Summary of Results 
In our sample patients were more likely than non- psychotic individuals to report an 
OC. The case-control logistic regression analysis showed that the people who had 
experienced OCs had a significantly increased risk of psychotic disorder compared to 
those who didn’t.  
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This study reports an effect for OCs in increasing the risk for psychosis of about 1.9 
similar to the widely reported risk of 2.0 for schizophrenia (Cannon et al., 2002). 
 
 
6.7     Discussions 
It now established that the risk of developing schizophrenia is increased in 
individuals who were exposed to various complications during pregnancy (Cannon et 
al., 2002). Moreover recent epidemiological studies further document the relationship 
between obstetric complications and psychosis-like symptoms or deficit in cognitive 
function (Zammit et al., 2009). My study confirms that patients are more likely than 
non- psychotic individuals to report an OC, with an effect for OCs in increasing the 
risk for psychosis of about 1.9, similar to the widely reported risk of 2.0 for 
schizophrenia (Cannon et al., 2002).  
OCs increase risk of schizophrenia but not everyone that experienced OCs develops 
psychosis later in life. It was of interest that in my study the siblings had the lowest 
prevalence of OCs. It is possible that in families carrying some genetic risk of 
schizophrenia, to remain well, siblings need to have less exposure to OCs. A difficult 
challenge is to identify plausible susceptibility genes to investigate how, and if, they 
moderate the effect of OCs on the risk of psychosis.  
In order to get a better insight into the mechanisms by which OCs impact on brain 
development to increase the risk of psychosis, in the next three chapters (CHAPTER 7, 
8 and 9) I tested, under a multiplicative model, the hypothesis that a range of genetic 
variants interacted with OCs in increasing the risk of psychotic disorder. It was also 
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suggested that OCs themselves alter the function, structure and consequently the 
expression of genes which could be another route resulting in schizophrenia, thus in 
CHAPTER 10 I examined whether rats that had experienced perinatal asphyxia during 




6.8    Limitations  
6.8.1   Sample Size 
The sample size is small and many of the individuals obstetric complications are 
uncommon. Moreover unless a specific complication could be reasonably ruled out, 
items were left as unknown and records were not used at all if they could not supply 
information for at least 10 items from the scale. It is possible that a larger sample size 
may have detected an increased risk for psychosis due to specific complications that 
the present study did not have sufficient power to assess. In addition, to maximise 
statistical power siblings and the healthy controls were collapsed in one group of 
“controls”.   It was of interest that the siblings had the lowest prevalence of OCs. This 
may have lowered the overall prevalence in my combined “controls/siblings” group.   
However, this should not interefere with the main purpose of this Thesis, which is to 
examine Gene x Environment Interactions 
6.8.2   Retrospective Data  
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The use of retrospective maternal reporting of obstetric data has been questioned as 
potentially unreliable.  Potential biases include cognitive impairment or schizotypical 
personality traits often found in relatives of schizophrenic (Buka et al; 2000); a 
tendency to false positive responses (Cantor- Graee et al., 1998; McIntosh et al., 
2002); increased parity, level of education and lower social class (Hoekelman et al., 
1976; Sheehan and MacAirt, 1981; Gayle et al., 1988). Moreover mothers of 
schizophrenic patients tend to underestimate the rate of OCs in their affected 
offspring compare to controls (Cantor- Graae et al., 1998; Buka et al., 2000).  
Studies assessing the validity of maternal recall compared to birth records have 
shown different results (Walshe et al., 2011). As reviewed by Walshe et al. (2011) 
two studies both reported good agreement between retrospective maternal recall and 
contemporaneous birth records using the Lewis–Murray scale (O’ Callaghan et al., 
1990; Franzek and Stober, 1995). Other studies have found that mothers were able to 
recall OCs decades after birth (Buka et al., 2004; Sou et al., 2006) and the sensitivity 
of maternal recall improves for severe or acute events (Filippi et al., 2000) especially 
for those occurring in the perinatal period (Yawn et al., 1998).  In contrast to these 
findings, Cantor-Graae et al. (1998) and McIntosh et al., (2002) reported considerable 
discrepancies between maternal interviews and birth records.  
As explained by Walshe et al. (2011), one major methodological difference which 
may account for this disagreement is the type of obstetric complication scale used 
such as The Lewis–Murray scale (Lewis and Murray, 1987) and the McNeil-Sjostrom 
scale (McNeil et al., 1995), used in the studies of Cantor-Graae et al. (1998) and 
McIntosh et al. (2002). 
! 118 
As explained in CHAPTER 5, the Lewis-Murray scale (Lewis and Murray, 1987) 
consists of 17 individual items and each item is evaluated as present or absent. In 
contrast, the McNeil-Sjostrom scale (McNeil et al., 1995) rates hundreds of 
pregnancy, delivery and neonatal events on a range of severity. Using this scale, 60–
80% of non-schizophrenic individuals tend to be rated as having experienced a clearly 
potentially harmful OC (Cantor-Graae et al., 1998; Gunduz et al., 1999; Jablensky et 
al., 2005; Verdoux et al., 2002), twice the rate of “definite complications” identified 
using the Lewis–Murray scale (Jones et al., 1998; Walshe et al., 2005; reviewed by 
Walshe et al., 2011). 
While the Lewis-Murray scale scoring system lacks exactitude, it maximizes 
statistical power in studies that are limited by sample size from examining individual 
complications.  Mothers are much better at remembering some events than others but 
it is likely that overall are more likely to remember relatively uncommon events 
requiring medical attention (Walshe et al., 2011).  
Clearly, birth records represent the “gold standard” for collecting obstetric history 
although largely unstandardized and lacking sufficient detail (Hewson and Bennett, 
1987; Buka et al., 2004). However, given the difficulty of accurately acquiring such 
records in most countries, the use of a maternal recall scale such as the Lewis–Murray 
scale remains valuable in schizophrenia research, for example to explore the 
association of significant obstetric complications with other risk factors and 





Genes Regulated by Hypoxia and Psychosis 
 
 
7.1     Introduction 
It is likely that genes play an important role in mediating the reactions of the CNS to 
environmental stimuli such hypoxia. A difficult challenge is to identify plausible 
susceptibility genes to investigate how, and if, they moderate the effect of OCs on the 
risk of psychosis.  
As described in the Introduction, in 2006 a systematic review suggested that more 
than 50% of genes associated with schizophrenia are subject to regulation by hypoxia 
and/or are expressed in the vasculature (Schmidt-Kastner et al., 2006). Nicodemus 
and colleagues (2008) examined 13 of these genes in a sample of 119 family-trios 
(affected individuals and their unaffected parents). They reported significant evidence 
for genes involved in neurovascular function or regulated by hypoxia interacting with 
the presence of serious OCs to increase risk for schizophrenia. Thus, AKT1, BDNF, 
DTNBP1 and GRM3 showed significant evidence for gene-by-environment 
interaction (LRT P-values ranged from 0.011 to 0.037) (Nicodemus et al., 2008). 
They hypothesized that causal variants that reduced expression levels of the 
neuroprotective products of AKT1, BDNF, GRM3 and DTNBP1 genes may lead to 
vulnerability to hypoxic insult during neurodevelopment (Nicodemus et al., 2008).  
So far only two small studies have examined the interaction of specific candidate 
genes with serious OCs in the development of schizophrenia (Nicodemus et al., 2008; 
Joo et al., 2009). Thus, this interaction model has not yet been fully empirically 
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tested.  In this study I selected genetic variants of 4 genes, which are regulated by 
hypoxia, namely AKT1, BDNF, DTNMBP1, GRM3, to replicate the interaction with 
OCs in increasing the risk of psychosis which Nicodemus et al (2008) found.  
 
 
7.2 V-Akt Murine Thymoma Viral Oncogene Homolog 1 (Akt1): rs1130233, 
rs2494735 and rs3803300. 
The first candidate to test for a gene x OCs interaction is the Akt1 gene, located on 
chromosome 14q32.32.  Akt1 gene variants have been associated with schizophrenia 
and bipolar disorders (Toyota et al., 2003; Emamian et al., 2004; Schwab et al., 2005; 
Thiselton et al., 2008; Mathur, et al. 2010; Van Winkel, 2011; Karege et al., 2012), 
though some authors failed to replicate these results (Ohtsuki et al., 2004; Lee et al., 
2010). 
The serine-threonine protein kinase encoded by the Akt1 gene is catalytically inactive 
in serum-starved primary and immortalized fibroblasts. Akt1 and the related Akt2 are 
activated by platelet-derived growth factor. The activation is rapid and specific, and it 
is abrogated by mutations in the pleckstrin homology domain of Akt1. The activation 
occurs through phosphatidylinositol 3-kinase (FIGURE 7.1).  
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FIGURE 7.1   The Upstream Signaling Mechanisms Regulating Akt Activity. Taken from Kim 
and Chung, 2002. 
 
In the developing nervous system Akt is a critical mediator of growth factor-induced 
neuronal survival (Dudek et al., 1997; Kim and Chung, 2002). Survival factors can 
suppress apoptosis in a transcription-independent manner by activating the 
serine/threonine kinase Akt1, which then phosphorylates and inactivates components 
of the apoptotic machinery (Kim and Chung, 2002) (FIGURE 7.2). 
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FIGURE 7.2   Inhibition of Apoptosis by Akt. Taken from Kim and Chung, 2002. 
 
Moreover, Akt1 has been shown to facilitate dopamine signaling (Beaulieu et al., 
2009) and is an important regulator of glycogen synthase kinase-3ß (GSK- 3ß), a 
protein known to be involved in both mood disorder and psychosis (Grimes and Jope, 
2001). 
Increased Akt1 has been reported in focal brain ischemia (Kitagawa et al., 1999), and 
a neuroprotective  role of Akt1 activation has been proposed (Yin et al., 2005). Akt1 
also participates in the HIF-1 signaling pathway (Zhong et al., 2000). 
In their study, Nicodemus et al. (2008) concluded that those who carried a particular 
allele of one of three polymorphisms of the Akt1 gene, namely rs1130233, rs3803300 
and rs2494735, were especially at risk of schizophrenia when exposed to OCs 
(Nicodemus et al., 2008). 
In light of these findings, I followed a hypothesis driven approach limiting the GXE 
analyses to rs1130233, rs3803300 and rs2494735 polymorphisms of the Akt1 gene. 
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7.3 Brain-Derived Neurotrophic Factor (BDNF): rs2049046 and rs56164415. 
Brain-derived neurotrophic factor (BDNF), a neurotrophin known to be responsible 
for development, regeneration, survival and maintenance of neurons (FIGURE 7.3) has 
been implicated in the pathophysiology of schizophrenia in some but not all studies 
(Sklar et al., 2002; Neves-Pereira et al., 2002; Hong et al., 2003; Geller et al., 2004; 
Oswald et al., 2004; Skibinska et al., 2004). In humans this gene is located on 
chromosome 11p13. 
 
FIGURE 7.3   BDNF Mechanism in Neurons. Taken from Hempstead, 2004. 
 
BDNF is protective against brain ischemia (Schabitz et al., 1997; Schmidt-Kastner et 
al., 2006). This gene is upregulated by ischemia (Lindvall et al., 1992; Schmidt-
Kastner et al., 2001) and is expressed in neurons and endothelial cells during 
development (Leventhal et al., 1999; Schmidt-Kastner et al., 2006).  
Nicodemus and colleagues found that two SNPs in BDNF, rs2049046 and 
ss76882600 (renamed as rs56164415), showed significant evidence for serious OC by 
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SNP interaction; probands who suffered a serious obstetric complication were 
preferentially transmitted the major allele at rs2049046 (OR= 0.15; 95% CI= 0.032, 
0.73; LRT P-value = 0.011; OR P-value = 0.019) whereas the opposite was observed 
at ss76882600 (OR= 12.45; 95% CI= 1.63, 94.6; LRT P-value = 0.028; OR P-value = 
0.015) (Nicodemus et al., 2008). 
In light of these findings, I attempted to replicate the GXE analyses looking at 




7.4 Dysbindin, Dystrobrevin-Binding Protein 1 (DTNBP1): rs875462. 
Dysbindin, which binds dystrobrevin, is found expressed in the vasculature of 
muscles by immunolabeling, and a complex containing dysbindin has been discussed 
for cranial blood vessels (Benson et al., 2001; Schmidt-Katstner, et al., 2006). 
DTNBP1 is expressed in the vasculature (Schmidt-Kastner et al., 2006), and is 
located on chromosome 6p22.3. Dystrobrevin is expressed in endothelial cells and 
perivascular glia (Schmidt-Kastner et al., 2006). Dysbindin appears to have 
neuroprotective functions (Numakawa et al., 2004; Schmidt-Kastner et al., 2006). 
Early evidence indicated that dysbindin was one of the most promising candidate 
genes for schizophrenia though some more recent studies have been less positive 
(reviewed by Williams et al., 2005) (FIGURE 7.4). 
! 125 
 
FIGURE 7.4   Complex Pattern of Genetic Association at DTNBP1. Taken from Williams et al., 
2005. 
 
In particular one SNP in DTNBP, namely rs875462, was found to show preferential 
transmission of the minor allele to probands who experienced serious OCs (OR= 
9.49; 95% CI = 1.23, 73.3; LRT P-value = 0.025; OR P-value = 0.031). 
In the present study I attempted further replication of the rs875462 gene 
polymorphism of DTNBP1 (Nicodemus et al., 2008).  
 
 
7.5 Metabotropic Glutamate Receptor 3 (GRM3): rs7808623. 
The metabotropic glutamate receptors are a family of G protein-coupled receptors 
located on 7q21.1-q21.2 chromosome. They have been divided into 3 groups on the 
basis of sequence homology, putative signal transduction mechanisms, and 
pharmacologic properties. Group I includes GRM1 and GRM5 and these receptors 
have been shown to activate phospholipase C. Group II includes GRM2 and GRM3 
while Group III includes GRM4, GRM6, GRM7 and GRM8. Group II and III 
receptors are linked to the inhibition of the cyclic AMP cascade but differ in their 
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agonist selectivities.  
Agonists of the metabotropic glutamate receptor mGlu2/3 (encoded by GRM3) are 
reported to exert neuroprotective effects (Bond et al., 2000; Schmidt-Kastner et al., 
2006). GRM3 mRNA is down regulated by brain ischemia (Raghavendra Rao et al., 
2002; Lu et al., 2004; Schmidt-Kastner et al., 2006).  
Some but not all studies find genetic association of GRM3 polymorphisms with 
psychosis (reviewed by Harrison et al., 2008) (FIGURE 7.5). 
 
 
FIGURE 7.5   GRM3 Genetic Associations with Schizophrenia. Taken from Harrison et al., 2008. 
 
 
Nicodemus et al. (2008) found that one SNP in GRM3, rs7808623, showed 
preferential transmission of the minor allele to probands who experienced serious 
OCs (OR= 3.39, 95% CI= 0.95, 12.17; LRT P-value = 0.035; OR P-value = 0.061) 
(Nicodemus et al., 2008). 
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For the present study I attempted further replication of the interaction between OCs 
and rs7808623 gene polymorphism of GRM3 in increasing the risk for schizophrenia 




I aim to: 
1. Test if each of the selected genetic variants is associated with an increased risk of 
psychotic disorders or the presence of OCs. 
2. Test if each of the selected genetic variants interacts with exposure to OCs to 
moderate the risk of psychotic disorders. 
 
 
7.7 Hypotheses  
I expect the following SNPs to interact with exposure to OCs in increasing the risk of 
psychotic disorders: 
1. AKT1 rs1130233 “G” allele  
2. AKT1 rs2494735 “C” allele  
3. AKT1 rs3803300 “G” allele. 
4. BDNF rs2049046 “T” allele. 
5. BDNF rs56164415 “A” allele. 
6. DTNBP1 rs875462 “G” allele. 
7. GRM3 rs7808623 “T” allele . 
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7.8 Methods  
The presence of OCs was assessed through maternal interview on 313 subjects, 
comprising 145 psychotic cases, 103 unaffected siblings and 65 healthy controls.  
7.8.1   Assessment  
Subjects were given a wide range of assessments, and donated blood for genetic 
analysis. OCs was retrospectively collected from mothers of each participant using 
the Maternal Schedule Interview (MIS) and coded using the Lewis-Murray scale as 
explained in details in CHAPTER 5.  
7.8.2 Genotyping  
DNA was obtained from 262 subjects in total (127 cases, 95 siblings, 40 controls) 
from either blood (75% of subjects) or from cheek swab samples (25% of subjects). 
AKT1 rs1130233, rs3803300 and rs2494735 alleles, BDNF rs2049046 and 
rs56164415 alleles, DTNBP1 rs875462 allele and GRM3 rs7808623 allele were 
chosen as the genetic variants. 
DNA was extracted using a standard phenol-chloroform extraction procedure. 
TaqMan® Gene Expression Assays Protocol was used to conduct the entire 




FIGURE 7.6   TaqMan® Gene Expression Assays Protocol. 
 
After an initial Taq polymerase activation/DNA denaturation step, samples were 
subjected to PCR reaction following standard Applied Biosystems dry DNA protocol. 
Amplification products were analyzed using the Applied Biosystems 7900HT Fast 
Real-time PCR System. Genotype calls were made based on a clustering algorithm 
with quality value of 95%.  
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Presence of each allele is marked by color and position on a generated plot due to 
level of fluorescence presented in each allele. Homozygotes are displayed on 
extremities of the Y and the X axes whereas heterozygotes are displayed in the 
middle. Allele discrimination can be visualized in a plot showing the two alleles and 
the distribution of the three genotypes, the two homozygous and the heterozygous one 
(FIGURE 7.7). 
 
FIGURE 7.7   Allelic Discrimination Plot Resulting from the TaqMan Gene Expression Assay 
Procedure. The two alleles are shown in the axis and in different colours are shown the three different 
genotypes: blue colour homozygous -Y allele-, red colour homozygous- X allele-, green colour 
heterozygous -both alleles-. 
 
7.8.3   Sample Size and Power Calculation 
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In order to have 80% power and a significance level of 0.05% (two-tailed) a sample 
of 355 case-control pairs is required to be able to detect an OR= 2. This assumes for 
an exposure of 30% among the general population (Cannon et al., 2002) and with a 
mean allele frequency of 0.5. Overall I collected genetic data on 262 subjects of the 
original 313 (51 refused to give blood or cheek swabs); with a sample of 127 patients 
and 135 controls (95 unaffected siblings and 40 healthy controls). Thus, I have the 
80% power of detecting an interaction of OR>4.5 with 95% confidence in our 
population. These calculations have been made using the Quanto 1.2.4 software using 
the gene-environment module (John Morrison and W. James Gauderman at the 
University of Southern California). 
7.8.4 Statistical Analysis 
Data was recorded in IBM SPSS version 20.0 and analysed in the software package 
UNPHASED 3.1.7 (Dudbridge, 2008) as a way of combining related and unrelated 
individuals.  
Based on the existing literature and on the findings reported in the previous chapter, I 
used history of OCs as the environmental exposures of interest. As explained in 
CHAPTER 5, the Lewis-Murray Scale (Lewis and Murray, 1987) was used as the 
principal measure of OCs; each item was evaluated as definite (score 1), or absent 
(score 0). Subjects were rated as having a “definite” (score 1) complication if they 
had suffered at least one significant complication (Lewis et al., 1989).  
As discussed earlier, AKT1 rs1130233, rs3803300 and rs2494735 alleles, BDNF 
rs2049046 and rs56164415 alleles, DTNBP1 rs875462 allele and GRM3 rs7808623 
alleles were chosen as the genetic variants.  
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Hardy-Weinberg equilibrium (HWE) test of SNP was performed looking at unrelated 
individuals using Pedigree Statistics - 0.6.12 (c) (Wigginton and Abecasis, 2005). 
χ2 tests and t-tests (or ANOVA) were used to test for associations between the 
potential confounding variables and the genotype. Further χ2 tests were carried out to 
establish whether OCs were more likely to occur in individual carriers of a particular 
genotype class (a Gene x Environment correlation).  
Each SNPs association was investigated using a likelihood-based association test for 
nuclear families and unrelated subjects under the assumption of Hardy-Weinberg 
Equilibrium (HWE), implemented in the software package UNPHASED 3.1.7 
(Dudbridge, 2008). Forward stepwise regression within each SNPs was applied to 
determine independent association signals. Using UNPHASED, for each SNP, one 
marker at a time was tested for association to case/control status and the presence of 
OCs. In order to determine whether there was a gene x environment interaction 
among the SNPs investigated and OCs, effect modification by OCs was explored.  
Adjustment for multiple testing was performed using Bonferroni and Holm (Holm, 





7.9.1     AKT1 x OCs Interaction and Risk of Psychosis 
7.9.1a   rs1130233 x OCs 
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I obtained AKT1 rs1130233 genotyping data on 112/127 cases, 86/95 siblings and 
37/40 controls, with an overall call rate of 89.7% (FIGURE 7.8 and 7.9). The AKT1 
rs1130233 polymorphism allele was in HWE (TABLE 7.1). 
 
FIGURE 7.8 and 7.9   TaqMan AKT1 rs1130233 Allelic Discrimination Plot. Blue colour 
homozygous -G allele-, red colour homozygous- A allele-, green colour heterozygous -AG alleles-.
 

































TABLE 7.1   AKT11 rs1130233 Genotype. Hardy-Weinberg equilibrium (HWE) was performed 
looking at unrelated individuals using Pedigree Statistics - 0.6.12 (c) (1999-2006 Goncalo Abecasis, 
2002-2006 Jan Wigginton). 
 
I found no significant difference in AKT1 rs1130233 allelic distribution by gender 
(χ2=1.88; p=0.39).  
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There was no evidence of a correlation between the AKT1 rs1130233 genotype and 
history of OCs (χ2=1.02, p=0.31) or with increased likelihood of a psychotic disorder 
(χ2=0.06, p=0.80). 
The effect of OCs on the likelihood to suffer from a psychotic disorder was not 
modified by the AKT1 rs1130233 genotype.  Among those who experienced OCs, 
there was no significant change in individual risk of psychosis according to AKT1 
rs1130233 genotype (OR=1.28, 95% CI 0.76-2.16, p=0.35). 
These findings indicate that AKT1 rs1130233 genotype doesn’t modify the effect of 
OCs on the risk of a psychotic disorder.  
7.9.1b   rs2494735 x OCs 
I obtained AKT1 rs2494735 genotyping data on 110/127 cases, 87/95 siblings and 
34/40 controls, with an overall call rate of 88.2% (FIGURE 7.10 and 7.11). The AKT1 
rs2494735 polymorphism allele was in HWE (TABLE 7.2).
FIGURE 7.10 and 7.11   TaqMan AKT1 rs2494735 Allelic Discrimination Plot. Blue colour 
homozygous -T allele-, red colour homozygous- C allele-, green colour heterozygous -CT-.
 


































TABLE 7.2 AKT11 rs2494735 Genotype.  Hardy-Weinberg equilibrium (HWE) was performed 
looking at unrelated individuals using Pedigree Statistics - 0.6.12 (c) (1999-2006 Goncalo Abecasis, 
2002-2006 Jan Wigginton). 
 
I found no significant difference in AKT1 rs2494735 allelic distribution by gender 
(χ2=0.94; p=0.62), 
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There was no evidence of a correlation between the AKT1 rs2494735 genotype and 
history of OCs (χ2=3.12, p=0.08) or with increased likelihood of a psychotic disorder 
(χ2=2.48, p=0.11). 
The effect of OCs on the likelihood to suffer from a psychotic disorder was not 
modified by the AKT1 rs2494735 genotype.  Among those who experienced OCs, 
there was no significant change in individual risk of psychosis according to AKT1 
rs2494735 genotype (OR=1.40, 95% CI 0.88-2.21, p=0.15). 
These findings indicate that AKT1 rs2494735 genotype does not modify the effect of 
OCs on the risk of a psychosis.  
7.9.1c   rs3803300 x OCs 
I obtained AKT1 rs3803300 genotyping data on 103/127 cases, 81/95 siblings and 
36/40 controls, with an overall call rate of 84% (FIGURE 7.12 and 7.13). The AKT1 





FIGURE 7.12 and 7.13   TaqMan AKT1 rs3803300 Allelic Discrimination Plot. Blue colour 
homozygous -G allele-, red colour homozygous- A allele-, green colour heterozygous -AG alleles-.
 

































TABLE 7.3   AKT11 rs3803300 Genotype. Hardy-Weinberg equilibrium (HWE) was performed 
looking at unrelated individuals using Pedigree Statistics - 0.6.12 (c) (1999-2006 Goncalo Abecasis, 
2002-2006 Jan Wigginton). 
 
I found no significant difference in AKT1 rs3803300 allelic distribution by gender 
(χ2=2.69; p=0.26). 
! 139!
There was no evidence of a correlation between the AKT1 rs3803300 genotype and 
history of OCs (χ2=0.34, p=0.56) or with increased likelihood of a psychotic disorder 
(χ2=0.05, p=0.82). 
The effect of OCs on the likelihood to suffer from a psychotic disorder was not 
modified by the AKT1 rs3803300 genotype.  Among those who experience OCs, 
there was no significant change in individual risk of psychosis according to AKT1 
rs3803300 genotype (OR=1.28, 95% CI 0.63-2.58; p=0.49). 
These findings indicate that the AKT1 rs3803300 genotype doesn’t seem to modify 
the effect of OCs on the risk of a psychotic disorder.  
7.9.2     BDNF x OCs Interaction and Risk of Psychosis 
7.9.2a   rs2049046 x OCs 
I obtained BDNF rs2049046 genotyping data on 100/127 cases, 78/95 siblings and 
31/40 controls, with an overall call rate of 79.8% (FIGURE 7.14 and 7.15). The BDNF 
rs2049046 polymorphism was in HWE (TABLE 7.4).  
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FIGURE 7.14 and 7.15   TaqMan BDNF rs2049046 Allelic Discrimination Plot. Blue colour 
homozygous -T allele-, red colour homozygous- A allele-, green colour heterozygous -AT alleles-.
 

































TABLE 7.4   BDNF rs2049046 Genotype. Hardy-Weinberg equilibrium (HWE) was performed 
looking at unrelated individuals using Pedigree Statistics - 0.6.12 (c) (1999-2006 Goncalo Abecasis, 
2002-2006 Jan Wigginton). 
 
I found no significant difference in BDNF rs2049046 allelic distribution by gender 
(χ2=1.57; p=0.46). 
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There was no evidence of a correlation between the BDNF rs2049046 genotype and 
history of OCs (χ2=1.50, p=0.22) or with increased likelihood of a psychotic disorder 
(χ2=0.08, p=0.78). 
The effect of OCs on the likelihood to suffer from a psychotic disorder was not 
modified by the BDNF rs2049046 genotype.  Among those who experience OCs, 
there was no significant change in individual risk of psychosis according to BDNF 
rs2049046 genotype (OR= 1.17 95% CI 0.76-1.79, p=0.48). 
These findings indicate that the BDNF rs2049046 genotype doesn’t seem to modify 
the effect of OCs on the risk of a psychotic disorder.  
7.9.2b   rs56164415 x OC 
I obtained BDNF rs56164415 genotyping data on 107/127 cases, 83/95 siblings and 
38/40 controls, with an overall call rate of 87% (FIGURE 7.16 and 7.17). The BDNF 
rs56164415 polymorphism was in HWE (TABLE 7.5).  
FIGURE 7.16 and 7.17   TaqMan BDNF rs56164415 Allelic Discrimination Plot. Blue colour 
homozygous –G allele-, red colour homozygous- A allele-, green colour heterozygous -AG alleles-.
 

































TABLE 7.5   BDNF rs56164415 Genotype. Hardy-Weinberg equilibrium (HWE) was performed 
looking at unrelated individuals using Pedigree Statistics - 0.6.12 (c) (1999-2006 Goncalo Abecasis, 
2002-2006 Jan Wigginton). 
 
I found no significant difference in BDNF rs56164415 allelic distribution by gender 
(χ2=2.57; p=0.28). 
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There was no evidence of a correlation between BDNF rs56164415 genotype and 
history of OCs (χ2=0.97, p=0.32) or with increased likelihood of a psychotic disorder 
(χ2=0.23, p=0.63). 
The effect of OCs on the likelihood to suffer from a psychotic disorder was not 
modified by the BDNF rs56164415 genotype.  Among those who experience OCs, 
there was no significant change in individual risk of psychosis according to BDNF 
rs56164415 genotype (OR= 0.93, 95% CI 0.35-2.52, p=0.89). 
These findings indicate that BDNF rs56164415 genotype doesn’t seem to modify the 
effect of OCs on the risk of a psychotic disorder.  
7.9.3     DTNBP1 rs875462 x OCs Interaction and Risk of Psychosis 
I obtained DTNBP1 rs875462 genotyping data on 85/127 cases, 83/95 siblings and 
34/40 controls, with an overall call rate of 77% (FIGURE 7.18 and 7.19).  The DTNBP1 
rs875462 polymorphism allele was in HWE (TABLE 7.6).  
FIGURE 7.18 and 7.19   TaqMan DTNBP1 rs875462 Allelic Discrimination Plot. Blue colour 
homozygous -A allele-, red colour homozygous- G allele-, green colour heterozygous -AG alleles-.
 

































TABLE 7.6   DTNBP1 rs875462 Genotype. Hardy-Weinberg equilibrium (HWE) was performed 
looking at unrelated individuals using Pedigree Statistics - 0.6.12 (c) (1999-2006 Goncalo Abecasis, 
2002-2006 Jan Wigginton). 
 
I found no significant difference in DTNBP1 rs875462 allelic distribution by gender 
(χ2=3.33; p=0.19). 
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There was no evidence of a correlation between the DTNBP1 rs875462 genotype and 
history of OCs (χ2=1.36, p=0.24) or with increased likelihood of a psychotic disorder 
(χ2=2.39, p=0.12). 
The effect of OCs on the likelihood to suffer from a psychotic disorder was not 
modified by the DTNBP1 rs875462 genotype.  Among those who experience OCs, 
there was no significant change in individual risk of psychosis according to DTNBP1 
rs875462 genotype (OR=0.71, 95% CI 0.43-1.18, p=0.19). 
These findings indicate that the DTNBP1 rs875462 genotype doesn’t seem to modify 
the effect of OCs on the risk of a psychotic disorder.  
7.9.4     GRM3 rs7808623 x OCs Interaction and Risk of Psychosis 
I obtained GRM3 rs7808623 genotyping data on 115/127 cases, 85/95 siblings and 
37/40 controls, with an overall call rate of 90.4% (FIGURE 7.20 and 7.21).  The GRM3 
rs7808623 polymorphism allele was in HWE (TABLE 7.7).  
FIGURE 7.20 and 7.21   TaqMan GRM3 rs7808623 Allelic Discrimination Plot. Blue colour 
homozygous -G allele-, red colour homozygous- T allele-, green colour heterozygous -GT alleles-. 
 

































TABLE 7.8   GRM3 rs7808623 Genotype. Hardy-Weinberg equilibrium (HWE) was performed 
looking at unrelated individuals using Pedigree Statistics - 0.6.12 (c) (1999-2006 Goncalo Abecasis, 
2002-2006 Jan Wigginton). 
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I found no significant difference in GRM3 rs7808623 allelic distribution by gender 
(χ2=0.28; p=0.87),  
There was no evidence of a correlation between the GRM3 rs7808623 genotype and 
history of OCs (χ2=1.55, p=0.21) or with increased likelihood of a psychotic disorder 
(χ2=0.10, p=0.75). 
The effect of OCs on the likelihood to suffer from a psychotic disorder was not 
modified by the GRM3 rs7808623 genotype.  Among those who experience OCs, 
there was no significant change in individual risk of psychosis according to GRM3 
rs7808623 genotype (OR=1.58, 95% CI 0.81-3.10, p=0.18). 
These findings indicate that the GRM3 rs7808623 genotype doesn’t seem to modify 
the effect of OCs on the risk of a psychotic disorder.  
 
 
7.10     Summary of Results  
OCs increase risk of schizophrenia but not everyone that experienced OCs develops 
psychosis later in life.  
In this study I selected known genotype variants of 4 genes, which are regulated by 
hypoxia, namely AKT1, BDNF, DTNMBP1, GRM3, in an attempt to replicate the 
findings of Nicodemus et al. (2008). I expected carriers of the above risk alleles to be 
significant at risk of developing a psychotic disorder in subjects exposed to definite 
OC.  
None of them was associated with psychosis or with likelihood to have had OC. 
Moreover my results do not suggest any interaction between the presence of OCs and 
selected genotype on the risk of a psychotic disorder. 
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Although I have failed to replicate the findings of Nicodemus et al. (2008), my final 
sample size (n= 262) was underpowered.  Therefore these findings do not provide 
definite evidence against a possible role of the above genotypes in modifying the 
effect of OCs on risk of psychotic disorders.  
 
 
7.11     Discussions 
There is no doubt a strong genetic component to psychosis, but family and twin 
studies have shown that simple genetic transmission is far from the whole story. In 
addition more than 50% of genes potentially associated with schizophrenia are subject 
to regulation by hypoxia and/or are expressed in the vasculature (Schmidt-Kastner et 
al., 2006; Schmidt-Kastner et al., 2012). Numbers of environmental factors have also 
been shown to increase risk of psychosis, among them OCs are the best replicated 
(Cannon et al., 2002). Variability in people’s responses to environmental risk factors 
suggests that genes and environments operate together to produce psychosis (Tsuang 
et al., 2004; Di Forti et al., 2007b).  
GxE research represents an important approach to explain the occurrence of 
psychosis. In the context of this chapter the major aim was to address the question of 
whether or not selected genes interact with the presence of OCs in the aetiology of 
psychosis. In particular I selected genotype variants of a total of 4 genes, namely 
AKT1, BDNF, DTNBP1 and GRM3, which are regulated by hypoxia and/or 
expressed in the vasculature to investigate the interaction. My study didn’t show any 
significant evidence for gene-by-environment interaction but, because of limitations 
of power, I am unable to provide definite evidence against a possible role of selected 
genotypes in modifying the effect of OCs on risk of psychotic disorders.  
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It is likely that genes play an important role in mediating the reactions of the CNS to 
environmental stimuli such hypoxia. A difficult challenge is to identify plausible 
susceptibility genes to investigate how, and if, they moderate the effect of obstetric 
complications on the risk of psychosis. An answer could be looking at the interaction 
among genes regulated by hypoxia and the presence of OCs regardless their 
involvement in schizophrenia. 
 
 
7.12  Limitations 
7.12.1     Recruitment 
Case-control designs are often prone to selection bias in both cases and controls 
recruitment.  
7.12.1a   Case Recruitment Bias 
The cases in this thesis are all individuals presenting with psychotic disorders, 
therefore includes patients who eventually will receive different categorical 
diagnoses. To date evidence is stronger for an association between OCs and increased 
risk of schizophrenia spectrum psychosis rather than for affective psychosis (bipolar, 
psychotic depression). Therefore, it is possible that because my outcome group 
includes both affective and non-affective psychosis, both the main effect of exposure 
to OCS and its interaction with the selected candidate genes on the risk of developing 
a psychotic disorder is underestimated. 
7.12.1b   Control Recruitment Bias 
Control recruitment is a challenge, as controls need to be a representative sample of 
the population from which cases are recruited. Controls used in the analyses were 
similar, according to the last UK census data, on a number of socio-demographic 
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factors (age, gender, ethnicity, level of education, employment rates) to the population 
that the cases come from (Census data 2001).  Moreover, there was no evidence that 
the control recruitment under/over sampled those who suffered an OCs. About 25%-
30% of births involve at least one Lewis-Murray complication (Jones et al., 1998; 
Cannon et al., 2002), thus the proportion of controls with a history of OC (21.4%) was 
comparable to the general population estimate. 
To overcome the above limitation siblings are increasingly used as comparison groups 
in case-control studies. The "within-pair" estimates acquired through these 
comparisons are free from confounding from all factors that are shared by the 
siblings, including cultural and social background, parental characteristics and 
genetics. Although within-pair estimates will not be confounded by factors shared by 
the siblings, attenuation of associations will be higher in the within-pair estimate, 
leading within-pair associations to be weaker than corresponding unpaired 
associations, even in the absence of confounding (Frisell et al., 2012).  
Finally to override genetic bias within-pair each SNPs association was investigated 
using a likelihood-based association test for unrelated subjects using UNPHASED 
3.1.7 (Dudbridge, 2008).  
7.12.2     Sample Size  
The final sample size (n= 262) was underpowered to estimate whether there was any 
interaction of OR<4.5 in our population, according to the QUANTO estimate.  The 
recruitment had proven very difficult and time consuming. It had required different 
steps, which delayed the start of the recruitment resulting in a smaller final number of 
subjects. 
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It is possible that a larger sample size may have detected an increased risk for 
psychosis due to Gene x Environment that the present study did not have sufficient 
power to assess.  
7.12.3     Retrospective Data 
One of the most common sources of bias is information bias as the history of 
exposure to OCs is collected retrospectively. However, as already mentioned in 
CHAPTER 6, studies assessing the validity of maternal recall compared to birth records 
have shown good agreement between retrospective maternal recall and 
contemporaneous birth records using the Lewis–Murray scale (reviewed by Walshe et 















GWAS Genetic Findings x OCs: the Role in Psychosis 
 
 
8.1     Introduction 
As discussed in the introduction, OCs explain a small, but significant, increase in risk 
for schizophrenia and psychosis in general possibly due to hypoxic insult to the brain.  
Different genetic variants can also influence the reaction to hypoxia as previously 
discussed (CHAPTER 7). 
Results from several GWAS in schizophrenia show interesting matches between 
genes and ischemia– hypoxia or vascular factors but unfortunately differences in 
design and data presentation in different GWAS studies preclude a quantitative 
analysis (Schmidt-Kastner et al., 2012).  Thus further research is warranted to identify 
direct links between hypoxia, genetic vulnerability and schizophrenia (Schmidt-
Kastner et al., 2012). 
No studies have yet provided direct evidence for an interaction between genes 
identified as genome wide significant in GWAS studies (abbreviated as GWAS 
genes) and hypoxia during pre- and perinatal life in increasing the risk for psychosis; 
therefore I aim to contribute with a GxE study in a sample of case controls looking at 
SNPs selected on the basis of recent GWAS studies. 
 
 
8.2     GWAS Genes Polymorphisms Selected for the Analysis. 
Genes selected for the analysis have been chosen looking at the GWAS published 
between 2008-2012 conducted on schizophrenia and psychosis in general. 39 SNPs 




Gene region Symbol Full name SNPs Significance Reference 
1 1p21.3 MIR137 (intron 3 of miRNA 
transcript) 
rs1625579 Significant Schizophrenia 
GWAS Consortium, 
2011 
 1q24.2   rs10489202 Significant Shi et al., 2011 
 
 1q32.2 PLXNA2 plexin A2 rs752016 Strongly 
Suggestive 
Mah et al., 2006 
 
 1p36.1 CDC42 cell division cycle 42 rs2473277 Strongly 
Suggestive 
Gilks et al., 2012 
 
 1q43 SDCCAG8 serologically defined 
colon cancer antigen 
8 
rs6703335 Significant Hamshere et al., 2013 
 
2 2p16.1 VRK2 vaccinia related 
kinase 2 
rs2312147 Significant Steinberg et al., 2011 




O’Donovan et al., 
2008  
 2q32.3 PCGEM1 prostate-specific 
transcript 1 (non-
protein coding) 
rs17662626 Significant Schizophrenia 
GWAS Consortium, 
2011 
 2q33.3-q34 Erbb4 v-erb-a erythroblastic 
leukemia viral 
























twist homolog 2 
(Drosophila) 
rs9751357 Significant Alkelai et al., 2011 
 2q37.3 
 
LRRFIP1 leucine rich repeat (in 
FLII)interacting 
protein 1 
rs12052937 Significant Alkelai et al., 2011 
3 3p21.1 ITIH3/4 nter-alpha-trypsin 
inhibitor heavy chain 
3/4 
rs2239547 Significant Schizophrenia 
GWAS Consortium, 
2011 
 3q21-q23 RELN reelin rs7341475 Strongly 
Suggestive 




TRIM26 tripartite motif 
containing 26 





ZKSCAN4 zinc finger with 
KRAB and SCAN 
domains 4 
rs1233710 Significant Yueet al., 2011 
 6p21.3 NOTCH4 notch 4 rs2071287 Strongly 
Suggestive 
Stefansson et al., 
2009 
 6p22.1 MHC region  rs3130375 Significant Shi et al., 2009; 




 6p22.1 NKAPL NFKB activating 
protein-like 














rs2066036 Significant Alkelai et al., 2011 
 




Athanasiu et al., 2010 
 




Alkelai et al., 2012 
8 8p12   rs16887244 Significant Shi et al., 2011 
 
 8q21 MMP16  rs7004633 Significant Schizophrenia 
GWAS Consortium, 
2011 
 8p21-p12 NRG1 neuregulin 1 rs4316112 Strongly 
Suggestive 
Shi et al., 2009 
 8p23.2 
 
CSMD1 CUB and sushi 
domain-containing 
protein 1; protein 
phosphatase 1, 
regulatory subunit 24 






sulfoxide reductase A 
rs7017212 Strongly 
Suggestive 
Ma et al., 2011 
10 10q21 
 
ANK3 ankyrin 3, node of 
Ranvier (ankyrin G) 




 10q24.32 CNNM2 cyclin M2 rs7914558 Significant Schizophrenia 
GWAS Consortium, 
2011 
 10q24.32 NT5C2 5'-nucleotidase, 
cytosolic II 
rs11191580 Significant Schizophrenia 
GWAS Consortium, 
2011 









11q24.2 NRGN neurogranin (protein 
kinase C substrate, 
RC3) 
rs12807809 Significant Stefansson et al., 
2009 
12 12p13.3 CACNA1C calcium channel, 
voltage-dependent, L 
type, alpha 1C 
subunit 





CCDC68 coiled-coil domain 
containing 68 
rs12966547 Significant Schizophrenia 
GWAS Consortium, 
2011 







adhesion molecule 21 





IL3RA interleukin 3 
receptor, alpha  
rs17883192 Strongly 
Suggestive 
Lencx et al., 2007 
TABLE 8.1   List of GWAS SNPs Related to Psychosis.  p value < 10-8 was considered strongly 
significant; p value comprises between 10-6 and 10-8 was considered significant; p value = 10-5 was 
considered strongly suggestive. 
 
For the given set of SNPs listed above I designed one MassEXTEND (hME) assay 
panel using the latest version of the Sequenom MassARRAY Assay Design Software 
under the supervision of Dr Conrad Iyegbe. Finally, among those listed above, the 
following 25 SNPs could be simultaneously assayed in one multiplex panel with 
standardized conditions: AK573765-TWIST2 rs9751357, CACNA1C rs4765905, 
CEACAM21 rs4803480, CNNM2 rs7914558, CSMD1 rs10503253, Erbb4 
rs1851196, ITIH3/4 rs2239547, LOC645434-NMBR rs2066036, LRRFIP1 
! 156!
rs12052937, MIR137 rs1625579, MMP16 rs7004633, NKAPL rs1635, NRGN 
rs12807809, NT5C2 rs11191580, PCLO rs6979348, PLXNA2 rs752016, PGBD1 
rs2142731, PCGEM1 rs17662626, RELN rs7341475, SDCCAG8 rs6703335, STT3A 
rs548181, TCF4 rs17512836, UGT1A1 HJURP rs741160, rs10489202, rs16887244. 
 
 
8.3    Aims 
I aim to: 
1. Test if each of the selected genetic variants is associated with an increased risk 
of psychotic disorders. 
2. Test if each of the selected genetic variants is associated with an increased risk 
of OCs occurrence. 
3. Test if each of the selected genetic variants interacts with exposure to OCs to 
moderate the risk of psychotic disorders. 
 
 
8.4     Hypothesis  
I expect each SNP minor allele to interact with exposure to OCs in increasing the risk 
of psychotic disorders. 
 
 
8.5     Methods  
The presence of OCs was assessed through maternal interview on 313 subjects, 
comprising 145 psychotic cases, 103 unaffected siblings and 65 healthy controls. The 
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sample comprised 252 individuals who are participants in The Maudsley Family 
Psychosis Study and 61 participants personally recruited from the GAP study.  
8.5.1    Assessment  
As previously discussed (CHAPTER 5 ) OCs were retrospectively collected from 
mothers of each participant using the MIS and coded using the Lewis-Murray scale.  
8.5.2   Genotyping  
DNA material was obtained from 262 subjects in total (127 cases, 95 siblings, 40 
controls) from either blood or from cheek swab samples with an overall call rate of 
79.4%. It comes almost entirely from the MFS, with the exception of 6 patients 
recruited in the GAP study. AK573765-TWIST2 rs9751357, CACNA1C rs4765905, 
CEACAM21 rs4803480, CNNM2 rs7914558, CSMD1 rs10503253, Erbb4 
rs1851196, ITIH3/4 rs2239547, LOC645434-NMBR rs2066036, LRRFIP1 
rs12052937, MIR137 rs1625579, MMP16 rs7004633, NKAPL rs1635, NRGN 
rs12807809, NT5C2 rs11191580, PCLO rs6979348, PLXNA2 rs752016, PGBD1 
rs2142731, PCGEM1 rs17662626, RELN rs7341475, SDCCAG8 rs6703335, STT3A 
rs548181, TCF4 rs17512836, UGT1A1 HJURP rs741160, rs10489202, rs16887244 
alleles were chosen as the genetic variants.  
The DNA was extracted using a standard phenol-chloroform extraction procedure. 
Sequenom MassARRAYplatform was used to conduct the entire genotyping 
following the manufacturer instructions under the supervision of Dr Rebecca Smith 
(FIGURE 8.1).  
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FIGURE 8.1   The MassEXTEND iPLEX Reaction. A schematic of the genotype reaction of a C-to-
G SNP. Taken from Gabriel et al., 2009. 
 
The assay consists of an initial locus-specific PCR reaction, followed by single base 
extension using mass-modified dideoxynucleotide terminators of an oligonucleotide 
primer which anneals immediately upstream of the polymorphic site of interest. Using 
MALDI-TOF mass spectrometry, the distinct mass of the extended primer identifies 
the SNP allele. 
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8.5.3   Sample Size and Power Calculation 
In order to have 80% power and a significance level of 0.05% (two-tailed) a sample of 
355 case-control pairs is required to be able to detect an OR= 2. This assumes for an 
exposure of 30% among the general population (Cannon et al., 2002) and with a mean 
allele frequency of 0.5.  Overall I collected genetic data on 262 subjects of the 
original 313 (51 refused to give blood or cheek swabs); with a sample of 127 patients 
and 135 controls (95 unaffected siblings and 40 healthy controls) I have the 80% 
power of detecting an interaction of OR>4.5 with 95% confidence in our population. 
These calculations have been made using the Quanto 1.2.4 software using the gene-
environment module (John Morrison and W. James Gauderman at the University of 
Southern California). 
8.5.4  Statistical Analysis 
Data was recorded in IBM SPSS version 20.0 and analysed in the software package 
UNPHASED 3.1.7 (Dudbridge, 2008) as a way of combining related and unrelated 
individuals.  
Based on the existing literature and on the findings reported in the previous chapter I 
used history of OCs as the environmental exposures of interest. AK573765-TWIST2 
rs9751357, CACNA1C rs4765905, CEACAM21 rs4803480, CNNM2 rs7914558, 
CSMD1 rs10503253, Erbb4 rs1851196, ITIH3/4 rs2239547, LOC645434-NMBR 
rs2066036, LRRFIP1 rs12052937, MIR137 rs1625579, MMP16 rs7004633, NKAPL 
rs1635, NRGN rs12807809, NT5C2 rs11191580, PCLO rs6979348, PLXNA2 
rs752016, PGBD1 rs2142731, PCGEM1 rs17662626, RELN rs7341475, SDCCAG8 
rs6703335, STT3A rs548181, TCF4 rs17512836, UGT1A1 HJURP rs741160, 
rs10489202, rs16887244 alleles were chosen as the genetic variants.   
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Hardy-Weinberg equilibrium (HWE) test of SNP was performed using Pedigree 
Statistics - 0.6.12 (c) (Wigginton and Abecasis, 2005). 
χ2 tests and t-tests (or ANOVA) were used to test for associations between the 
potential confounding variables and the genotype. Further χ2 tests were carried out to 
establish whether OCs were more likely to occur in individual carriers of a particular 
genotype class (a Gene x Environment correlation).  
Each SNPs association was investigated using a likelihood-based association test for 
nuclear families and unrelated subjects under the assumption of Hardy-Weinberg 
equilibrium, implemented in the software package UNPHASED 3.1.7 (Dudbridge, 
2008). Forward stepwise regression within each SNPs was applied to determine 
independent association signals. Using UNPHASED, for each SNP, one marker at a 
time was tested for association to case/control status and the presence of OCs. In 
order to determine whether there was a gene x environment interaction among the 
SNPs investigated and OCs, effect modification by OCs was explored.  Adjustment 
for multiple testing was performed using Bonferroni and Holmes (1979) correction. 
 
 
8.6     Results 
8.6.1   Description of the Whole Sample  
I obtained genotyping data on 123 cases, 93 siblings and 35 controls, with an overall 
call rate of 79.4%; marker rs10489202 failed. 
8.6.1a   Demographic Characteristic of the Sample  
For those subjects on whom I obtained DNA, cases were significantly younger (mean 
age 22.7 years; SD 4.7) than the control group (mean age 31.1 years; SD 8.1) (mean 
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difference -9.66, SE 0.87, 95% CI 6.69- 10.13; p<0.001). Moreover patients were 
more likely to be male (p<0.001) (TABLE 8.2). 
 






  Mean (SD) Mean (SD)  
Age  22.7 (4.7) 31.1 (8.1) p<0.001 








TABLE 8.2   Demographic Characteristics of Cases and Controls.  P values from t-tests and χ2  
tests. 
 
Analyzing the allelic distribution of each gene by gender no significant difference 
were found (p>0.05).  
8.6.1b   Genetic Characteristics of the Sample 
I analyzed the allelic distribution of each gene together with the Hardy-Weinberg 
Equilibrium (HWE) (TABLE 8.3).  
 























































































































































































































































































































































































































































































































TABLE 8.3   Allelic Frequencies of Genes and Hardy-Weinberg Equilibrium (HWE). Marker 
rs10489202 failed. 
 
Two genes polymorphisms allele breached a Hardy-Weinberg Equilibrium (HWE) p-
value of 0.05, namely UGT1A1-HJURP rs741160 and NRGN rs12807809 (TABLE 
8.3). Although, traditionally a p < 0.05 was considered to breach the HWE, recent 
GWAS have suggested a much higher threshold of significance (10-4) before 
discarding a SNP on the assumption of genotyping error (WTCC, Nature 2007).  
Therefore a small difference, even though statistically significant, between expected 
and observed frequencies of a particular SNP can be explained by population mixture 
rather than simply by genotyping error. For instance, even the White British, are a 
heterogeneous population, having been shaped by several waves of immigration from 
elsewhere in Europe.  
After Bonferroni and Holm (1979) correction for multiple testing, the HWE p value in 
rs741160 and rs12807809 were no longer significant (pc≤ 0.002), thus none of the 
genes showed significant difference in distribution.  
8.6.2     Genes Allele and Psychotic Disorder Correlation 
There was evidence of a correlation between selected genotype and psychosis.  
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In particular, CEACAM21 rs4803480 risk allele “A” increases the risk of the 
occurrence of psychosis about 3 fold (OR= 2.79, 95% CI 1.42- 5.48; p= 0.002). After 
Bonferroni and Holm (1979) correction for multiple testing (pc ≤ 0.002) this remained 
significant.  
8.6.3     Genes Allele and Obstetric Complication Correlation 
There was evidence of a correlation between MIR137 rs1625579  (χ2=4.29; p=0.04) 
and LRRFIP1 rs12052937  (χ2=4.64; p=0.03) polymorphisms and history of OCs. 
After Bonferroni and Holm (1979) correction for multiple testing (pc≤ 0.002) neither 
of them remained significant. 
8.6.4     Genes Allele x OCs  
The association of the interaction between risk allele of each gene polymorphisms x 
OCs with presence of a psychotic disorder was then investigated. No significant 










MIR137 rs1625579 χ2=-0.43 
 
p=0.51 
- rs10489202 NA NA 
 
PLXNA2 rs752016 χ2=0.28 
 
p=0.59 
SDCCAG8 rs6703335 χ2=0.95 
 
p=0.33 
PCGEM1 rs17662626 χ2=0.98 
 
p=0.32 
Erbb4 rs1851196 χ2=0.88 
 
p=0.35 
UGT1A1-HJURP  rs741160 χ2=0.01 
 
p=0.92 
AK573765-TWIST2  rs9751357 χ2=1.12 
 
p=0.29 
LRRFIP1 rs12052937 χ2=3.25 
 
p=0.07 
ITIH3/4 rs2239547 χ2=0.56 
 
p=0.45 
RELN rs7341475 χ2=1.30 
 
p=0.25 
NKAPL rs1635 χ2=0.09 p=0.76 
 
PGBD1 rs2142731 χ2=0.96 p=0.33 
 
LOC645434-NMBR rs2066036 χ2=1.89 p=0.17 
 
PCLO rs6979348 χ2=0.20 p=0.65 
 
Xxx rs16887244 χ2=2.79 p=0.09 
 
MMP16 rs7004633 χ2=0.43 p=0.51 
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TABLE 8.4   Likelihood Ratio  χ2 of OCs X Gene in Increasing the Risk of Psychosis. Each SNPs 
association was investigated using a likelihood-based association test for nuclear families and unrelated 
subjects under the assumption of Hardy-Weinberg equilibrium, implemented in the software package 
UNPHASED 3.1.7 (Dudbridge, 2008). 
 
These findings indicate that the genotypes I examined do not modify the effect of OCs 
on the risk of a psychosis. 
 
 
8.7     Summary of Results 
In this study I selected known genotype variants of 25 genes from the GWAS findings 
published so far in an attempt to show an interaction between each SNPs risk allele 
and OCs.  
CSMD1 rs10503253 χ2=-0.35 
 
p=0.55 
CNNM2 rs7914558 χ2=0.27 
 
p=0.60 
NT5C2 rs11191580 χ2=1.03 
 
p=0.31 
STT3A rs548181 χ2=0.16 
 
p=0.68 
NRGN rs12807809 χ2=0.01 
 
p=0.91 
CACNA1C rs4765905 χ2=3.28 
 
p=0.07 
TCF4 rs17512836 χ2=0.29 
 
p=0.59 




Among them CEACAM21 was associated with psychosis while none was associated 
with likelihood to have had OC. Moreover my results do not suggest any interaction 




8.8     Discussions 
Since 2008 GWAS have identified a substantial number of polymorphisms associated 
with schizophrenia, although these findings are characterized by small effect sizes (O’ 
Donovan et al., 2009). Moreover, it is likely that the effect of genes on the disease 
causal path might partly depend on environmental exposures through interaction 
and/or via epigenetic mechanism (Tsuang et al., 2004; Rutten and Mill, 2009).  
Results from recent GWAS show several interesting matches between genes and 
ischemia/hypoxia or vascular factors but so far no studies have yet provided direct 
evidence for their interaction with hypoxia during pre- and perinatal life in increasing 
the risk for psychosis (Schmidt-Kastner et al., 2012). In this chapter I investigated the 
interaction among genotype variants of a total of 25 SNPs that have been chosen 
looking at the GWAS conducted on schizophrenia and psychosis in general with OCs 
in increasing the risk of psychosis.  
Although I have failed to show any evidence for an interaction the final sample size 
(n= 262) was underpowered.  Therefore these findings do not provide definite 
evidence against a possible role of the above genotypes in modifying the effect of 




8.9     Limitations 
As part of the same sample, limitations are already discussed in previous Chapters 
(CHAPTER 6 and 7). 
In particular for this set of analyses the final (n= 262) was underpowered to estimate 
whether there was any interaction of OR<4.5 in our population, according to the 
QUANTO estimate.  It is possible that a larger sample size may have detected an 
increased risk for psychosis due to Gene x Environment that the present study did not 




















Gene X Environment: a Case- Only Study 
 
 
9.1     Introduction 
As discussed earlier, OCs increase risk of schizophrenia but not everyone that 
experienced OCs develops psychosis later in life. In this Thesis, in an attempt to 
replicate the findings of Nicodemus et al. (2008), I selected known genotype variants 
of 4 genes, namely AKT1, BDNF, DTNMBP1, and GRM3, to look at their interaction 
with OCs in increasing the risk of psychosis (CHAPTER 7).  There were no statistically 
significant findings but because of limitations of power, I was unable to definitively 
exclude interaction. Thus, this interaction model has not yet been fully empirically 
tested.   
A case-only design can be a valid approach to evaluate gene-environment interaction 
in disease etiology (Piegorsch, et al., 1994; Khoury and Flanders, 1996; Yanget al., 
1997; Andrieu and Goldstein, 1998; Weinberg and Umbach, 2000). As explained in 
Khoury and Flanders, 1996, the odds ratio relating the exposure and the allele among 
case subjects only is a function of the odds ratios for the exposure alone, the genotype 
alone, and their joint effects in a standard case-control study as follow: 
COR = ORge/ (ORe X ORg) X Z. 
COR is the case-only odds ratio and Z refers to the odds ratio among control subjects 
relating the exposure and the susceptibility genotype. It can be summarized as COR = 
ad/bc (FIGURE 9.1).  
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FIGURE 9.1   Gene-Environment Interaction Analysis in the Context of a Case-Only Study. 
COR, case-only odds ratio = ad/bc. Under assumption of independence between exposure and genotype 
among controls. Taken from Khoury and Flanders, 1996. 
 
If the genotype and the exposures are independent, Z becomes unity and the odds 
ratio obtained from a case-only study becomes simply the synergy index on a 
multiplicative scale derived from a regular case-control study (Khoury and Flanders, 
1996).  
Thus, in order to overcome difficulties associated with the recruitment of an 
appropriate control group and to have greater statistical power with fewer subjects, in 
this chapter I perform a case only design statistical analysis in a group of affected 
subjects to examine GxE interaction.  
 
 
9.2     Aims 
I aim to: 
1. Test if each of the selected genetic variants is associated with an increased risk of 
OCs; 
2. Test if each of the selected genetic variants interacts with exposure to OCs to 
moderate the risk of psychotic disorders. 
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9.3     Hypotheses  
I expect the following SNPs to interact with exposure to OCs in increasing the risk of 
psychotic disorders: 
8. AKT1 rs1130233 “G” allele  
9. AKT1 rs2494735 “C” allele  
10. AKT1 rs3803300 “G” allele. 
11. BDNF rs2049046 “T” allele. 
12. BDNF rs56164415 “A” allele. 
13. DTNBP1 rs875462 “G” allele. 
14. GRM3 rs7808623 “T” allele . 
 
 
9.4     Methods  
The presence of OCs was assessed through maternal interview on 377 psychotic 
cases. 
9.4.1 Recruitment and Assessment  
I increased the available sample of patients thanks to collaboration with the Psychosis 
Incidence Cohort Study  (PICOS), Verona (Lasalvia et al., 2012). Under the overall 
supervision of Professor Mirella Ruggero and Dr Sarah Tosato the project aims to 
clarify, in a cohort of patients diagnosed with psychosis, the role of specific factors 
(i.e clinical, environmental, genetic and functional) in predicting the clinical and 
social outcome. The project also aims to acquire knowledge on environmental, 
psychological, biological and clinical factors related to the characteristic clinical 
picture, and on predictors of outcome and response to treatment. 
! 172!
The project used similar diagnostic criteria and recruitment strategy to collect OCs 
data. OCs was retrospectively collected from mothers and coded using the Lewis-
Murray scale as explained in details in CHAPTER 5.  
Overall the sample comprises 112 individuals who are participants in the MFS, 33 
from the GAP and a total of 232 individuals recruited from PICOS. To maximise 
statistical power, participants from the MFS and GAP were collapsed in one group 
called “UK”. 
9.4.2 Genotyping  
DNA material was obtained from 290 subjects in total. AKT1 rs1130233, rs3803300 
and rs2494735 alleles, BDNF rs2049046 and rs56164415 alleles, DTNBP1 rs875462 
allele and GRM3 rs7808623 allele were chosen as the genetic variants. 
The DNA was extracted using a standard phenol-chloroform extraction procedure. 
TaqMan® Gene Expression Assays Protocol was used to conduct the entire 
genotyping following the manufacturer instructions (CHAPTER 7).  
9.4.3     Sample Size and Power Calculation 
In order to have 80% power and a significance level of 0.05% (two-tailed) a sample of 
203 case is required to be able to detect an OR= 2. This assumes for an exposure of 
30% among the general population (Cannon et al., 2002) and with a mean allele 
frequency of 0.5.  Overall I collected genetic data on 290 subjects, thus I have the 
80% power of detecting an interaction of OR>1.8 with 95% confidence in our 
population. These calculations have been made using the Quanto 1.2.4 software using 
the gene-environment module (Gauderman and Morrison, 2002). 
9.4.4 Statistical Analysis 
Data was recorded and analysed in IBM SPSS version 20.0. Based on the existing 
literature and on the findings reported in CHAPTER 6, I used history of OCs as the 
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environmental exposures of interest. AKT1 rs1130233, rs3803300 and rs2494735 
alleles, BDNF rs2049046 and rs56164415 alleles, DTNBP1 rs875462 allele and 
GRM3 rs7808623 alleles were chosen as the genetic variants. 
χ2 tests and t-tests (or ANOVA) were used to test for associations between the 
potential confounding variables and the genotype. Further χ2 tests were carried out to 
establish whether OCs were more likely to occur in individual carriers of a particular 
genotype class (a Gene x Environment correlation).  
Logistic regression was used to analyse the association between candidate genotype 
and presence of a psychotic disorder along with the exposure to OCs. Separate 
analyses were run for each exposure of interest, and an interaction between exposure 
and genotype was included in the model. The interaction term was used to identify the 
effect of genotype on presence of psychosis, conditional on history of OCs.  
 
 
9.5   Results 
9.5.1   Description of the Whole Sample 
9.5.1a   Clinical Characteristics of the Sample  
Subjects included in the study consisted in 377 subjects who met ICD10 criteria for a 
diagnosis of non-organic psychosis (F20-F29 and F30-F33). 
9.5.1b   Demographic Characteristic of the Sample  
As I mentioned above the sample comprises 112 individuals who are participants in 
the MFS, 33 from the GAP and a total of 232 individuals recruited from PICOS. To 
maximise statistical power participants from the MFS and GAP were collapsed in one 
group called “UK”. The sample includes only Caucasians. 
The demographic characteristics for the two groups are shown in TABLE 9.1.  
! 174!






  Mean (SD) Mean (SD)  








 57.89 (6.5) 57.42 (8.7) p=0.62 












TABLE 9.1   Demographic Characteristics of the Sample.  P values from t-tests and χ2  tests. 
 
The mean age of the whole sample is 27.77 years (SD 8.79); among the groups, UK 
patients were more than 7 years younger than PICOS patients (-7.38 years old, SE 
0.87, 95% CI -9.09 - -5.67, F = 74.83; p<0.001). There was no significant group 
difference for gender with an excess of males in both patients’ group (χ2=2.86; 
p=0.06).  
9.5.1c   Maternal Characteristics of the Sample  
The demographic characteristics for the two groups are shown in TABLE 8.1. The 
mean age of the mother at the time of the interview was 57.67 years (SD 7.62). The 
groups differ in the measure of maternal age at delivery, with UK mothers being 
slightly younger than PICOS (-0.28 years, SE 0.63; 95% CI -1.53 – 0.96, F = 9.29, 
p=0.003).  
9.5.2     Obstetric Complications  
The rate of definite OCs for each groups are displayed in TABLE 9.2 and individual 










 n (%) n (%)  
Definite OCs  56 (38.9%) 62 (26.7%) p=0.01 
TABLE 9.2   Rates of Definite OCs in Each Group.  P values from χ2  tests. 
 
38.9% of UK psychotic patients had a positive history for OCs compared to 26.7% of 
the PICOS subjects (χ2=6.11, p=0.01).  
 UK PICOS P value 
 n (%) n (%)  
Rubella - - - 
Syphilis  - - - 
Rhesus 
incompatibility 
0 (0%) 3 (1.3%) p=0.66 
Antepartum 
hemorrhage 
6 (4.1%) 15 (6.6%) p=0.23 
Severe  
Pre-eclampsia 
16 (11%) 4 (1.8%) p<0.001* 
Premature rupture of 
membrane 
0 (0%) 5 (2.3%) p=0.49 
Labour > 36 hours 9 (6.3%) 14 (6.4%) p=0.58 
Birth weight 2000 gr 
or less 
2 (1.4%) 6 (2.7%) p=0.34 
Complicated twin 
birth 
- - - 
Cord prolapse 0 (0%) 9 (4.1%) p=0.01* 
Gestational age <37 
weeks 
9 (6.2%) 17 (7.7%) p=0.38 
Gestational age >42 
weeks 
5 (3.5%) 0 (0%) p=0.79 
Emergency Caesarian 
Section  
5 (3.1%) 0 (%) p=0.47 
Breach or abnormal 
presentation 
7 (4.9%) 11 (4.9%) p=0.6 
Mid to high forceps 19(13.2%) 2 (0.9%) p<0.001* 
Incubator > 4 weeks 3 (2.1%) 19 (8.4%) p=0.01* 
 
TABLE 9.3   Individual Obstetric Events on Lewis-Murray Scale.  I did not rate as a “Definite” 
OCs labour lasting less than 3 hours. 
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9.5.3     Gene-Environment Interaction Analyses In The Context Of a Case-Only 
Study 
The association of the interaction between of OCs and selected genotype with 
presence of a psychotic disorder was investigated using the COR analysis (Khoury 
and Flanders, 1996). 
9.5.3a     AKT1 x OCs Interaction and Risk of Psychosis 
rs1130233 x OCs 
I obtained AKT1 rs1130233 genotyping data on 241 cases, with an overall call rate of 
83.1% (TABLE 9.4).  
I found no significant difference in AKT1 rs1130233 allelic distribution by gender 
(χ2=0.18; p=0.91), or between groups (χ2=2.92; p=0.23). 






  Mean (SD) Mean (SD)  
Age  23.02 (4.9) 30.12 (8.9) p<0.001* 



























TABLE 9.4    Characteristics of Patients with AKT11 rs1130233 Genotype.  P values from t-tests 
and χ2  tests. 
 
There was no evidence of a correlation between the AKT1 rs1130233 genotype and 
history of OCs in neither of the two groups (UK: χ2=1.21, p=0.55; PICOS: χ2=1.06, 
p=0.59). Moreover the effect of OCs on the likelihood to suffer from a psychotic 
























































P value p=0.23 p=0.29 p=0.69 
TABLE 9.5   AKT1 rs1130233 x OCs Analyses In The Context Of a Case-Only Study.  ORs 
calculated using Logistic Regression tests. 
 
rs2494735 x OCs 
I obtained AKT1 rs2494735 genotyping data on 224 cases, with an overall call rate of 
77.2% (TABLE 9.6).  
I found no significant difference in AKT1 rs2494735 allelic distribution by gender 
(χ2=1.93; p=0.38), or between groups (χ2=0.49; p=0.78). 
 






  Mean (SD) Mean (SD)  
Age  23.02 (4.9) 30.73 (9.2) p<0.001* 



























TABLE 9.6    Characteristics of Patients with AKT11 rs2494735 Genotype.  P values from t-tests 
and χ2  tests. 
 
There was no evidence of a correlation between the AKT1 rs2494735 genotype and 
history of OCs in either of the two groups (UK: χ2=3.21, p=0.2; PICOS: χ2=1.19, 
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p=0.55).  In addition the effect of OCs on the likelihood to suffer from a psychotic 





















































P value p=0.18 p=0.26 p=0.49 
TABLE 9.7   AKT1 rs2494735 x OCs Analyses In The Context Of a Case-Only Study.  ORs 
calculated using Logistic Regression tests. 
 
rs3803300 x OCs 
I obtained AKT1 rs3803300 genotyping data on 241 cases, with an overall call rate of 
83.1% (TABLE 9.8). I found no significant difference in AKT1 rs3803300 allelic 
distribution by gender (χ2=2.05; p=0.29), or between groups (χ2=2.27; p=0.32).  






  Mean (SD) Mean (SD)  
Age  22.94 (5.1) 30.04 (9) p<0.001* 



























TABLE 9.8   Characteristics of Patients with AKT11 rs3803300 Genotype.  P values from t-tests 
and χ2  tests. 
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There was no evidence of a correlation between the AKT1 rs3803300 genotype and 
history of OCs in either of the two groups (UK: χ2=0.03, p=0.53; PICOS: χ2=1.14, 
p=0.93). The effect of OCs on the likelihood to suffer from a psychotic disorder was 



















































P value p=0.72 p=0.86 p=0.71 
TABLE 9.9   AKT1 rs3803300 x OCs Analyses In The Context Of a Case-Only Study.  ORs 
calculated using Logistic Regression tests. 
 
9.5.3b     BDNF x OCs Interaction and Risk of Psychosis 
rs2049046 x OCs 
I obtained BDNF rs2049046 genotyping data on 236 cases, with an overall call rate of 
81.4% (TABLE 9.10). 
I found no significant difference in BDNF rs2049046 allelic distribution by gender 













  Mean (SD) Mean (SD)  
Age  23.08 (4.8) 30.03 (9) p<0.001* 
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TABLE 9.10   Characteristics of Patients with BDNF rs2049046 Genotype.  P values from t-tests 
and χ2  tests. 
 
There was no evidence of a correlation between the BDNF rs2049046 genotype and 
history of OCs in either of the two groups (UK: χ22.35, p=0.31; PICOS: χ2=1.77, 
p=0.41).  Furthermore the effect of OCs on the likelihood to suffer from a psychotic 


















































P value p=0.37 p=0.93 p=0.20 
TABLE 9.11   BDNF rs2049046 x OCs Analyses In The Context Of a Case-Only Study.  ORs 
calculated using Logistic Regression tests. 
 
rs56164415 x OC 
I obtained BDNF rs56164415 genotyping data on 248 cases, with an overall call rate 
of 85.5% (TABLE 9.12).  
I found no significant difference in BDNF rs56164415 allelic distribution by gender 
(χ2=2.31; p=0.31), or between groups (χ2=1.57; p=0.46).  
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  Mean (SD) Mean (SD)  
Age  23.1 (5) 30.06 (9) p<0.001* 
  n (%) n (%)  
Gender  al  
 
























TABLE 9.12   Characteristics of Patients with BDNF rs56164415 Genotype.  P values from t-tests 
and χ2  tests. 
 
There was no evidence of a correlation between the BDNF rs56164415 genotype and 
history of OCs in either of the two groups (UK: χ2=1.64, p=0.44; PICOS: χ2=1.14, 
p=0.23). Again the effect of OCs on the likelihood to suffer from a psychotic disorder 


















































P value p=0.98 p=0.25 p=0.29 
TABLE 9.13   BDNF rs56164415 x OCs Analyses In The Context Of a Case-Only Study.  ORs 
calculated using Logistic Regression tests. 
 
9.5.3.c     DTNBP1 rs875462 x OCs Interaction and Risk of Psychosis 
I obtained DTNBP1 rs875462 genotyping data on 225 cases, with an overall call rate 
of 77.6% (TABLE 9.14) 
! 182!
I found no significant difference in DTNBP1 rs875462 allelic distribution by gender 
(χ2=1.17; p=0.56). Between groups there was a significant expression of the minor 
allele “G” in the PICOS subjects (χ2=10.33; p=0.006). 





  Mean (SD) Mean (SD)  
Age  22.94 (5.1) 30.04 (9) p<0.001* 




























TABLE 9.14   Characteristics of Patients with DTNBP1 rs875462 Genotype.  P values from t-tests 
and χ2  tests. 
 
There was no evidence of a correlation between the DTNBP1 rs875462 genotype and 
history of OCs in either of the two groups (UK: χ2=0.83, p=0.25; PICOS: χ2=1.82, 
p=0.40). Moreover the effect of OCs on the likelihood to suffer from a psychotic 



















































P value p=0.51 p=0.36 p=0.19 
TABLE 9.15   DTNBP1 rs875462 x OCs Analyses In The Context Of a Case-Only Study.  ORs 
calculated using Logistic Regression tests. 
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9.5.3d     GRM3 rs7808623 x OCs Interaction and Risk of Psychosis 
I obtained GRM3 rs7808623 genotyping data on 255 cases, with an overall call rate of 
87.93% (TABLE 9.16). 
I found no significant difference in GRM3 rs7808623 allelic distribution by gender 
(χ2=0.54; p=0.76), or between groups (χ2=3.8; p=0.15).  






  Mean (SD) Mean (SD)  
Age  22.94 (5.1) 30.04 (9) p<0.001* 



























TABLE 9.16   Characteristics of Patients with GRM3 rs7808623 Genotype.  P values from t-tests 
and χ2  tests. 
 
There was no evidence of a correlation between the GRM3 rs7808623 genotype and 
history of OCs in either of the two groups (UK: χ2=4.89, p=0.09; PICOS: χ2=0.63, 
p=0.28).  Moreover the effect of OCs on the likelihood to suffer from a psychotic 






















































TABLE 9.17   GRM3 rs7808623 x OCs Analyses In The Context Of a Case-Only Study.  ORs 
calculated using Logistic Regression tests. 
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9.6     Summary of Results 
In order to overcome difficulties which I run across in CHAPTER 6, comprising the 
recruitment of appropriate control group, and to have greater statistical power with 
fewer subjects, in this chapter I performed a case only design statistical analysis in an 
attempt to replicate the findings of Nicodemus et al. (2008).  




9.7    Discussions 
GxE research represents an important approach to explain the occurrence of 
psychosis. In CHAPTER 7 I aimed to address the question of whether or not genotype 
variants of AKT1, BDNF, DTNBP1 and GRM3 interact with OCs in increasing the 
risk of psychosis. Because of limitation of power, I was unable to provide definite 
evidence against a possible role of those genes in modifying the effect of OCs on risk 
of psychotic disorders. As explained in the introduction a case-only design can be a 
valid approach to evaluate gene-environment interaction in disease etiology 
(Piegorsch, et al., 1994; Khoury and Flanders, 1996; Yanget al., 1997; Andrieu and 
Goldstein, 1998; Weinberg and Umbach, 2000). Thanks to collaboration with the 
Psychosis Incidence Cohort Study  (PICOS), Verona (Lasalvia et al., 2012) in this 
chapter I was able to definitively exclude an interaction between the above genetic 
variants and OCs in increasing the risk of psychosis.  
 
 
9.8    Limitations 
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Various authors have highlighted advantages of the case-only design in detecting 
gene-environment interactions in observational studies (Piegorsch, et al., 1994; 
Khoury and Flanders, 1996;  Yanget al., 1997; Andrieu and Goldstein, 1998; 
Weinberg and Umbach, 2000;  reviewed by Albert et al., 2001). 
Of course, the case-only design is subject to methodological problems such as 
uncontrolled confounding, exposure misclassification, and nonresponse bias (Albert et 
al., 2001). On the other hand in its favor, the case-only design is immune to bias from 
poor control selection and to exposure misclassification that is differential by disease 
status (Albert et al., 2001). In addition case-only design can be highly sensitive to the 
assumption of independence between the environmental exposure and the genetic 
marker (Albert et al., 2001).  
In conclusion, the case-only approach is nonetheless a useful tool, if used cautiously, 
for assessing interaction when the independence assumption is justified by empirical 
evidence or when selection of appropriate controls is difficult or impossible.  
As shown in CHAPTER 7, in this study the assumptions of independency between 
exposure to OCs and AKT1, BDNF, GRM3 and DTNBP1selected SNPs are met, thus 








Is Hypoxia The Remote Controller of Schizophrenia Genes? 
 
10.1     Introduction 
Recent advances in molecular technologies have made mouse models the first choice 
for studying most human genetic diseases and for schizophrenia have provided 
evidence in support of the abnormal neurodevelopment hypothesis (reviewed by Chen 
et al., 2006). Perinatal hypoxia models in rats and mice have revealed several 
behavioural, pharmacological, neurochemical and neuroanatomical abnormalities in 
adulthood with relevance to schizophrenia (Brake et al., 1997; Brake et al., 2000; El-
Khodor and Boksa, 2000; Wakuda et al., 2008).  As described in previous chapters 
(CHAPTER 7, 8 and 9), gene variants could influence the response to environmental 
risk factors such as OCs in the aetiology of schizophrenia. Alternatively, hypoxic 
regulation of genetic expression could be a potential mechanism in the pathogenesis 
of schizophrenia (Nicodemus et al., 2008; Joo et al., 2009). It has therefore been 
suggested that schizophrenia may arise from alterations in how some genes are 
‘‘turned on or off’’ due to exposure to non-genetic factors (Rutten and Mill, 2009).  
In this Chapter, I examined the genetic expression and methylation status of rat brain 
following hypoxic insult at three developmental stages.  
 
10.2     Genes Selected for the Analysis 
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Genes were selected on the basis of the GWAS published in 2011 (GWAS, 2011); in 
particular among them, I selected the genes that are expressed in rat brain (namely 
CCDC68, CNNM2, CSMD1, MMP16, STT3A, TCF4 and TRIM26). 
10.2.1    Coiled-Coil Domain Containing 68 (CCDC68)  
CCDC68 gene encodes for a human protein, the Coiled-Coil Domain Containing 
Protein – 68, whose function is not presently understood. 
10.2.2     Cyclin M2 (CNNM2)  
This gene encodes a member of the ancient conserved domain containing protein 
family. CNNM2 is a member of a family of four proteins, CNNM1-4. Members of 
this protein family contain a cyclin box motif and have structural similarity to the 
cyclins and may play an important role in magnesium homeostasis in kidney (The 
National Center for Biotechnology Information (NCBI) Reference Sequence (RefSeq) 
database). The highest expression of CNNM2 is reported to be ubiquitous in kidney 
and brain (Stuiver et al., 2011). In kidney CNNM2 transcript is up regulated under 
conditions of Mg2+ deficiency in mouse distal convoluted tubule cells suggesting a 
specific response to extracellular Mg2+ concentrations an thus involvement of 
CNNM2 in Mg+ transport (Stuiver et al., 2011).  Tissue damage resulting from 
trauma to the CNS appears to result from secondary, delayed biochemical changes 
that follow primary mechanical injury (Vink et al., 1988). Mg2+ is essential for a 
number of critical enzyme reactions, including those of glycolysis, oxidative and 
substrate level phosphorylation, protein synthesis, phospholipid synthesis, and in 
maintaining membrane stability; changes in free Mg2+ after brain trauma may 
represent a critical early factor leading to irreversible tissue damage and possible 
impairment of DNA synthesis (Vink et al., 1988; Blair et al., 1989).  Zhang and 
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colleagues studying primary hippocampal neurons show an increasing of 1.51-fold in 
Mg2+ after 1 hour of oxygen-glucose deprivation suggesting that there may be a 
Mg2+ overload inside the neurons induced by hypoxia (Zhang et al., 2011). In this 
regards hypoxia induce cellular potential depolarization that cause a subsequent 
intracellular magnesium surge (Kato et al., 1998). CNNM2 expression regulation may 
be explained by high concentration of extracellular Mg2+ induced by hypoxia. 
10.2.3     CUB and Sushi Multiple Domains 1 (CSMD1)  
This gene encodes a protein, the CUB and Sushi multiple domains 1. It is a potential 
tumour suppressor (NCBI RefSEq). CSMD1 is a novel multiple domain complement-
regulatory protein highly expressed in regions of neuronal differentiation and 
outgrowth, remaining high in the adult in areas of great neuronal plasticity, such as 
the cerebral cortex and especially, the hippocampus (Kraus et al., 2006).  
schizophrenia is established as a brain developmental disorder and it is becoming 
increasingly clear that immune molecules contribute to brain development and 
function (Kraus et al., 2006). Epidemiologic studies have often correlated the risk of 
schizophrenia to hyperactivation of the peripheral immune systems i.e., prenatal 
infections and autoimmune disorders (Brown and Susser, 2002; Ortega-Hernandez et 
al., 2009; reviewed by Håvik et al., 2011). Recent studies on candidate genes also 
suggest immunity pathways as major risk factors for schizophrenia (Guilloux et al., 
2010). Acute hypoxia and reperfusion activates the neuroimmune system (Johnson et 
al., 2007). Restoration of blood flow to ischemic tissue initiates a cascade of 
inflammatory events, including complement activation (C-activation) which all 
contribute to post ischemic injury (Jang and Rabb, 2009). Complement regulatory 
proteins may be important in protecting synapses from aberrant elimination during 
development and disease. These results suggest that CSMD1 may be an important 
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regulator of complement activation and inflammation in the developing CNS (Kraus 
et al., 2006). Genetic association of CSMD molecules to schizophrenia may reflect a 
heritable impairment in the regulation of the classical complement cascade (Havik et 
al., 2011).  
10.2.4     Matrix Metallopeptidase 16 (MMP16)  
MMP16 codes for proteins of the matrix metalloproteinase (MMP) family involved in 
the breakdown of extracellular matrix in normal physiological processes, such as 
embryonic development, reproduction, and tissue remodeling, as well as in disease 
processes, such as arthritis and metastasis (Andersson et al., 1996). Most MMP's are 
secreted as inactive pro-proteins which are activated when cleaved by extracellular 
proteinases (NCBI RefSEq). A reduction in MMP16 expression has been shown on 
exposure to hypoxia in PC-3 prostate cancer (Kakkad et al., 2010).  
10.2.5    Transcription Factor 4 (TCF4)  
TCF4 encodes transcription factor 4, a basic helix-loop-helix transcription factor. 
TCF4 is widely expressed in human tissues and appears to be involved in multiple 
biological processes (reviewed by Navarrete et al., 2012).  In the brain TCF4 encodes 
a transcription factor involved in the development of a subset of neural progenitors 
(Flora et al., 2007). It is likely to play a major role in neurodevelopment, especially as 
haploinsufficiency has been associated with Pitt-Hopkins syndrome, a severe epileptic 
encephalopathy with mental retardation and intermittent hyperventilation. Thus 
showing the importance of a proper gene dosage and tight control of TCF4 expression 
during brain developmental (Zweir et al., 2007; Navarrete et al., 2012). Brzozka et al. 
(2011) found that TCF4-overexpressing transgenic mice show schizophrenia-
associated behavior (Brzozka et al., 2010). Moreover it seems plausible- based on the 
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genomics, biological function and interaction of TCF4 in the context of 
schizophrenia- suggest that TCF4 plays an important role during CNS development 
and in acute functional effects in neurons (Navarrete et al., 2012). 
10.2.6     Tripartite Motif Containing 26 (TRIM26)  
 TRIM26 code a member of the tripartite motif (TRIM) family protein. The TRIM 
motif includes three zinc-binding domains, a RING, a B-box type 1 and a B-box type 
2, and a coiled-coil region. The protein localizes to cytoplasmic bodies. Although the 
function of the protein is unknown, the RING domain suggests that the protein may 
have DNA-binding activity. The gene localizes to the major histocompatibility 
complex (MHC) class I region on chromosome 6(NCBI RefSEq). Alternatively 
spliced transcript variants encoding the same protein have been found for this gene. 
Recent studies have shown that members of the TRIM superfamily are expressed in 
response to IFNs and are involved in a range of biological processes associated with 
innate immunity (Ozato et al., 2008). In addition to their role in innate immunity, 
TRIM proteins are involved in some genetic disorders, neurological disorders and 
cancers suggesting and important role in variety of different biological processes 
(Meroni and Diez-Roux, 2005).  
10.2.7     Subunit of the Oligosaccharyl-Transferase Complex, Homolog A 
(SST3A) 
SST3A encodes for a component of the N-oligosaccharyl transferase enzyme. SST3A 
seems to be involved in complex substrate specificity (by similarity) (NCBI RefSEq). 
Mutations in a gene encoding an ortholog of STT3a cause salt/osmotic stress 
hypersensitivity in Arabidopsis (Koiwa et al., 2003).  
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10.3     DNA Methyltransferases (DNMT) 
DNA methylation plays an important role in genomic imprinting through regulation 
of gene expression, and is essential for development.  Several DNA 
methyltransferases (DNMT1, DNMT2, DNMT3A, DNMT3B and DNMT3L) have 
been identified. DNMT1 preferentially methylates hemimethylated DNA and is 
thought to be a maintenance DNA methyltransferase. DNMT3A and DNMT3B 
appear to function as de novo methyltransferases since they can methylate 
unmethylated and hemimethylated DNA with equal efficiencies. Thus, the study of 
DNMT expression can be a valid approach for an indirect evaluation of rat brain 
following hypoxic insult. 
 
10.4     Aims  
The aims of the present study are to: 
1. Examine whether rats that had experienced perinatal asphyxia (A-rats) 
during birth show any abnormality in gene expression (CCDC68, CNNM2, 
CSMD1, MMP16, STT3A, TCF4 and TRIM26) in Prefrontal Cortex (PFC), 
Hippocampus (HiP) and Striatum (STR) at three developmental periods, 
post natal day (PND) (T1: 0 week), adolescence (T2: 5 weeks old) and 
adulthood (T3: 12 weeks old).  
2. Measure DNMTs expression in PFC, HiP and STR at two developmental 
periods, PND and adolescence (T1 and T2) in order to have an indirect 
measure of the methylation status of different brain regions followed by 
hypoxic insult. 
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10.5     Hypotheses 
1. I expect that rats exposed to hypoxia during birth (A-rats) will show an 
abnormal gene expression in PFC, HiP and STR at three developmental 
stages 
2. I expect the methylation status of different brain regions to be related to the 
perinatal asphyxia exposure. 
 
10.6     Methods  
I will briefly outline any general materials and methods used in the research reported 
in this chapter.  
10.6.1     Animals and Hypoxia 
All experiments were performed in accordance with the Guide for Animal 
Experimentation at the Hamamatsu University School of Medicine.   
Following the methods previously described by Bjelke and Wakuda, intrauterine 
anoxia was induced immediately after isolation of the uterus in rats delivered by 
caesarian section (C- section) (Bjelke et al., 1991; Wakuda et al., 2008). Pregnant 
Sprague–Dawley rats (Japan SLC, Hamamtsu, Japan) within the last day of gestation 
were anesthetized by diethyl ether and hysterectomized. The isolated intact uterus 
including the fetuses was placed in a water bath at 37C to induce 15 minutes of 
asphyxia (100% survival). After delivery, the umbilical cord was legated and the pups 
were left to recover on a heating pad for 40 minutes. Rats that had delivered normally 
were used as surrogate mothers, and their pups were used as vaginal delivered pups. 
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Each surrogate mother received four pups from another surrogate mother, four C-
section delivered pups and four asphyxia exposed pups identified by different ear 
tags.  
They were housed three per cage in polycarbonate cages (42.5×26.6×18.5) and 
maintained in a controlled environment with 12-h light/ 12-h dark cycle (lights on at 
7:00 a.m.) at 22 ± 2°C (relative humidity 55 ± 10%), with free access to food and 
water.  
 After rats were sacrificed and the brain removed, the Prefrontal Cortex (PFC), 
Hippocampus (HiP) and Striatum (STR) were immediately dissected.  Coronal brain 
slices of the brain were prepared using Stainless Steel Rat Brain Slicer. The slices 
were immediately transferred to ice-cold buffer. Samples were stored at –80°C until 
RNA extraction. 
The animals at T1, T2 and T3 were divided in three groups based on the circumstance 
of delivery: Vaginal delivery (V group), Cesarean section (C group) and Cesarean 
section with 15 minutes of perinatal asphyxia (A group).  
10.6.2     RNA Extraction 
10.6.2a   Preventing RNA Degradation 
The major source of failure in any attempt to produce RNA is contamination by 
ribonuclease. Ribonucleases (RNases) are very stable enzymes hard to inactivate and 
great care must be taken to avoid introducing them into RNA preparations both during 
and after extraction. The following procedures were routinely used to prevent RNA 
degradation: 
- Gloves were always worn and sterile laboratory techniques used at all times 
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- Sterile, disposable plastic ware was used where possible 
- Non-disposable glassware was treated to remove RNase’s (baked at 200 °C 
overnight, and then rinsed with Diethyl Pyrocarbonate (DEPC) -treated water) 
- Chemicals used in RNA isolation and analysis were kept separate from other uses 
- Any solutions made-up were treated by addition of DEPC to 0.05% and overnight 
incubation at room-temperature, followed by autoclaving for 30 minutes to remove 
any traces of the DEPC 
10.6.2b   Extraction of RNA from Brain Tissue 
Brain tissue was obtained from Sprague–Dawley rats, deep-frozen at -80 °C. The 
following protocol, using TRIzol reagent (Life Technologies, Carlsbad, CA), was 
used to extract RNA from the tissue: 
- Up to 200 mg of tissue homogenized in 2 ml TRIzol reagent 
- 1 ml transferred to each of two 2.0 ml Eppendorf tubes 
- Incubated at room temperature (20 to 25 °C) for 5 minutes 
- 0.2 ml chloroform (CHCl3) added to each tube 
- Vortex vigorously for 15 seconds  
- Incubated at room temperature for 2-3 minutes 
- Spun at 12,000g for 15 minutes at 4°C 
- Combined aqueous phases transferred to a new 2.0 ml Eppendorf tube 
- Precipitated with 0.5 ml Isopropanol 
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- Incubated at room temperature for 10 minutes 
- Spun at 12,000g for 15 minutes at 4°C and supernatant immediately decanted 
- Pellet disrupted in 1 ml 75% ethanol and centrifuged at 7,500g for 5 minutes, 
immediately decanted supernatant and carefully removed excess with pipette tip 
- Dried and resuspended in 100 ml DEPC-dH2O 
10.6.2c   RNA Sample Clean-up   
All traces of genomic DNA need to be removed from samples before applications 
such as Reverse Transcript- Polymerase Chain Reaction (RT-PCR) can be performed. 
DNase I (Invitrogen Cat. No. 18068015) was thus used to degrade both double-
stranded and single-stranded DNA endonucleolytically. 
The DNase digestion reaction was set up as follows: 
Following extraction from tissue, RNA samples were cleaned-up using RNeasy spin 
column kits (Qiagen, Crawley, UK) following the manufacturers protocol. 
- Bring RNA to 100 µl with dH20 
- Add 350 µl buffer RLT and mix by light vortex (Buffer RLT must have 10 µl 
of 2-mercaptoethanol added per 1 ml of buffer beforehand) 
- Add 250 µl 100% ethanol, mix by pipetting up/down 
- Apply sample (700 µl) to RNeasy spin column, centrifuge 10,000 rpm for 15 
sec, RT 
- Transfer the column into a new 2 ml collection tube and wash with 350 µl 
buffer RW1, centrifuge as above 
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- Transfer the column into a new 2 ml collection tube, add DNase I mix (80ml) 
to the spin column, and incubate for 15 min at room temperature 
- Add 350 µl buffer RW1, and centrifuge as above 
- Transfer the column into a new 2 ml collection tube, wash with 500ml buffer 
RPE, and centrifuge as above 
- Transfer the column into a new 2 ml collection tube, wash with 500ml 80% 
EtOH, and centrifuge 10,000 rpm for 2 min at room temperature 
- Transfer the column into a new 2 ml collection tube, open the lid of the spin 
column, and centrifuge full speed for 5min at room temperature 
- To elute, transfer the column to a 1.5 ml tube, pipet 50 µl of RNase-free water 
directly onto the column membrane 
- Incubate RT 1 min and centrifuge full speed for 2min at room temperature 
10.6.2d   RNA Quality Control  
The RNA quality was calculated after measuring absorbance with a 
spectrophotometer at 260 nm. Following extraction, each RNA sample was quantified 
using the NanoDrop ND-1000 spectrophotometer. Good quality RNA should have an 
OD260 / OD280 ratio of between 1.7 and 2.1, and ratios smaller than this can occur 
because of factors like protein contamination. After quantification, samples were 
stored in 1.5 ml Eppendorf tube at -20°C prior to further use.  
10.6.3     cDNA Synthesis  
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Following extraction of RNA, cDNA synthesis was set up as follows using III First-
Strand Synthesis System for RT-PCR (Invitrogen Cat. No. 18080-051) following the 
manufacturers’ protocol: 
- Combine the following in a 0.5-ml tube: 
1. Up to 5 µg of total RNA  
2. Primer1 µl of 50 µM oligo(dT)20 
3. 10 mM dNTP mix 1 µl 
4. DEPC-treated water to 10 µl 
- Incubate at 65°C for 5 min, then place on ice for at least 1 min. 
- Prepare the following cDNA Synthesis Mix, adding each component in the 
indicated order: 
1. 10X RT buffer 2 µl  
2. 25 mM MgCl2 4 µl 
3. 0.1 M DTT 2 µl  
4. RNaseOUTTM (40 U/µl) 1 µl  
5. SuperScriptTM III RT (200 U/µl) 1 µl  
- Add 10 µl of cDNA Synthesis Mix to each RNA/primer mixture, mix gently, 
and collect by brief centrifugation. Incubate 50 min at 50°C 
- Terminate the reactions at 85°C for 5 min. Chill on ice. 
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- Collect the reactions by brief centrifugation. Add 1 µl of RNase H to each tube 
and incubate for 20 min at 37°C. 
10.6.3a   cDNA Quality Control  
Following extraction, each cDNA sample was diluted in 50 ml DEPC-dH2O and 
quantified using the NanoDrop ND-1000 spectrophotometer. Clean cDNA should 
have an OD260 / OD280 ratio of between 1.7 and 2.1, and ratios smaller than this can 
occur because of factors like protein contamination. Samples were stored in 1.5 ml 
Eppendorf tube at -20°C prior to further use. 
10.6.4     Quantitative Real-Time RT-PCR 
10.6.4a   Primer Design 
Primer specificity was initially assessed in silico by searching NCBI and ENSEMBL 
Browsers for nontarget complementary sequences throughout the genome. Probe and 
primer sets for the candidate genes tested (CCDC68, CNNM2, CSMD1, MMP16, 
STT3A, TCF4 and TRIM26) were designed using Oligo7 and Primer3Plus (http:// 
www.bioinformatics.nl/cgi-bin/primer3plus/primer3plus.cgi). The specificity of the 
primer was evaluated by whole genome alignment using the BLAST. 
The primer design strategy is outlined in FIGURE 10.1 along with the primer sequences 














FIGURE 10.1   Primers Design. 
 
Gene Forward primers Reverse primers 
CCDC68 CACACTGGACGGAATCTCCT TCGTAGCCGAATCAACATCA 
CNNM2 TTGTCAGCAGGACAGAGGTG GTCGCTCCGACTGAGAGAGT 
CSMD1 ATCATTACCAGGGCACCAG TTTTCATGGCCAGCATAGC 
MMP16 AGCTTTCGTCCACAAGGAAA CCTTGAGGATGGATCTTGGA 
STT3a GAACATTGGCTGGTCAGGAT TCAGTGCGAAGCATATCAGG 
TCF4 CGAATCACATGGGTCAGATG GGAGCAGTGTTTATGTGGGTTT 
TRIM26 AAGGCAAGCTGCTGAGAGAC ACTGGCCGGTGTAGGTAATG 
Internal Control     
GAPDH GACATGCCGCCTGGAGAAAC AGCCCAGGATGCCCTTTAGT 
  
TABLE 10.1   Primers Sequences. 
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10.6.4b   RT- PCR Procedure 
Real-time PCR was performed the SYBR GREEN I PCR Master Mix (Qiagen, 
Hilden, Germany). The optimization of the real-time PCR reaction was performed 
according to the manufacturer's instructions but scaled down to 16µl per reaction. The 
PCR conditions were standard (SYBR-Green I core reagent protocol) and all reagents 
were provided in the SYBR-Green I core reagent kit (Qiagen, Hilden, Germany). 
Relative expression of specific candidate genes was determined by comparing their 
expression of to a set of four housekeeping control genes: b-actin (ACTB), CYCRO, 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The following PCR cycling 
conditions were used: 
- 50°C for 2 minutes 
- 95°C for 15 minutes 
- 95°C for 15 seconds 
- 60°C for 1 minute 
Repeat 40 cycles. 
Using the comparative gene expression method, a validation experiment to check the 
efficiencies of the assays were equal was performed. After optimization, nucleotide 
primers were used at various concentrations for the detection and quantification of 
GAPDH, signal and coding CCDC68, CNNM2, CSMD1, MMP16, STT3A, TCF4 
and TRIM26 (primer sequences table 1). In particular GAPDH expression served as a 
control for mRNA expression. Quantitative RT-PCR was performed in triplicate for 
each sample  (5 each group) on an ABI Prism 7900HT. Gene expression changes 
were quantified using the delta-delta CT method. In particular the expression data 
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produced were analyzed and converted into threshold cycle values (CT values) using 
Excel (Microsoft Office Excel 2003).  
 
10.7         Statistical Analysis 
All the statistical analysis was performed using IBM SPSS Statistics 20.0 (IBM 
Corporation 1989, 2011).  
Values were expressed as means ± Standard Error of the Mean (SEM) and compared 
using repeated measures ANOVA and post hoc comparisons with Tukey’s Multiple 
Comparisons Test, differences among experimental conditions were considered 
statistically significant when p≤0.05. 
 
10.8     Results 
10.8.1   Genetic Expression of Different Brain Regions Followed by Hypoxic 
Insult at Birth 
10.8.1a   T1: Post Neonatal Day 
Examining genes expression abnormalities at T1, of 7 genes tested, CNNM2 was 
significantly down regulated in PFC (mean difference -0.73, SE 0.21, F (2,18)=6.02; 
p=0.009), HiP (mean difference -0.58, SE 0.20, F (2,16)=5.19; p=0.027) and STR 
(mean difference -0.91, SE 0.28, F (2,15)=5.61; p=0.015) of A-rats compared with 
controls (FIGURE 10.2b). In contrast, as result of hypoxia, CSMD1 (mean difference 
1.14, SE 0.48, F (2,18)=4.71; p=0.025) and TCF4 (mean difference 0.33, SE 0.08, F 




FIGURE 10.2   Gene Expression Differences Following Hypoxia at PND. (A) Genetic expression 
changes in PFC. (B) CNNM2 deregulation in PFC, HiP and STR of A-rats compared to V-rats. Data 
represent Mean ± SEM, p < 0.05. 
 
10.8.1b   T2: Childhood 
Looking at the genetic expression of A-rats at 5 weeks I observed a significant 
reduction of most of the genes examined in PFC, namely CNNM2 (versus C rats: 
mean difference -0.61, SE 0.15, F (2,18)=9.20; p=0.003/ versus V rats: mean 
difference 0.47, SE 0.14, F (2,18)=9.20; 0.011), CSMD1 (mean difference -0.59, SE 
0.21, F (2,18)=4.18; p= 0.031), MMP16 (mean difference -0.83, SE 0.26, F 
(2,18)=5.23; p= 0.015) and STT3a (mean difference -0.68, SE 0.22, F (2,18)=5.39; p= 
0.019) (FIGURE 9.3a). SST3a was under expressed in STR (versus C rats: mean 
difference -0.90, SE 0.23, F (2,18)=8.13; p=0.004/ versus V rats: mean difference 
0.57, SE 0.21, F (2,18)=8.13; 0.038) (FIGURE 10.3c). Interestingly Ifound TRIM26 
elevated in HiP (mean difference 0.97, SE 0.30, F (2,17)=6.24; p=0.016) and STR 







FIGURE 10.3   Gene Expression Differences Following Hypoxia at 5 Weeks. (A) and (B) genetic 
expression changes  in PFC and STR. (C) STT3a deregulation in PFC and STR of A-rats compared 
controls. (D) TRIM26 over expression in HiP and STR of A-rats. Data represent Mean ± SEM, p < 
0.05.  
 
10.8.1c   T3: Adulthood 
Global hypoxia at birth did not affect the genetic expression in PFC, HiP and STR of 
12 weeks rats.  
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10.8.2   Methylation Status of Different Brain Regions at T1 and T2 Following 
Hypoxic Insult at Birth 
Looking at DNMTs expression abnormality following hypoxia I didn’t find any 
significant abnormality at T1. On the other hand, at T2 I found an over expression in 
the HiP of 5 weeks old rats of DNMT3b (mean difference 0.73, SE 0.17, F 
(2,17)=9.43; p=0.003) (FIGURE 10.4a) and an over expression of in the STR of 5 









FIGURE 10.4   DNMTs Expression Abnormality Following Hypoxia at 5 Weeks. (a) DNMT3b 
over expression in HiP. (b) DNMT3a over expression in STR. Data represents Mean ± SEM, p < 0.05.  
 
 
10.9     Summary of Results  
Following hypoxic insult, 7 genes were analyzed for expression as above, namely 
CCDC68, CNNM2, CSMD1, MMP16, STT3A, TCF4 and TRIM26. Overall, many of 
these genes had heterogeneous pattern of expression, with specific up regulation or 
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down regulation in A-rats. In general, at post neonatal day CNNM2 was down 
regulated, whereas CSMD1 and TCF4 were up regulated; at 5 weeks CNNM2, 
CSMD1, MMP16, STT3a were down regulated, whereas TRIM26 was overexpressed. 
In addition in my sample I found an over expression of DNMT3b and DNMT3a at 5 
weeks. 
 
10.10    Discussions 
Increasing evidence from animal studies indicates that both prenatal and early 
postnatal environmental factors can result in altered epigenetic programming and 
subsequent changes in the risk of developing disease (Jirtle and Skinner, 2007). In 
particular many OCs seem to compromise neurodevelopment inducing the oxygen 
deprivation in the foetus (Mc Grath and Murray, 2003). Nevertheless, no studies have 
yet examined the direct link between early environmental exposures such as OCs with 
epigenetic profiles and risk of psychotic disorders.  
In my study rats showed a heterogeneous pattern of expression overall the brain in 
many of the genes tested following hypoxic insult. It seems that the hypoxic 
regulation of expression of some of these genes could be a potential key player in the 
aetiopathogenesis of schizophrenia. Moreover at 5 weeks DNMT3b and DNMT3a 
were over expressed. DNA methylation plays an important role in genomic imprinting 
through regulation of gene expression, and is essential for development. In mice after 
30 min of cerebral artery occlusion mutants heterozygous for a DNA 
methyltransferase gene deletion (DnmtS/1) were resistant to mild ischemic damage, 
suggesting that increased DNA methylation contributes to poor tissue outcome after 
mild ischemic brain injury (Endres et al., 2000). DNMT3a and DNMT3b appear to 
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function as de novo methyltransferases. Both of them could then contribute to the 
generation of the genome methylation pattern, suggesting a hypoxic regulation to the 
genetic expression throughs epigenetic mechanism.  
It is likely that genes play an important role in mediating the reactions of the CNS to 
environmental stimuli such as hypoxia. Epigenetic regulation of gene expression is a 
plausible mechanism behind abnormal gene expression and aberrant 
neurodevelopmental processes under the effect of perinatal hypoxia–ischemia 
(Schmidt-Kastner et al., 2012). My study shows that hypoxia in the prenatal and 
perinatal period regulates the expression of specific genes suggesting a possible 
contribution to the neurodevelopmental alterations later found in schizophrenic 
patient. Changes in de novo methylation due to hypoxic insult could also contribute to 













General Discussion and Future Directions 
 
11.1     Initial Hypotheses and Final Results   
In this last chapter findings obtained from the different investigations undertaken in 
the PhD project are discussed. Based on them, main conclusions are drawn, and 
directions for future research are presented.  TABLE 5.1 (CHAPTER 5) summarized the 
main investigations and related hypotheses (and associated statistical analyses) of the 
project. TABLE 11.1 summarizes the results for each of the initial hypotheses.  
 
TABLE 11.1   Summary of Results for Each Initial Investigation 
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This study confirms that patients are more likely than non- psychotic individuals to 
report an OC, with an effect for OCs in increasing the risk for psychosis of about 1.9, 
similar to the widely reported risk of 2.0 for schizophrenia (Cannon et al., 2002). As I 
discussed in the Introduction, OCs are among the best-documented environmental risk 
factors for schizophrenia, with the first evidence for an association with schizophrenia 
dated 1934 (Rosanoff et al., 1934). It now established that the risk of developing 
schizophrenia is increased in individuals who were exposed to various complications 
during pregnancy (Cannon et al., 2002). Moreover recent epidemiological studies 
further document the relationship between obstetric complications and psychosis-like 
symptoms or deficit in cognitive function (Zammit et al., 2009).  
OCs increase risk of schizophrenia but not everyone that experienced OCs develops 
psychosis later in life. Variability in people’s responses to environmental risk factors 
suggests that genes and environments operate together to produce psychosis (Tsuang 
et al., 2004; Di Forti et al., 2007b). It is likely that genes play an important role in 
mediating the reactions of the CNS to environmental stimuli such hypoxia. A difficult 
challenge is to identify plausible susceptibility genes to investigate how, and if, they 
moderate the effect of obstetric complications on the risk of psychosis. In this study I 
selected genotype variants of a total of 32 SNPs to investigate the interaction with 
OCs in increasing the risk of psychosis. In particular this is the first study examining 
the interaction between OCs and GWAS selected genes in increasing the risk of 
psychosis. Despite all the effort I spent to recruit a decent sample, the present study 
did not have sufficient power to detect any Gene x Environment interaction. Thus my 
results, although negative, do not provide definite evidence against a possible role of 
selected genotypes in modifying the effect of OCs on risk of psychotic disorders. 
For several labour and delivery complications associated with increased incidence of 
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schizophrenia perinatal hypoxia is highly likely to be a common factor and the 
incidence of schizophrenia increases linearly with the number of hypoxia-associated 
birth complications (Cannon et al., 2002). Many obstetric complications seem to 
compromise neurodevelopment inducing the oxygen deprivation (hypoxia) in the 
foetus (Mc Grath and Murray, 2003). Increasing evidence from animal studies 
indicates that both prenatal and early postnatal environmental factors can result in 
altered epigenetic programming and subsequent changes in the risk of developing 
disease (Jirtle and Skinner, 2007; Pishva et al., 2014).  This is the first study 
examining the direct link between early environmental exposures to OCs and 
abnormal epigenetic profile of psychosis related genes. In particular rats following 
hypoxic insult showed a heterogeneous pattern of expression in many genes tested. 
Moreover DNMT3b and DNMT3a were over expressed at 5 weeks.  DNMT3a and 
DNMT3b appear to function as de novo methyltransferases, which may contribute to 
the generation of the genome methylation pattern.  
Thus my findings suggest that OCs are involved in the aetiopathogenesis of 
schizophrenia probably troughs hypoxic regulation of gene expression via epigenetic 
mechanism.  
 
11.2      Discussions 
Many studies have uncovered the strong association between specific OCs and an 
increased risk of developing schizophrenia (Cannon et al., 2002). On the other hand 
GWAS provided a significant contribution in identifying novel common and rare 
genetic variants associated with psychotic disorder (GWAS, 2011). It is very likely 
that OCs and genotype are independent of each other, which is striking enough to 
! 210!
suggest that the key to understand why some subjects who experienced OC develop 
psychotic disorders while most come to no harm, is to investigate the interplay 
between the exposure to specific OCs with genetic variants.  
Despite there being many SNPs identified so far, the effects of the genotype on 
phenotype will be far easier to assess if I know what those genes identified code for. 
In recent years Mittal et al. (2008) directly addressed wasys of linking genes to the 
environment trough various models including different varieties of the Multi-factorial 
Polygenic Threshold Model (MPTP): 
• Phenocopy Model  
A specific population of affected individuals may not be genetically predisposed to 
schizophrenia, but may have, at some point in time, been overexposed to a particular 
stimulus which exceeded the threshold for liability. This model is not particularly 
well-suited to fitting genetic predispositions. However the external stimulus that 
breaches the phenotypic threshold for this disease can be interpreted to be an OC, 
suggesting that an OC is more like to cause schizophrenia, regardless of genotype.  
• Gene-Environment Covariation Model 
Genetics and OCs might both be confounders and not contribute to the etiology of 
schizophrenia - together they may increase the liability of onset, but individually are 
not responsible for the onset. The delicate balance between gene and environment 
interplay is enough to elicit a synergistic effect in predisposing a subject to 
schizophrenia.  
• Gene-environment Interaction and Additive Influences 
Disease-promoting genes may have a more severe effect coupled with an 
environmental influence, rather than by themselves. This model also suggests that the 
! 211!
two (i.e. the OC and the gene) can occur independently of each other, but the presence 
of both exacerbates the effect in bringing on the disease.  
Mittal’s study concluded that different types of OCs could influence the liability to 
schizophrenia via different specific mechanisms (Mittal et al., 2008). 
GxE research represents an important approach to explain the occurrence of psychosis 
but not the only way to explain how hypoxia in the prenatal and perinatal period could 
influence the liability to the illness later in life. Potentially overlapping gene-
environment mechanism and/or epigenetic mechanism seem to be a plausible 
explanation (Mittalet al., 2008). Moreover the absence of clear genetic effects in 
psychosis supports the concept that the biological risk factors are epigenetic in form 
rather than solely DNA sequence based (Rutten an Mill, 2009). Epigenetic processes 
regulate key neurobiological and cognitive processes in the brain through regulation 
of gene expression. Epigenetic mechanisms are influenced by a spectrum of external 
environmental factors including early inviromental factors, diet, toxins, drugs, and 
stress. In addition polymorphisms can also exert an effect on gene function via 
epigenetic processes (Gamazon et al., 2013). These suggest a common pathway 
behind both genetic and environmental effect possibly trough gene–environment 
interaction (Dempster et al., 2013).  
OCs occur at critical periods early in development, a time of rapid cell replication 
when the epigenome is known to be particularly labile in response to external factors 
and the standard epigenetic signals driving development and tissue differentiation are 
being established (Rutten and Mill, 2009: Dempster et al., 2013).  In rats following 
hypoxic insult many of the genes had heterogeneous pattern of expression, suggesting 
! 212!
an important role for genes in mediating the reactions of the CNS to environmental 
stimuli such hypoxia.  
 
11.3     Conclusion 
Nobody would dispute that research into gene environment interaction gave an 
important contribution to the etiology of psychotic disorders while trying to explain 
variations in the effect of environmental factors on behavior. Most scientists would 
accept that variations in the effects of environment on health in general are often 
mediated by the individual genotype make-up.  
My findings do not support a GxE between OCs and selected genetic polymorphisms 
in increasing the risk of psychosis. On the other hand they suggest that hypoxia in the 
prenatal and perinatal period seems to regulate the expression of specific genes 
contributing to the neurodevelopmental alterations later found in schizophrenic 
patient. 
Findings from this PhD project add to the understanding in the extent to which 
epigenetics provides useful information to explain early environmental exposure 
impact on psychotic disorders. It can be relevant for future studies whose major 
challenge would be the inclusion of an epigenetic assessment together with genetic 
and environmental data. Thus, the key to understand why some people who 
experience OCs develop psychotic disorders while most come to no harm is to 
investigate the interplay between the exposure to hypoxia in the prenatal and perinatal 
period and the epigenome.  
In conclusion epigenetics would help to map new pathophysiological pathways 
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underlining psychosis. Epigenetic mechanisms may mediate the link between 
environment and the development of psychosis.  
 
11.4    Future Directions 
Although much research that has gone into determining the pathophysiology of 
psychotic disorders, only parts of the puzzle have been found.  
The evidence for OCs increasing schizophrenic liability has been established for some 
time, and further research into this area is perhaps not necessary.  In the next decade 
or so, the focus should probably move to larger case-control studies that incorporate 
and interpret demographic information rather than use it to adjust statistical values 
only.  
The ongoing research into genetic information should also continue. My findings 
didn’t show any interaction between genes and OCs in increasing the risk of 
psychosis. Hopefully, more research will continue into the role of gene-environment 
interaction in the aetiology of schizophrenia and lead to methods of primary 
prevention. However, these will need to be carried out on a much larger scale than in 
this PhD. It also gives a flicker of hope to other mental illnesses, and further 
controlled trials may well act as a double-edged sword in finding a pathophysiology 
and a specific intervention.  
 Moreover, a better understanding of the epigenetic mechanisms of certain 
environmental factors, such as hypoxia, could help to draw a more precisely 
biological process behind the neurodevelopmental nature of psychosis. Nevertheless, 
no studies have yet examined in human the direct link between early environmental 
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exposures with epigenetic profiles and risk of psychotic disorders. Although the 
epigenetic profile of somatic cells is mitotically heritable, there is evidence that 
epigenetic mechanisms may be heritable during meiosis in humans and thus 
potentially transmitted across generations (Rutten and Mill, 2009).  This field has re-
opened the Lamarckian concept of heritability of acquired traits receiving support 
from rodent studies (Pishva et al., 2014). Thus epigenetic profiles and their 
subsequent behavioral expression seem to be transmitted to subsequent generations 
(Pishva et al., 2014). It needs to be established whether epigenetic inheritance is 
indeed relevant for humans (Pishva et al., 2014). It may be worth exploring weather 
the exposure to early environmental factors such as OCs induces any abnormal 
epigenetic profiles in the offspring and weather subsequent phenotypes are 
specifically transmitted to the offspring. These findings may have strong implications 
for understanding the impact of environmental influences on epigenome and may help 
to unreveal the missing heritability of psychosis.  
Longitudinal cohort studies with data collection on environmental exposures, genetic 
predisposition and epigenetic profiles are therefore needed. 
 
11.5     Implications of Using Obstetric Records on Clinical Setting 
At the moment, pre-natal screening exists for either very common or very serious 
conditions in the UK. However, family history of psychotic illness is not routinely 
taken into account, and extra care during the birth, or being equipped with 
demographic and past family OC history, could play a key role in diverting OCs and 
the repercussions they have on both mother and child. If OCs were to follow the 
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phenocopy model, then primary prevention of OC should be sufficient in reducing 
psychosis liability. 
For those neonates who have suffered from adverse pre and perinatal conditions, 
careful monitoring and early intervention may lead to better management and early 
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Obstetric Complications Questionnaire 
 
!1 !2 ……...………… 1 
Early Developmental 
 
!1 !2 ……...………… 19 
Assessment of Premorbid Schizoid-Schizotypal Traits  
 



















GAP ID Number: 
 
........................ 
Subject’s Initials:   
                                           
…........................                    
Rater’s Initials:                  Date of Completion:   
       
.......................              .............. / ............ / ..................... 
 













Mother’s date of birth 
 
 
Father’s date of birth  
         
   
 
 
.............. / .............. / ............................... 
 
  
.............. / .............. / ............................... 




Children’s date of birth and gender   
(tick the box of proband) 
                                                                                      
 Male    Female  
 
























.............. (1=1st, 2=2nd etc)                 
Place of birth of proband 
 
 
Town, Country ……………………………  
                                                                                              
Post code.………………………………… 
                                                                                             
Population………………………………… 
 













BRIEF MATERNAL HEALTH QUESTIONNAIRE 
 
 Have you ever suffered from any of the following diseases? 
                  No               Yes              Unknown 
 
1.  Endocrinological and/or metabolic diseases 
 
1a.  Any thyroid disorders 
1b.  Any glandolar disorders 
1c.  Type I Diabetes 
1d.  Other 
 






If yes, please note details 
                                                  
…………………………………………………                                                                                            
………………………………………………… 
 
2.  Cerebro-cardiovascolar diseases 
2a.  Rheumatic heart disorder 
2b.  Congenital heart disorder 
2c.  High blood pressure  
2d.  Low blood pressure  
2e.  Coagulation defects 
2f.  Hemostatic disorders  
2g.  Anemia 
2h.  Other  









If yes, please note details 
                                           
…………………………………………………                                                                                            
………………………………………………… 
                                                                                                           
3.  Respiratory diseases 
 
3a.  Idiopathic Asthma 
3b.  Allergic Asthma 
3d.  Other 
 





If yes, please note details 
                                                  
…………………………………………………                                                                                            
…………………………………………………  
                                                                                                          
4.  Nervous system diseases 
 
4a.  Epilepsy 
 
!0                       !1                      ! -77 
 
!1 
If yes, please note details 
                                                  
…………………………………………………                                                                                            
………………………………………………… 
                                                                                                           
 
5.  Gynaecological diseases 
 
     !0                       !1                      ! -77 
If yes, please note details 
                                                     
……………………………………………………                                                                                            
…………………………………………………… 
 
6.  Any other diseases       !0                       !1                      ! -77 
If yes, please note details 
                                                     
……………………………………………………                                                                                         
………………………………………………… 








[Part 1] PREGNANCY COMPLICATIONS   
 
 
1.  When did you first know that you were pregnant? 
     
  
 ….................. / .............. / ....................... 
 
     No                 Yes           Unknown 
 
2.  Do you recall anything in particular about the 
pregnancy?         
 !0                       !1                      ! -77 
If yes, please note details 
                                                     
………………………………………………                                                                                            
……………………………………………… 
 
3.  Proband's birth weight   ............. grams/lb 
 
4.  Proband's birth age                                                      ..............weeks 
 
5.  Did you suffer any of the following before becoming pregnant with the proband? 
 
                      No                 Yes         Unknown     
 
5.1 Rhesus disease/incompatibility    
                                   
!0                       !1                      ! -77 
      5.2  Spontaneous abortion/miscarriage 
  
             5.2a. During which trimester 
 
             5.2b. Total number of the events 
 






      5.3  Rubella   
                                                                        
!0                       !1                      ! -77 
      5.4  Syphilis       
                                                                    
!0                       !1                      ! -77 
6. During the pregnancy, did any of the following occur? 
 
                                                                                                    No               Yes            Unknown               Trimester        N of episodes                       
 
 
6.1  Falls, trauma   !0                      !1                      ! -77               1st!2nd!3rd!  Tot! 
 
 
6.2  Hyperemesis/ excessive 
vomiting  
  !0                      !1                      ! -77               1st!2nd!3rd!  Tot! 
 
 
6.3  Threatened miscarriage/ any 
ante-partum haemorrhage 
  !0                      !1                      ! -77               1st!2nd!3rd!  Tot! 
 
 
6.4  Albuminuria/ presence of 
albumin in the urine 
  !0                      !1                      ! -77               1st!2nd!3rd!  Tot! 
 
 
6.5  High blood pressure   !0                      !1                      ! -77               1st!2nd!3rd!  Tot! 
 
 
6.6  Pre- eclampsia 
 
  !0                      !1                      ! -77               1st!2nd!3rd!  Tot! 
 
 
6.7  Eclampsia 
 
  !0                      !1                      ! -77               1st!2nd!3rd!  Tot! 









6.8  Not putting on weight as 
expected 
  !0                      !1                      ! -77               1st!2nd!3rd!  Tot! 
 
 
6.9  Abdomen not growing as 
expected 
  !0                      !1                      ! -77               1st!2nd!3rd!  Tot! 
 
 
6.10  Putting on excessive weight    !0                      !1                      ! -77               1st!2nd!3rd!  Tot! 
 
 
6.11  Other 
 
  !0                      !1                      ! -77               1st!2nd!3rd!  Tot! 
                       
                            If yes, please give description of problems 
 
… ………………………………………………………………………                                                                                            
… ………………………………………………………………………                                                                                         
… ………………………………………………………………………                                                                                             
… ………………………………………………………………………                                                                                               
… ……………………………………………………………………… 
 







 7. During the pregnancy, do you remember having suffered any of the following? 
 
 
                                                                                                                               No               Yes            Unknown                   
Trimester                               
 
7.1   Herpes/cold sores   
 








  !0                      !1                      ! -77                     
1st!2nd!3rd!  
7.3. Cytomegalovirus infection           
                                                    
  !0                      !1                      ! -77                     
1st!2nd!3rd!  
7.4. Measles              
                                                                                
  !0                      !1                      ! -77                     
1st!2nd!3rd!  
7.5. Toxoplasmosis                
                                                                   
  !0                      !1                      ! -77                     
1st!2nd!3rd!  
7.6. Malaria                         
                                                                       
  !0                      !1                      ! -77                     
1st!2nd!3rd!  
7.7. Tuberculosis                     
          
  !0                      !1                      ! -77                     
1st!2nd!3rd!  
7.8. Typhoid fever          
                                                                                                                        
  !0                      !1                      ! -77                     
1st!2nd!3rd!  
7.9. Listeria  
 








  !0                      !1                      ! -77                     
1st!2nd!3rd!  
7.12. Respiratory tract infection    !0                      !1                      ! -77                     




0= No 1= Yes; Missing values: -77 = Don't know   -88 = Refused to answer   -99 = Not applicable 
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 1st!2nd!3rd!  
7.13. Gastro-enteritis 
 
  !0                      !1                      ! -77                     
1st!2nd!3rd!  
7.14. Urinary tract infections  
 








  !0                      !1                      ! -77                     
1st!2nd!3rd!  
7.17. Any other infections/diseases 
 
  !0                      !1                      ! -77                     
1st!2nd!3rd!  
If yes, please give description of problems 
 
                                            … ………………………………………………………………………                                                                                            
… ………………………………………………………………………                                                                                            
… ………………………………………………………………………                                                                                             




                                                                                                                                                                                         
!0                       !1                      ! -77 
!0                       !1                      ! -77 
!0                       !1                      ! -77
!0                       !1                      ! -77
!0                       !1                      ! -77
!0                       !1                      ! -77 
!0                       !1                      ! -77 
!0                       !1                      ! -77 
 












  Trimester 
Monthly or less !  1st!2nd!3rd!  
2-4 time per month !  1st!2nd!3rd!  
2-3 time per week !  1st!2nd!3rd!  
4 or more time per week !  1st!2nd!3rd!  
Everyday !  1st!2nd!3rd!  
 
 
8.2 How many UNITS of alcohol did you have on a typical day when you were 
drinking?    ! -99 
 
                                                                  Trimester                                                                     
Trimester 
1 or 2   !             1! 2! 3!   10 to 14   !             1! 2! 3!  
3 or 4   !             1! 2! 3!   15 to 19   !             1! 2! 3!  
5 or 6   !             1! 2! 3!   20 to 29   !             1! 2! 3!  






    !             1! 2! 3!  
Units of alcohol 
 
2 units= A pint of standard beer/ lager 
1 unit= A single measure of spirit/small glass of wine   
 




0= No 1= Yes; Missing values: -77 = Don't know   -88 = Refused to answer   -99 = Not applicable 
 
6 
3 units= A pint/can of strong beer/lager 















!    Trimester 
6-9 cigarettes !  1st!2nd!3rd!  
10-20 cigarettes !  1st!2nd!3rd!  
>20 cigarettes per day      !  1st!2nd!3rd!  
 
    
 
  9.2 Did anyone in your house smoke while you were pregnant?  No!0     Yes !1      unknown ! -77 
 
                                                                                                                                        
                                                                                               Total number of people smoking            
…..                                                                                                 
 
 
6-9 cigarettes !  
10-20 cigarettes  !  





























 !  
 
 !  
 
 !  
 
 !  
 
 !  
 
 !  
 
 !  
 
 !  
 
  !  






















































































































































0= No 1= Yes; Missing values: -77 = Don't know   -88 = Refused to answer   -99 = Not applicable 
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                                                              No               Yes            Unknown               Trimester                  Dose and 
duration 

















!0                      !1                      ! -77                
1st!2nd!3rd! ………………………………… 
  
11.4 Smooth muscle  
relaxants 





!0                      !1                      ! -77                
1st!2nd!3rd! ………………………………… 
  
11.6 Hormones !0                      !1                      ! -77                
1st!2nd!3rd! ………………………………… 
  
11.7 Antihistamines !0                      !1                      ! -77                
1st!2nd!3rd! ………………………………… 
  
11.8 Immunosuppressive !0                      !1                      ! -77                
1st!2nd!3rd! ………………………………… 
  
11.2 Anticoagulants !0                      !1                      ! -77                
1st!2nd!3rd! ………………………………… 
  
11.2 Blood pressure 
medication 





!0                      !1                      ! -77                
1st!2nd!3rd! ………………………………… 
  
11.2 Antibiotics !0                      !1                      ! -77                
1st!2nd!3rd! ………………………………… 
  
11.2 Vaccinations !0                      !1                      ! -77                
1st!2nd!3rd! ………………………………… 
  




0= No 1= Yes; Missing values: -77 = Don't know   -88 = Refused to answer   -99 = Not applicable 
 
8 
11.2 Vitamins !0                      !1                      ! -77                
1st!2nd!3rd! ………………………………… 
  








  12. Did you breast feed?                                                                                              No !0                       
Yes    !1 
 
  
                                                                                                                       If yes, please give length of 
time 
 
                                                                                              
………………………………………………………….                                                                                    
 
 





                                                                           No               Yes            Unknown                                   Dose and 
duration   
           
ALCOHOL 
 
!0                      !1                      ! -77                                    ………………………………… 
 



















             Khat 
 
Inhalants 
!0                      !1                      ! -77                                      
 
 
!                                                                                 ……………………………… 
 
!                                                                                 ……………………………… 
 
!                                                                                 ……………………………… 
  
!                                                                                 ……………………………… 
  
!                                                                                 ……………………………… 
  
!                                                                                 ……………………………… 
  
!             ……………………………… 
                                                                                 
             !             ……………………………… 
 











!                                                                                 ……………………………… 
Anti-rheumatic !                                                                                 ……………………………… 














!                                                                                 ……………………………… 
Anticonvulsives 
 
!                                                                                 ……………………………… 
Hormones 
 
!                                                                                 ……………………………… 
Antihistamines 
 
!                                                                                 ……………………………… 
Immunosuppressive 
 
!                                                                                 ……………………………… 
Anticoagulants 
 
!                                                                                 ……………………………… 
Blood pressure  
Medication 
 
!                                                                                 ……………………………… 
Psychopharmaca 
 
!                                                                                 ……………………………… 
Antibiotics 
 
!                                                                                 ……………………………… 
Vaccinations 
 
!                                                                                 ……………………………… 
Vitamins 
 







































































[Part 2] LABOUR AND DELIVERY COMPLICATIONS 
  
                                                                                                                                   No                Yes            
Unknown 
 1.  Do you recall any difficulties during the birth of your son/daughter? 
                                                                                                                                   !0                       !1                      
! -77 
If yes, please note details 
 
 ……………………………………………………                                                                                            
…………………………………………………… 
 
2.  Did you give birth to twins? 
 
2a. If yes, who came first? 
 
2b. How much later? 
 






 3. How long did the labour last?                                                                                                       
.........hours 
 
3a. > 24 hours 
 
3b. > 36 hours 
 
3c. < 3 hours 
         !0                       !1                      ! -77 
 
 
         !0                       !1                      ! -77 
 
 
         !0                       !1                      ! -77 








4. Was the labour induced?                     !0                         !1                      ! -77 
If yes, please note details 
 
……………………………………………………                                                                                            
…………………………………………………… 
 
  5. Did you have a premature rupture of 
membrane? 
         !0                       !1                      ! -77 
 
          5a. > 24 h before delivery? 
 
         !0                       !1                      ! -77 
          5b. > 12 h before delivery?          !0                       !1                      ! -77 
 
  6. Was it a caesarean birth? 
 
         !0                       !1                      ! -77 
          6a. If yes, why was it done? ……………………………………………………                                                                                            
...………………………………………………… 
……………………………………………………                                                                                            
…………………………………………………… 
 
          6b. Was it done in emergency?          !0                       !1                      ! -77 
 
   7. Did the baby come out head first?          !0                       !1                      ! -77 
 
          7a. If not, was it a face birth? 
 
         !0                       !1                      ! -77 
          7b. Was it a forehead birth? 
 
         !0                       !1                      ! -77 
          7c. Was it a breech birth? 
 
         !0                       !1                      ! -77 
          7d. Other abnormal presentation?          !0                       !1                      ! -77 
If yes, please note details 
 
……………………………………………………                                                                                            
…………………………………………………… 
 
   8.  Were forceps used/was a suction delivery?          !0                       !1                      ! -77 
 
   9.  Did you have any bleeding during the 
delivery? 
         !0                       !1                      ! -77 
 
  10.  Did you have any bleeding soon/after the 
delivery? 
      !0                       !1                      ! -77 
 
  11.  Did you have any problem with the 
placenta? 
         !0                       !1                      ! -77 
 
   11a. If yes, was it an ablatio placenta? 
 
         !0                       !1                      ! -77 
          11b. Was it a placenta praevia?          !0                       !1                      ! -77 
 
12. Was the cord prolapsed?          !0                       !1                      ! -77 
 
  13.  Was the cord around the baby’s neck?          !0                       !1                      ! -77 
 






















































[Part 3] NEONATAL COMPLICATIONS 
 
                                                                                                                                                               No              Yes             
Unknown 
 1.  Did the baby have any health problems 





2.  Was the meconium (the fluid around your 
child) stained or discoloured? 
 
         !0                       !1                      ! -77 
If yes, please note details 
 
……………………………………………………                                                                                            
…………………………………………………… 
 
         !0                       !1                      ! -77 
 3.  Did your baby have any breathing problem 
at birth?  
 
3a. Did the baby have any foetal distress? 
 
3b. Was the baby cyanotic/ blue? 
 
3c. Did your baby have underdeveloped 
lungs? 
 




         !0                       !1                      ! -77 
 
         !0                       !1                      ! -77 
 
         !0                       !1                      ! -77 
  




0= No 1= Yes; Missing values: -77 = Don't know   -88 = Refused to answer   -99 = Not applicable 
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 4. Do you know the Apgar score of your 
baby? 
         !0                       !1                      ! -77 
If yes, note the 1st, 5th, 10th minutes score 
 
……………………………………………………  
                                                                                      
 5.  Did your baby require resuscitation?           !0                       !1                      ! -77 
 
 6.  Was the baby ventilated?          !0                       !1                      ! -77 
 
 7.  Was the baby intubated?          !0                       !1                      ! -77 
 
 8.  Was the baby in incubator?          !0                       !1                      ! -77 
 
………days 
                                                                                            
 9. Did the baby have any malformations at 
birth? 
         !0                       !1                      ! -77 




 10. Did the baby have any infections at/soon   
after birth? 
 
         !0                       !1                      ! -77 
10.1 Congenital syphilis 
 
















         !0                       !1                      ! -77 
 
10.6 Herpes virus 
 
         !0                       !1                      ! -77 
 
10.7  Smallpox 
 
         !0                       !1                      ! -77 
 
10.8  Hepatitis A or B          !0                       !1                      ! -77 
 
10.9 Coxsackie A or B 
 
         !0                       !1                      ! -77 
 
10.10  HIV 
 
         !0                       !1                      ! -77 
10.11 Malaria          !0                       !1                      ! -77 
 
 
10.12 Enterovirus          !0                       !1                      ! -77 
 
 






10.16  Parvovirus 
 
       10.17  RSV (Respiratory Syncytial 
Virus)  
 
10.18  Other  
 
 
         !0                       !1                      ! -77 
 
 
         !0                       !1                      ! -77 
 
 
         !0                       !1                      ! -77 
 
 
         !0                       !1                      ! -77 
 
 
         !0                       !1                      ! -77 
 
 
         !0                       !1                      ! -77 
 
If yes, please note details 
                                                     




0= No 1= Yes; Missing values: -77 = Don't know   -88 = Refused to answer   -99 = Not applicable 
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 ……………………………………………………                                                                                            
…………………………………………………… 
 
 11.  Did the baby have to have any 
treatment/medication at/soon after birth? 
         !0                       !1                      ! -77 





 12.  Did the baby have to have a blood 
transfusion at/soon after birth? 
         !0                       !1                      ! -77 































                
 
            
 
                No               Yes            Unknown 
 
1 Did you breast feed your baby? 
 
1.1 If yes, from what age to what age (in 
months)  






2 In the first few weeks after birth, or as a young 
baby, did s/he suffer from any infection affecting the 
central nervous system or brain like meningitis or 
encephalitis? 
 
2.1  If yes, what?  
 
2.2 At what age? 
 
2.3 Were they admitted to hospital? 








!0                       !1                      ! -77 
 








2.4  If yes, where? 
 
2.5 Were there any long lasting effects? 
(Prompt if necessary:  such as 
epilepsy/convulsions/fits       weakness or 
learning problems) 
 
2.6 If yes, what? 
 
2.7 Where were they treated? 
 
2.8 Was any treatment given, such as 



























3 What about later in childhood, perhaps during the 
school years,   did s/he suffer from any similar 
infection affecting the central nervous system or 
brain, again like meningitis or encephalitis? 
 
3.1    If yes, what? 
 
3.2   At what age? 
 
3.3  Were they admitted to hospital? 
 
3.4  If yes, where? 
 
3.5 Were there any long lasting effects? (Prompt 
if necessary:  such as 
epilepsy/convulsions/fits       weakness or 
learning problems) 
 
3.6 If yes, what? 
 
3.7 Where were they treated? 
 
3.8 Was any treatment given, such as 
anticonvulsants, physiotherapy, other? 
 
 
































4 Did your child suffer any serious head injury whilst a 
baby or later in childhood? 
 
4.1 If yes, at what age? 
 
4.2 Was your child knocked out, or did they 
!0                       !1                      ! -77 
 
 
……………………………..months /years  
 
!0                       !1                      ! -77 




0= No 1= Yes; Missing values: -77 = Don't know   -88 = Refused to answer   -99 = Not applicable 
 
16 
lose consciousness at all? 
 
4.3 If yes, for how long? 
 
4.4 Was your child admitted to hospital for 
treatment for this head injury? 
 
4.5 If yes, where? 
 
4.6 Did s/he have a head scan or CT scan?     
 
4.7 Were there any long-lasting effects, like 
epilepsy/ convulsions/fits, or learning 
problems, speech problems or problems 
with weakness or in walking?   
 
4.8 Did your child have to have any long-term 
treatment, like anticonvulsants for fits, or 
physiotherapy or help with learning? 
 
4.9 If yes, what? 
 






























5 Did your child ever receive any special help at 
school or go to a special school?    For example, 
some children need special help with reading, or 
arithmetic/mathematics. 
 
5.1 If yes, what? 
 
5.2 How old were they when it started? 
 
5.3 Who gave it / where was it given? 
 
5.4 How old were they when it stopped? 
 
 












6 Did your child ever need to see a psychologist or 
educational psychologist or did they have their 
special educational needs assessed (were they 
"statemented")? 
 
6.1 If yes, how old were they? 
 
6.2 Who did they see?   
 
6.3 Where was that? 
 
6.4 Why was that? 












7 Did your child ever need to see a psychologist, 
doctor or other    specialist because of his/her 
behaviour?  (Were they ever referred to a child 
guidance clinic or other type of clinic?) 
 









0= No 1= Yes; Missing values: -77 = Don't know   -88 = Refused to answer   -99 = Not applicable 
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7.1 If yes, why? 
 
7.2 How old were they?       
 
7.3 Where was that? 
 
7.4 Did they get any treatment or other 
special help?   
 













8 Did your child ever need to see a psychologist, 
doctor or other specialist because of problems at 
school?  
 
8.1 If yes, why? 
 
8.2 How old were they?  
 
8.3 Where was that?      
 
8.4 Did they get any treatment or other 
special help? 
 
8.5 If yes, what?    















9  Did your child ever have to see a child psychiatrist 
or psychologist for any other reason?   
 
9.1 If yes, why? 
 
9.2 How old were they?  
 
9.3 Where was that?      
 
9.4 Did they get any treatment or other 
special help? 
 
9.5 If yes, what?    
 
 















10 Did your child reach all his/her milestones at the 
same time as his/her brothers and sisters, or other 
children of a similar age? For example, crawling, 
walking talking, stopping wetting the bed, that sort 
of thing. 
 
10.1 If not, were they earlier or later in any of 
these compared with other children? 
 
 
10.2 If they were later, what did you notice?  
 
10.3 Which milestones were later? 













11 Did your child ever have to see a doctor or other 
specialist     because of problems with the way they 
developed, like walking or talking later than other 
children? 
 
11.1 If yes, why? 














11.2 How old were they? 
 
11.3 Where was that? 
 
11.4 Did they get any treatment or other 
special help? 
 











12 Now I'd like to ask you about each of the 
milestones, so thinking back to the first few years of 
their life: 
 
12.1 At what age did s/he sit up?  
     
   
 
 
12.2 At what age did s/he crawl? 










12.4 At what age did s/he speak single words 










12.5 At what age did s/he string two or more 




!1  3-6 months  
!2 7-12 months 
!3 over 12 month    
! -77 don't know 
 
!1  6-12 months 
!2 12-18 months 
!3 over 18 month    
! -77 don't know 
 
!1  under 1 year 
!2 1-2 years 
!3 3-4 years                   
!4 over 4 years 
! -77 don't know 
 
!1  9-13 months 
!2 14-18 months 
!3 19-24 months 
!4 2-3 years 
!5 3-4 years 
!6 over 4 years 
! -77 don't know 
 
 
!1  9-13 months 
!2 14-18 months 
!3 19-24 months 
!4 2-3 years 
!5 3-4 years 
!6 over 4 years 
! -77 don't know 
 
 
13 Did your child have any serious illnesses, either as a 
baby or later while they were at school – I mean 
illnesses other than the usual mild childhood 
illnesses? 
 
13.1 If yes, what? 
 
13.2 How old were they? 
 
13.3 Were they admitted to hospital?   








!0                       !1                      ! -77 
 




0= No 1= Yes; Missing values: -77 = Don't know   -88 = Refused to answer   -99 = Not applicable 
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13.4 If so, where?  
 
13.5 Did they get any treatment or other 
special help? 
 









14 While they were growing up, was there anything 
you thought was different about …… compared with 
other children? 
 
14.1 If so, what? 
 
14.2  How old were they? 
 
14.3 Did you or his /her teachers do anything 
about this? 
    










15 Is there anything about ……………. while they were 
a child that you think may be important or 
significant in any way, but that we have not 
covered? 
!0                       !1                      ! -77 
 


















ASSESSMENT OF PREMORBID SCHIZOID-SCHIZOTYPAL TRAITS 
 
 
Information from either parent 
 
The starred questions must be asked and then followed by further questions to define the 
degree of any abnormality. 
N.B. For cases all questions refer to enduring personality traits present before the first 
episode of psychosis.  
 
*  Cases: We are interested in the sort of person that ……………….was before he/she first 
 became ill at the age of ………. (work out age from baseline file). 
 
 
1. Social Isolation 
 
 * How social and outgoing was he/she? 
 * Did he/she have many close friends? 
 




0= No 1= Yes; Missing values: -77 = Don't know   -88 = Refused to answer   -99 = Not applicable 
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Not withdrawn, active social interaction !1  
 
Casual friends only !2   
 
Moderately withdrawn, excessive 
daydreaming and fantasy, or deviant 
friendship patterns only (with children older 
or younger only, or relatives only, or with 1 or 
2 individuals only) 
 
!3   
Unable to form relationships, withdrawn 
  isolated – no friends   





 * How warm and affectionate was he/she? 
 
Warm spontaneous shows of affection !1  
 
Displays affection with family, but often cold 
and aloof with others 
 
!2   
 
Hardly ever displays affection even with close 
relations  
  
!3   





 * Was he/she at ease when with other people, or did he/she sometimes appear to be unduly  
anxious or suspicious? 
* Did he/she mind being criticised? 
 
Neither suspicious nor unduly socially anxious !1  
 
Undue social anxiety or occasionally suspicious 
or occasionally sensitive to criticism 
 
!2   
 
Marked social anxiety or suspicious/distrustful 
or hypersensitive to imagined criticism  
 
!3   
All characteristics listed in 1 to 3 above plus 
believed that someone was deliberately trying 
to harm him/her 




4. Thought Content/Beliefs 
 
 * Did he/she ever express any strange or unusual ideas, or behave oddly? 
 
No abnormality !1  
 
Occasionally (less than once a month) 
expresses odd ideas, strange or unusual 
perceptions, magical thinking or ideas of 
reference or occasional odd behaviour 
 
!2   
 
Often (more than once a month) 
   
!3   
Above features predominate (daily) !4   




0= No 1= Yes; Missing values: -77 = Don't know   -88 = Refused to answer   -99 = Not applicable 
 
21 




 * Was his/her speech ever odd, vague or difficult to follow? 
 * Did he/she ever use odd words or words in an unusual way? 
 
  
Normal !1  
 
Occasionally (less than once a month) deviant 
(see below) 
 
!2   
 
Often (more than once a month) deviant (see 
below) 
 
!3   
Consistent pattern of clearly deviant speech !4   
 
 
 (Deviant speech:  ie digressive, over elaborate, vague, circumstantial.  Difficult to carry out 




6. Antisocial behaviour (i.e. with delinquent peer group) 
 
 * Did he/she ever commit any of the following: Lying, stealing, fire-setting, violence, drugs, 
truancy, vandalism, sex offences? 
 If yes: Did he/she do this alone or with others? 
 
 NB. Rate based only on those activities carried out with others. 
 
None !1  
 
Mild !2   
 
Moderate (leading to complaints by 
neighbours, teachers, police etc) 
!3   
Severe and repeated (child arrested on more 
than one occasion or parents  sought help 
from outside agencies) 




7. Asocial, Antisocial behaviour (i.e. carried out alone) 
 
 NB. Rate from answer to question 6 based on activities carried out alone. 
 
None !1  
 
Mild !2   
 
Moderate (leading to complaints by 
neighbours, teachers, police etc) 
!3   
Severe and repeated (child arrested on more 
than one occasion or parents  sought help 
from outside agencies) 
!4   
 
 
8. Any Other Abnormalities 
 
 Try to obtain verbatim account of premorbid personality 
 




0= No 1= Yes; Missing values: -77 = Don't know   -88 = Refused to answer   -99 = Not applicable 
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 * How would you describe ……… before they first became unwell? 
 
What was his/her mood like? 
Was he/she a calm sort of person who took life as it came? 
How did he/she cope with the normal demands of life? 
What was his/her temper like? 
What sort of standards does he/she have (at home, at work for example) 
 
Normal !1  
 




!3   




9.   Total score   
 
 
 
 
 
  
